id	sid	tid	token	lemma	pos
bjos-8641642	1	1	oral	oral	ADJ
bjos-8641642	1	2	sciences	sciences	PROPN
bjos-8641642	1	3	n3	n3	PROPN
bjos-8641642	1	4	braz	braz	PROPN
bjos-8641642	1	5	j	j	PROPN
bjos-8641642	1	6	oral	oral	PROPN
bjos-8641642	1	7	sci	sci	PROPN
bjos-8641642	1	8	.	.	PUNCT
bjos-8641642	2	1	10(2):83	10(2):83	NUM
bjos-8641642	2	2	-	-	SYM
bjos-8641642	2	3	87	87	NUM
bjos-8641642	2	4	original	original	ADJ
bjos-8641642	2	5	article	article	NOUN
bjos-8641642	2	6	braz	braz	PROPN
bjos-8641642	2	7	j	j	PROPN
bjos-8641642	2	8	oral	oral	PROPN
bjos-8641642	2	9	sci	sci	PROPN
bjos-8641642	2	10	.	.	PUNCT
bjos-8641642	3	1	april	april	PROPN
bjos-8641642	3	2	|	|	CCONJ
bjos-8641642	3	3	june	june	PROPN
bjos-8641642	3	4	2011	2011	NUM
bjos-8641642	3	5	volume	volume	NOUN
bjos-8641642	3	6	10	10	NUM
bjos-8641642	3	7	,	,	PUNCT
bjos-8641642	3	8	number	number	NOUN
bjos-8641642	3	9	2	2	NUM
bjos-8641642	3	10	cytokine	cytokine	NOUN
bjos-8641642	3	11	profiles	profile	NOUN
bjos-8641642	3	12	in	in	ADP
bjos-8641642	3	13	the	the	DET
bjos-8641642	3	14	sera	sera	NOUN
bjos-8641642	3	15	of	of	ADP
bjos-8641642	3	16	egyptian	egyptian	ADJ
bjos-8641642	3	17	patients	patient	NOUN
bjos-8641642	3	18	with	with	ADP
bjos-8641642	3	19	oral	oral	ADJ
bjos-8641642	3	20	pemphigus	pemphigus	NOUN
bjos-8641642	3	21	vulgaris	vulgaris	NOUN
bjos-8641642	3	22	hossam	hossam	NOUN
bjos-8641642	3	23	eid1	eid1	PROPN
bjos-8641642	3	24	,	,	PUNCT
bjos-8641642	3	25	basiouny	basiouny	PROPN
bjos-8641642	3	26	el	el	PROPN
bjos-8641642	3	27	-	-	PUNCT
bjos-8641642	3	28	gamal2	gamal2	NOUN
bjos-8641642	4	1	1phd	1phd	NUM
bjos-8641642	4	2	,	,	PUNCT
bjos-8641642	4	3	oral	oral	ADJ
bjos-8641642	4	4	medicine	medicine	NOUN
bjos-8641642	4	5	,	,	PUNCT
bjos-8641642	4	6	oral	oral	ADJ
bjos-8641642	4	7	diagnosis	diagnosis	NOUN
bjos-8641642	4	8	and	and	CCONJ
bjos-8641642	4	9	periodontology	periodontology	NOUN
bjos-8641642	4	10	department	department	NOUN
bjos-8641642	4	11	,	,	PUNCT
bjos-8641642	4	12	faculty	faculty	NOUN
bjos-8641642	4	13	of	of	ADP
bjos-8641642	4	14	dentistry	dentistry	NOUN
bjos-8641642	4	15	,	,	PUNCT
bjos-8641642	4	16	suez	suez	PROPN
bjos-8641642	4	17	canal	canal	PROPN
bjos-8641642	4	18	university	university	PROPN
bjos-8641642	4	19	,	,	PUNCT
bjos-8641642	4	20	egypt	egypt	PROPN
bjos-8641642	4	21	2phd	2phd	PROPN
bjos-8641642	4	22	,	,	PUNCT
bjos-8641642	4	23	clinical	clinical	ADJ
bjos-8641642	4	24	biochemistry	biochemistry	NOUN
bjos-8641642	4	25	department	department	PROPN
bjos-8641642	4	26	,	,	PUNCT
bjos-8641642	4	27	college	college	NOUN
bjos-8641642	4	28	of	of	ADP
bjos-8641642	4	29	medicine	medicine	NOUN
bjos-8641642	4	30	,	,	PUNCT
bjos-8641642	4	31	king	king	PROPN
bjos-8641642	4	32	khalid	khalid	PROPN
bjos-8641642	4	33	university	university	PROPN
bjos-8641642	4	34	,	,	PUNCT
bjos-8641642	4	35	abha	abha	NOUN
bjos-8641642	4	36	,	,	PUNCT
bjos-8641642	4	37	saudi	saudi	PROPN
bjos-8641642	4	38	arabia	arabia	PROPN
bjos-8641642	4	39	correspondence	correspondence	NOUN
bjos-8641642	4	40	to	to	ADP
bjos-8641642	4	41	:	:	PUNCT
bjos-8641642	4	42	basiouny	basiouny	PROPN
bjos-8641642	4	43	el	el	PROPN
bjos-8641642	4	44	-	-	PROPN
bjos-8641642	4	45	gamal	gamal	PROPN
bjos-8641642	4	46	department	department	PROPN
bjos-8641642	4	47	of	of	ADP
bjos-8641642	4	48	clinical	clinical	ADJ
bjos-8641642	4	49	biochemistry	biochemistry	NOUN
bjos-8641642	4	50	college	college	PROPN
bjos-8641642	4	51	of	of	ADP
bjos-8641642	4	52	medicine	medicine	NOUN
bjos-8641642	4	53	,	,	PUNCT
bjos-8641642	4	54	king	king	PROPN
bjos-8641642	4	55	khalid	khalid	PROPN
bjos-8641642	4	56	university	university	PROPN
bjos-8641642	4	57	,	,	PUNCT
bjos-8641642	4	58	abha	abha	NOUN
bjos-8641642	4	59	,	,	PUNCT
bjos-8641642	4	60	saudi	saudi	PROPN
bjos-8641642	4	61	arabia	arabia	PROPN
bjos-8641642	4	62	phone	phone	NOUN
bjos-8641642	4	63	:	:	PUNCT
bjos-8641642	5	1	+966	+966	X
bjos-8641642	5	2	543175779	543175779	NUM
bjos-8641642	5	3	e	e	NOUN
bjos-8641642	5	4	-	-	NOUN
bjos-8641642	5	5	mail	mail	NOUN
bjos-8641642	5	6	:	:	PUNCT
bjos-8641642	5	7	basiouny_el_gamal@hotmail.com	basiouny_el_gamal@hotmail.com	NOUN
bjos-8641642	5	8	abstract	abstract	ADJ
bjos-8641642	5	9	cytokines	cytokine	NOUN
bjos-8641642	5	10	have	have	AUX
bjos-8641642	5	11	been	be	AUX
bjos-8641642	5	12	suggested	suggest	VERB
bjos-8641642	5	13	to	to	PART
bjos-8641642	5	14	play	play	VERB
bjos-8641642	5	15	an	an	DET
bjos-8641642	5	16	important	important	ADJ
bjos-8641642	5	17	role	role	NOUN
bjos-8641642	5	18	in	in	ADP
bjos-8641642	5	19	the	the	DET
bjos-8641642	5	20	pathogenesis	pathogenesis	NOUN
bjos-8641642	5	21	of	of	ADP
bjos-8641642	5	22	various	various	ADJ
bjos-8641642	5	23	inflammatory	inflammatory	ADJ
bjos-8641642	5	24	and	and	CCONJ
bjos-8641642	5	25	autoimmune	autoimmune	ADJ
bjos-8641642	5	26	diseases	disease	NOUN
bjos-8641642	5	27	,	,	PUNCT
bjos-8641642	5	28	including	include	VERB
bjos-8641642	5	29	the	the	DET
bjos-8641642	5	30	potentially	potentially	ADV
bjos-8641642	5	31	fatal	fatal	ADJ
bjos-8641642	5	32	blistering	blister	VERB
bjos-8641642	5	33	disease	disease	NOUN
bjos-8641642	5	34	,	,	PUNCT
bjos-8641642	5	35	oral	oral	ADJ
bjos-8641642	5	36	pemphigus	pemphigus	NOUN
bjos-8641642	5	37	vulgaris	vulgaris	NOUN
bjos-8641642	5	38	(	(	PUNCT
bjos-8641642	5	39	pv	pv	NOUN
bjos-8641642	5	40	)	)	PUNCT
bjos-8641642	5	41	.	.	PUNCT
bjos-8641642	6	1	no	no	DET
bjos-8641642	6	2	data	datum	NOUN
bjos-8641642	6	3	are	be	AUX
bjos-8641642	6	4	currently	currently	ADV
bjos-8641642	6	5	available	available	ADJ
bjos-8641642	6	6	on	on	ADP
bjos-8641642	6	7	the	the	DET
bjos-8641642	6	8	cytokine	cytokine	NOUN
bjos-8641642	6	9	levels	level	NOUN
bjos-8641642	6	10	in	in	ADP
bjos-8641642	6	11	the	the	DET
bjos-8641642	6	12	sera	sera	NOUN
bjos-8641642	6	13	of	of	ADP
bjos-8641642	6	14	egyptian	egyptian	ADJ
bjos-8641642	6	15	patients	patient	NOUN
bjos-8641642	6	16	with	with	ADP
bjos-8641642	6	17	oral	oral	ADJ
bjos-8641642	6	18	pv	pv	NOUN
bjos-8641642	6	19	.	.	PUNCT
bjos-8641642	7	1	aim	aim	NOUN
bjos-8641642	7	2	:	:	PUNCT
bjos-8641642	7	3	the	the	DET
bjos-8641642	7	4	aim	aim	NOUN
bjos-8641642	7	5	of	of	ADP
bjos-8641642	7	6	this	this	DET
bjos-8641642	7	7	study	study	NOUN
bjos-8641642	7	8	was	be	AUX
bjos-8641642	7	9	to	to	PART
bjos-8641642	7	10	measure	measure	VERB
bjos-8641642	7	11	the	the	DET
bjos-8641642	7	12	serum	serum	NOUN
bjos-8641642	7	13	levels	level	NOUN
bjos-8641642	7	14	of	of	ADP
bjos-8641642	7	15	some	some	DET
bjos-8641642	7	16	proinflammatory	proinflammatory	ADJ
bjos-8641642	7	17	and	and	CCONJ
bjos-8641642	7	18	antiinflammatory	antiinflammatory	NOUN
bjos-8641642	7	19	cytokines	cytokine	NOUN
bjos-8641642	7	20	in	in	ADP
bjos-8641642	7	21	egyptian	egyptian	ADJ
bjos-8641642	7	22	patients	patient	NOUN
bjos-8641642	7	23	with	with	ADP
bjos-8641642	7	24	pv	pv	NOUN
bjos-8641642	7	25	.	.	PUNCT
bjos-8641642	7	26	methods	method	NOUN
bjos-8641642	7	27	:	:	PUNCT
bjos-8641642	7	28	using	use	VERB
bjos-8641642	7	29	highly	highly	ADV
bjos-8641642	7	30	sensitive	sensitive	ADJ
bjos-8641642	7	31	elisa	elisa	NOUN
bjos-8641642	7	32	kits	kit	NOUN
bjos-8641642	7	33	,	,	PUNCT
bjos-8641642	7	34	the	the	DET
bjos-8641642	7	35	levels	level	NOUN
bjos-8641642	7	36	of	of	ADP
bjos-8641642	7	37	tnf	tnf	PROPN
bjos-8641642	7	38	-	-	PUNCT
bjos-8641642	7	39	α	α	PROPN
bjos-8641642	7	40	,	,	PUNCT
bjos-8641642	7	41	il-2	il-2	NUM
bjos-8641642	7	42	,	,	PUNCT
bjos-8641642	7	43	il-4	il-4	NOUN
bjos-8641642	7	44	and	and	CCONJ
bjos-8641642	7	45	il-6	il-6	NOUN
bjos-8641642	7	46	were	be	AUX
bjos-8641642	7	47	measured	measure	VERB
bjos-8641642	7	48	in	in	ADP
bjos-8641642	7	49	the	the	DET
bjos-8641642	7	50	sera	sera	NOUN
bjos-8641642	7	51	of	of	ADP
bjos-8641642	7	52	10	10	NUM
bjos-8641642	7	53	patients	patient	NOUN
bjos-8641642	7	54	affected	affect	VERB
bjos-8641642	7	55	with	with	ADP
bjos-8641642	7	56	oral	oral	ADJ
bjos-8641642	7	57	pv	pv	NOUN
bjos-8641642	7	58	and	and	CCONJ
bjos-8641642	7	59	10	10	NUM
bjos-8641642	7	60	healthy	healthy	ADJ
bjos-8641642	7	61	subjects	subject	NOUN
bjos-8641642	7	62	.	.	PUNCT
bjos-8641642	8	1	results	result	NOUN
bjos-8641642	8	2	:	:	PUNCT
bjos-8641642	8	3	serum	serum	NOUN
bjos-8641642	8	4	levels	level	NOUN
bjos-8641642	8	5	of	of	ADP
bjos-8641642	8	6	tnf	tnf	PROPN
bjos-8641642	8	7	-	-	PUNCT
bjos-8641642	8	8	α	α	PROPN
bjos-8641642	8	9	and	and	CCONJ
bjos-8641642	8	10	il-6	il-6	NOUN
bjos-8641642	8	11	were	be	AUX
bjos-8641642	8	12	found	find	VERB
bjos-8641642	8	13	to	to	PART
bjos-8641642	8	14	be	be	AUX
bjos-8641642	8	15	significantly	significantly	ADV
bjos-8641642	8	16	higher	high	ADJ
bjos-8641642	8	17	in	in	ADP
bjos-8641642	8	18	patients	patient	NOUN
bjos-8641642	8	19	with	with	ADP
bjos-8641642	8	20	oral	oral	ADJ
bjos-8641642	8	21	pv	pv	NOUN
bjos-8641642	8	22	than	than	ADP
bjos-8641642	8	23	in	in	ADP
bjos-8641642	8	24	healthy	healthy	ADJ
bjos-8641642	8	25	controls	control	NOUN
bjos-8641642	8	26	(	(	PUNCT
bjos-8641642	8	27	p<0.001	p<0.001	PROPN
bjos-8641642	8	28	)	)	PUNCT
bjos-8641642	8	29	.	.	PUNCT
bjos-8641642	9	1	on	on	ADP
bjos-8641642	9	2	the	the	DET
bjos-8641642	9	3	other	other	ADJ
bjos-8641642	9	4	hand	hand	NOUN
bjos-8641642	9	5	,	,	PUNCT
bjos-8641642	9	6	no	no	DET
bjos-8641642	9	7	significant	significant	ADJ
bjos-8641642	9	8	differences	difference	NOUN
bjos-8641642	9	9	were	be	AUX
bjos-8641642	9	10	observed	observe	VERB
bjos-8641642	9	11	in	in	ADP
bjos-8641642	9	12	the	the	DET
bjos-8641642	9	13	levels	level	NOUN
bjos-8641642	9	14	of	of	ADP
bjos-8641642	9	15	il-2	il-2	NUM
bjos-8641642	9	16	and	and	CCONJ
bjos-8641642	9	17	il-4	il-4	NOUN
bjos-8641642	9	18	between	between	ADP
bjos-8641642	9	19	oral	oral	ADJ
bjos-8641642	9	20	pv	pv	NOUN
bjos-8641642	9	21	and	and	CCONJ
bjos-8641642	9	22	control	control	NOUN
bjos-8641642	9	23	sera	sera	NOUN
bjos-8641642	9	24	(	(	PUNCT
bjos-8641642	9	25	p<0.05	p<0.05	PROPN
bjos-8641642	9	26	)	)	PUNCT
bjos-8641642	9	27	.	.	PUNCT
bjos-8641642	10	1	conclusions	conclusion	NOUN
bjos-8641642	10	2	:	:	PUNCT
bjos-8641642	10	3	these	these	DET
bjos-8641642	10	4	data	datum	NOUN
bjos-8641642	10	5	showed	show	VERB
bjos-8641642	10	6	that	that	SCONJ
bjos-8641642	10	7	tnf	tnf	PROPN
bjos-8641642	10	8	-	-	PUNCT
bjos-8641642	10	9	α	α	PROPN
bjos-8641642	10	10	and	and	CCONJ
bjos-8641642	10	11	il-6	il-6	NOUN
bjos-8641642	10	12	levels	level	NOUN
bjos-8641642	10	13	were	be	AUX
bjos-8641642	10	14	significantly	significantly	ADV
bjos-8641642	10	15	increased	increase	VERB
bjos-8641642	10	16	in	in	ADP
bjos-8641642	10	17	the	the	DET
bjos-8641642	10	18	sera	sera	NOUN
bjos-8641642	10	19	of	of	ADP
bjos-8641642	10	20	egyptian	egyptian	ADJ
bjos-8641642	10	21	patients	patient	NOUN
bjos-8641642	10	22	with	with	ADP
bjos-8641642	10	23	oral	oral	ADJ
bjos-8641642	10	24	pv	pv	NOUN
bjos-8641642	11	1	and	and	CCONJ
bjos-8641642	11	2	this	this	PRON
bjos-8641642	11	3	might	might	AUX
bjos-8641642	11	4	suggest	suggest	VERB
bjos-8641642	11	5	its	its	PRON
bjos-8641642	11	6	role	role	NOUN
bjos-8641642	11	7	in	in	ADP
bjos-8641642	11	8	the	the	DET
bjos-8641642	11	9	pathogenesis	pathogenesis	NOUN
bjos-8641642	11	10	of	of	ADP
bjos-8641642	11	11	this	this	DET
bjos-8641642	11	12	disease	disease	NOUN
bjos-8641642	11	13	.	.	PUNCT
bjos-8641642	12	1	keywords	keyword	NOUN
bjos-8641642	12	2	:	:	PUNCT
bjos-8641642	12	3	pemphigus	pemphigus	NOUN
bjos-8641642	12	4	vulgaris	vulgaris	NOUN
bjos-8641642	12	5	,	,	PUNCT
bjos-8641642	12	6	oral	oral	ADJ
bjos-8641642	12	7	lesions	lesion	NOUN
bjos-8641642	12	8	,	,	PUNCT
bjos-8641642	12	9	cytokines	cytokine	NOUN
bjos-8641642	12	10	.	.	PUNCT
bjos-8641642	13	1	introduction	introduction	NOUN
bjos-8641642	13	2	pemphigus	pemphigus	NOUN
bjos-8641642	13	3	vulgaris	vulgaris	NOUN
bjos-8641642	13	4	(	(	PUNCT
bjos-8641642	13	5	pv	pv	NOUN
bjos-8641642	13	6	)	)	PUNCT
bjos-8641642	13	7	is	be	AUX
bjos-8641642	13	8	a	a	DET
bjos-8641642	13	9	chronic	chronic	NOUN
bjos-8641642	13	10	,	,	PUNCT
bjos-8641642	13	11	vesiculobullous	vesiculobullous	ADJ
bjos-8641642	13	12	,	,	PUNCT
bjos-8641642	13	13	mucocutaneous	mucocutaneous	ADJ
bjos-8641642	13	14	autoimmune	autoimmune	ADJ
bjos-8641642	13	15	fatal	fatal	ADJ
bjos-8641642	13	16	disease	disease	NOUN
bjos-8641642	13	17	,	,	PUNCT
bjos-8641642	13	18	characterized	characterize	VERB
bjos-8641642	13	19	by	by	ADP
bjos-8641642	13	20	the	the	DET
bjos-8641642	13	21	presence	presence	NOUN
bjos-8641642	13	22	of	of	ADP
bjos-8641642	13	23	antibodies	antibody	NOUN
bjos-8641642	13	24	against	against	ADP
bjos-8641642	13	25	adhesion	adhesion	NOUN
bjos-8641642	13	26	molecules	molecule	NOUN
bjos-8641642	13	27	(	(	PUNCT
bjos-8641642	13	28	desmoglein	desmoglein	NOUN
bjos-8641642	13	29	,	,	PUNCT
bjos-8641642	13	30	dsg3	dsg3	PROPN
bjos-8641642	13	31	)	)	PUNCT
bjos-8641642	13	32	present	present	ADJ
bjos-8641642	13	33	on	on	ADP
bjos-8641642	13	34	the	the	DET
bjos-8641642	13	35	surface	surface	NOUN
bjos-8641642	13	36	of	of	ADP
bjos-8641642	13	37	keratinocytes	keratinocyte	NOUN
bjos-8641642	13	38	,	,	PUNCT
bjos-8641642	13	39	leading	lead	VERB
bjos-8641642	13	40	to	to	ADP
bjos-8641642	13	41	the	the	DET
bjos-8641642	13	42	loss	loss	NOUN
bjos-8641642	13	43	of	of	ADP
bjos-8641642	13	44	cellular	cellular	ADJ
bjos-8641642	13	45	adhesion	adhesion	NOUN
bjos-8641642	13	46	or	or	CCONJ
bjos-8641642	13	47	acantholysis	acantholysis	NOUN
bjos-8641642	13	48	and	and	CCONJ
bjos-8641642	13	49	is	be	AUX
bjos-8641642	13	50	typically	typically	ADV
bjos-8641642	13	51	associated	associate	VERB
bjos-8641642	13	52	with	with	ADP
bjos-8641642	13	53	oral	oral	ADJ
bjos-8641642	13	54	lesions1	lesions1	NOUN
bjos-8641642	13	55	-	-	PUNCT
bjos-8641642	13	56	5	5	NUM
bjos-8641642	13	57	.	.	PUNCT
bjos-8641642	14	1	histologically	histologically	ADV
bjos-8641642	14	2	,	,	PUNCT
bjos-8641642	14	3	pv	pv	PRON
bjos-8641642	14	4	can	can	AUX
bjos-8641642	14	5	be	be	AUX
bjos-8641642	14	6	detected	detect	VERB
bjos-8641642	14	7	by	by	ADP
bjos-8641642	14	8	indirect	indirect	ADJ
bjos-8641642	14	9	immunofluorescence	immunofluorescence	NOUN
bjos-8641642	14	10	assay	assay	NOUN
bjos-8641642	14	11	of	of	ADP
bjos-8641642	14	12	anti	anti	ADJ
bjos-8641642	14	13	-	-	ADJ
bjos-8641642	14	14	dsg3	dsg3	ADJ
bjos-8641642	14	15	antibodies	antibody	NOUN
bjos-8641642	14	16	in	in	ADP
bjos-8641642	14	17	the	the	DET
bjos-8641642	14	18	sera6	sera6	NOUN
bjos-8641642	14	19	and	and	CCONJ
bjos-8641642	14	20	blister	blister	NOUN
bjos-8641642	14	21	fluid7	fluid7	NOUN
bjos-8641642	14	22	.	.	PUNCT
bjos-8641642	15	1	in	in	ADP
bjos-8641642	15	2	fact	fact	NOUN
bjos-8641642	15	3	,	,	PUNCT
bjos-8641642	15	4	the	the	DET
bjos-8641642	15	5	oral	oral	ADJ
bjos-8641642	15	6	mucosa	mucosa	NOUN
bjos-8641642	15	7	is	be	AUX
bjos-8641642	15	8	the	the	DET
bjos-8641642	15	9	first	first	ADJ
bjos-8641642	15	10	site	site	NOUN
bjos-8641642	15	11	to	to	PART
bjos-8641642	15	12	be	be	AUX
bjos-8641642	15	13	involved	involve	VERB
bjos-8641642	15	14	in	in	ADP
bjos-8641642	15	15	up	up	ADP
bjos-8641642	15	16	to	to	PART
bjos-8641642	15	17	70	70	NUM
bjos-8641642	15	18	%	%	NOUN
bjos-8641642	15	19	of	of	ADP
bjos-8641642	15	20	cases	case	NOUN
bjos-8641642	15	21	,	,	PUNCT
bjos-8641642	15	22	and	and	CCONJ
bjos-8641642	15	23	it	it	PRON
bjos-8641642	15	24	is	be	AUX
bjos-8641642	15	25	the	the	DET
bjos-8641642	15	26	only	only	ADJ
bjos-8641642	15	27	site	site	NOUN
bjos-8641642	15	28	to	to	PART
bjos-8641642	15	29	be	be	AUX
bjos-8641642	15	30	affected	affect	VERB
bjos-8641642	15	31	in	in	ADP
bjos-8641642	15	32	over	over	ADP
bjos-8641642	15	33	50	50	NUM
bjos-8641642	15	34	%	%	NOUN
bjos-8641642	15	35	of	of	ADP
bjos-8641642	15	36	patients8	patients8	NOUN
bjos-8641642	15	37	.	.	PUNCT
bjos-8641642	16	1	most	most	ADJ
bjos-8641642	16	2	patients	patient	NOUN
bjos-8641642	16	3	exhibit	exhibit	VERB
bjos-8641642	16	4	oral	oral	ADJ
bjos-8641642	16	5	lesions	lesion	NOUN
bjos-8641642	16	6	at	at	ADP
bjos-8641642	16	7	some	some	DET
bjos-8641642	16	8	time	time	NOUN
bjos-8641642	16	9	of	of	ADP
bjos-8641642	16	10	the	the	DET
bjos-8641642	16	11	disease8	disease8	PROPN
bjos-8641642	16	12	.	.	PUNCT
bjos-8641642	17	1	clinically	clinically	ADV
bjos-8641642	17	2	,	,	PUNCT
bjos-8641642	17	3	the	the	DET
bjos-8641642	17	4	most	most	ADV
bjos-8641642	17	5	common	common	ADJ
bjos-8641642	17	6	sites	site	NOUN
bjos-8641642	17	7	of	of	ADP
bjos-8641642	17	8	oral	oral	ADJ
bjos-8641642	17	9	pv	pv	NOUN
bjos-8641642	17	10	lesions	lesion	NOUN
bjos-8641642	17	11	are	be	AUX
bjos-8641642	17	12	the	the	DET
bjos-8641642	17	13	labial	labial	ADJ
bjos-8641642	17	14	and	and	CCONJ
bjos-8641642	17	15	buccal	buccal	ADJ
bjos-8641642	17	16	mucosa	mucosa	NOUN
bjos-8641642	17	17	or	or	CCONJ
bjos-8641642	17	18	the	the	DET
bjos-8641642	17	19	edentulous	edentulous	ADJ
bjos-8641642	17	20	ridges	ridge	NOUN
bjos-8641642	17	21	.	.	PUNCT
bjos-8641642	18	1	oral	oral	ADJ
bjos-8641642	18	2	lesions	lesion	NOUN
bjos-8641642	18	3	are	be	AUX
bjos-8641642	18	4	commonly	commonly	ADV
bjos-8641642	18	5	characterized	characterize	VERB
bjos-8641642	18	6	by	by	ADP
bjos-8641642	18	7	the	the	DET
bjos-8641642	18	8	presence	presence	NOUN
bjos-8641642	18	9	of	of	ADP
bjos-8641642	18	10	vesiculobullous	vesiculobullous	ADJ
bjos-8641642	18	11	and	and	CCONJ
bjos-8641642	18	12	ulcerative	ulcerative	ADJ
bjos-8641642	18	13	lesions	lesion	NOUN
bjos-8641642	18	14	.	.	PUNCT
bjos-8641642	19	1	recently	recently	ADV
bjos-8641642	19	2	,	,	PUNCT
bjos-8641642	19	3	there	there	PRON
bjos-8641642	19	4	has	have	AUX
bjos-8641642	19	5	been	be	AUX
bjos-8641642	19	6	increasing	increase	VERB
bjos-8641642	19	7	interest	interest	NOUN
bjos-8641642	19	8	in	in	ADP
bjos-8641642	19	9	the	the	DET
bjos-8641642	19	10	role	role	NOUN
bjos-8641642	19	11	of	of	ADP
bjos-8641642	19	12	cytokines	cytokine	NOUN
bjos-8641642	19	13	in	in	ADP
bjos-8641642	19	14	the	the	DET
bjos-8641642	19	15	pathogenesis	pathogenesis	NOUN
bjos-8641642	19	16	of	of	ADP
bjos-8641642	19	17	various	various	ADJ
bjos-8641642	19	18	inflammatory	inflammatory	ADJ
bjos-8641642	19	19	and	and	CCONJ
bjos-8641642	19	20	autoimmune	autoimmune	ADJ
bjos-8641642	19	21	diseases	disease	NOUN
bjos-8641642	19	22	,	,	PUNCT
bjos-8641642	19	23	including	include	VERB
bjos-8641642	19	24	the	the	DET
bjos-8641642	19	25	potentially	potentially	ADV
bjos-8641642	19	26	fatal	fatal	ADJ
bjos-8641642	19	27	blistering	blister	VERB
bjos-8641642	19	28	disease	disease	NOUN
bjos-8641642	19	29	,	,	PUNCT
bjos-8641642	19	30	pv1	pv1	NOUN
bjos-8641642	19	31	-	-	ADJ
bjos-8641642	19	32	2,4,8	2,4,8	NUM
bjos-8641642	19	33	-	-	SYM
bjos-8641642	19	34	13	13	NUM
bjos-8641642	19	35	.	.	PUNCT
bjos-8641642	20	1	cytokines	cytokine	NOUN
bjos-8641642	20	2	are	be	AUX
bjos-8641642	20	3	regulatory	regulatory	ADJ
bjos-8641642	20	4	compounds	compound	NOUN
bjos-8641642	20	5	produced	produce	VERB
bjos-8641642	20	6	by	by	ADP
bjos-8641642	20	7	cells	cell	NOUN
bjos-8641642	20	8	of	of	ADP
bjos-8641642	20	9	the	the	DET
bjos-8641642	20	10	immune	immune	ADJ
bjos-8641642	20	11	system	system	NOUN
bjos-8641642	21	1	[	[	X
bjos-8641642	21	2	t(h)1	t(h)1	NOUN
bjos-8641642	21	3	and	and	CCONJ
bjos-8641642	21	4	t(h)2	t(h)2	NOUN
bjos-8641642	21	5	]	]	PUNCT
bjos-8641642	21	6	and	and	CCONJ
bjos-8641642	21	7	act	act	VERB
bjos-8641642	21	8	as	as	ADP
bjos-8641642	21	9	intracellular	intracellular	ADJ
bjos-8641642	21	10	mediators	mediator	NOUN
bjos-8641642	21	11	and	and	CCONJ
bjos-8641642	21	12	control	control	VERB
bjos-8641642	21	13	the	the	DET
bjos-8641642	21	14	immune	immune	ADJ
bjos-8641642	21	15	and	and	CCONJ
bjos-8641642	21	16	inflammatory	inflammatory	ADJ
bjos-8641642	21	17	reponses9	reponses9	NOUN
bjos-8641642	21	18	.	.	PUNCT
bjos-8641642	22	1	t(h)1	t(h)1	NOUN
bjos-8641642	22	2	control	control	VERB
bjos-8641642	22	3	the	the	DET
bjos-8641642	22	4	cell	cell	NOUN
bjos-8641642	22	5	-	-	PUNCT
bjos-8641642	22	6	mediated	mediate	VERB
bjos-8641642	22	7	response	response	NOUN
bjos-8641642	22	8	and	and	CCONJ
bjos-8641642	22	9	produce	produce	VERB
bjos-8641642	22	10	a	a	DET
bjos-8641642	22	11	number	number	NOUN
bjos-8641642	22	12	of	of	ADP
bjos-8641642	22	13	proinflammatory	proinflammatory	ADJ
bjos-8641642	22	14	cytokines	cytokine	NOUN
bjos-8641642	22	15	,	,	PUNCT
bjos-8641642	22	16	e.g.	e.g.	ADV
bjos-8641642	22	17	il-1	il-1	ADP
bjos-8641642	22	18	,	,	PUNCT
bjos-8641642	22	19	il-2	il-2	NUM
bjos-8641642	22	20	,	,	PUNCT
bjos-8641642	22	21	il-6	il-6	NUM
bjos-8641642	22	22	and	and	CCONJ
bjos-8641642	22	23	tnf	tnf	PROPN
bjos-8641642	22	24	-	-	PUNCT
bjos-8641642	22	25	α	α	PROPN
bjos-8641642	22	26	which	which	PRON
bjos-8641642	22	27	are	be	AUX
bjos-8641642	22	28	counterbalanced	counterbalance	VERB
bjos-8641642	22	29	by	by	ADP
bjos-8641642	22	30	a	a	DET
bjos-8641642	22	31	number	number	NOUN
bjos-8641642	22	32	of	of	ADP
bjos-8641642	22	33	received	receive	VERB
bjos-8641642	22	34	for	for	ADP
bjos-8641642	22	35	publication	publication	NOUN
bjos-8641642	22	36	:	:	PUNCT
bjos-8641642	22	37	january	january	PROPN
bjos-8641642	22	38	01	01	NUM
bjos-8641642	22	39	,	,	PUNCT
bjos-8641642	22	40	2011	2011	NUM
bjos-8641642	22	41	accepted	accept	VERB
bjos-8641642	22	42	:	:	PUNCT
bjos-8641642	22	43	april	april	PROPN
bjos-8641642	22	44	20	20	NUM
bjos-8641642	22	45	,	,	PUNCT
bjos-8641642	22	46	2011	2011	NUM
bjos-8641642	22	47	84	84	NUM
bjos-8641642	22	48	braz	braz	PROPN
bjos-8641642	22	49	j	j	PROPN
bjos-8641642	22	50	oral	oral	PROPN
bjos-8641642	22	51	sci	sci	PROPN
bjos-8641642	22	52	.	.	PUNCT
bjos-8641642	23	1	10(2):83	10(2):83	NUM
bjos-8641642	23	2	-	-	SYM
bjos-8641642	23	3	87	87	NUM
bjos-8641642	23	4	antiinflammatory	antiinflammatory	NOUN
bjos-8641642	23	5	cytokines	cytokine	NOUN
bjos-8641642	23	6	,	,	PUNCT
bjos-8641642	23	7	e.g.	e.g.	ADV
bjos-8641642	23	8	il-4	il-4	PRON
bjos-8641642	23	9	and	and	CCONJ
bjos-8641642	23	10	il-10	il-10	NOUN
bjos-8641642	23	11	that	that	PRON
bjos-8641642	23	12	are	be	AUX
bjos-8641642	23	13	produced	produce	VERB
bjos-8641642	23	14	by	by	ADP
bjos-8641642	23	15	t(h)2	t(h)2	NOUN
bjos-8641642	23	16	that	that	PRON
bjos-8641642	23	17	participate	participate	VERB
bjos-8641642	23	18	in	in	ADP
bjos-8641642	23	19	humoral	humoral	ADJ
bjos-8641642	23	20	response	response	NOUN
bjos-8641642	23	21	and	and	CCONJ
bjos-8641642	23	22	antibody	antibody	NOUN
bjos-8641642	23	23	production	production	NOUN
bjos-8641642	23	24	.	.	PUNCT
bjos-8641642	24	1	recent	recent	ADJ
bjos-8641642	24	2	studies	study	NOUN
bjos-8641642	24	3	point	point	VERB
bjos-8641642	24	4	out	out	ADP
bjos-8641642	24	5	at	at	ADP
bjos-8641642	24	6	proinflammatory	proinflammatory	ADJ
bjos-8641642	24	7	cytokines	cytokine	NOUN
bjos-8641642	24	8	such	such	ADJ
bjos-8641642	24	9	as	as	ADP
bjos-8641642	24	10	tnf	tnf	PROPN
bjos-8641642	24	11	-	-	PUNCT
bjos-8641642	24	12	α	α	PROPN
bjos-8641642	24	13	,	,	PUNCT
bjos-8641642	24	14	il-1	il-1	ADP
bjos-8641642	24	15	,	,	PUNCT
bjos-8641642	24	16	or	or	CCONJ
bjos-8641642	24	17	il-6	il-6	NOUN
bjos-8641642	24	18	as	as	ADP
bjos-8641642	24	19	strong	strong	ADJ
bjos-8641642	24	20	players	player	NOUN
bjos-8641642	24	21	involved	involve	VERB
bjos-8641642	24	22	in	in	ADP
bjos-8641642	24	23	this	this	DET
bjos-8641642	24	24	process13	process13	NOUN
bjos-8641642	24	25	.	.	PUNCT
bjos-8641642	25	1	moreover	moreover	ADV
bjos-8641642	25	2	,	,	PUNCT
bjos-8641642	25	3	experimental	experimental	ADJ
bjos-8641642	25	4	studies	study	NOUN
bjos-8641642	25	5	revealed	reveal	VERB
bjos-8641642	25	6	that	that	SCONJ
bjos-8641642	25	7	synergistic	synergistic	ADJ
bjos-8641642	25	8	cooperation	cooperation	NOUN
bjos-8641642	25	9	of	of	ADP
bjos-8641642	25	10	pemphigus	pemphigus	PROPN
bjos-8641642	25	11	antibodies	antibody	NOUN
bjos-8641642	25	12	with	with	ADP
bjos-8641642	25	13	il-6	il-6	PRON
bjos-8641642	25	14	and	and	CCONJ
bjos-8641642	25	15	tnf	tnf	PROPN
bjos-8641642	25	16	-	-	PUNCT
bjos-8641642	25	17	α	α	PROPN
bjos-8641642	25	18	in	in	ADP
bjos-8641642	25	19	the	the	DET
bjos-8641642	25	20	pathogenesis	pathogenesis	NOUN
bjos-8641642	25	21	of	of	ADP
bjos-8641642	25	22	pv	pv	INTJ
bjos-8641642	25	23	.	.	PUNCT
bjos-8641642	26	1	there	there	PRON
bjos-8641642	26	2	is	be	VERB
bjos-8641642	26	3	a	a	DET
bjos-8641642	26	4	fairly	fairly	ADV
bjos-8641642	26	5	strong	strong	ADJ
bjos-8641642	26	6	genetic	genetic	ADJ
bjos-8641642	26	7	background	background	NOUN
bjos-8641642	26	8	to	to	ADP
bjos-8641642	26	9	pemphigus	pemphigus	NOUN
bjos-8641642	26	10	vulgaris	vulgaris	NOUN
bjos-8641642	26	11	with	with	ADP
bjos-8641642	26	12	linkage	linkage	NOUN
bjos-8641642	26	13	to	to	ADP
bjos-8641642	26	14	hla	hla	PROPN
bjos-8641642	26	15	class	class	PROPN
bjos-8641642	26	16	ii	ii	PROPN
bjos-8641642	26	17	alleles	allele	NOUN
bjos-8641642	26	18	.	.	PUNCT
bjos-8641642	27	1	certain	certain	ADJ
bjos-8641642	27	2	ethnic	ethnic	ADJ
bjos-8641642	27	3	groups	group	NOUN
bjos-8641642	27	4	,	,	PUNCT
bjos-8641642	27	5	such	such	ADJ
bjos-8641642	27	6	as	as	ADP
bjos-8641642	27	7	ashkenazi	ashkenazi	ADJ
bjos-8641642	27	8	jews	jews	PROPN
bjos-8641642	27	9	and	and	CCONJ
bjos-8641642	27	10	those	those	PRON
bjos-8641642	27	11	of	of	ADP
bjos-8641642	27	12	mediterranean	mediterranean	PROPN
bjos-8641642	27	13	and	and	CCONJ
bjos-8641642	27	14	south	south	ADJ
bjos-8641642	27	15	asian	asian	ADJ
bjos-8641642	27	16	origin	origin	NOUN
bjos-8641642	27	17	are	be	AUX
bjos-8641642	27	18	especially	especially	ADV
bjos-8641642	27	19	liable	liable	ADJ
bjos-8641642	27	20	to	to	ADP
bjos-8641642	27	21	pv14	pv14	PROPN
bjos-8641642	27	22	-	-	PUNCT
bjos-8641642	27	23	15	15	NUM
bjos-8641642	27	24	.	.	PUNCT
bjos-8641642	28	1	no	no	DET
bjos-8641642	28	2	data	datum	NOUN
bjos-8641642	28	3	are	be	AUX
bjos-8641642	28	4	currently	currently	ADV
bjos-8641642	28	5	available	available	ADJ
bjos-8641642	28	6	on	on	ADP
bjos-8641642	28	7	the	the	DET
bjos-8641642	28	8	cytokine	cytokine	NOUN
bjos-8641642	28	9	levels	level	NOUN
bjos-8641642	28	10	in	in	ADP
bjos-8641642	28	11	the	the	DET
bjos-8641642	28	12	sera	sera	NOUN
bjos-8641642	28	13	of	of	ADP
bjos-8641642	28	14	egyptian	egyptian	ADJ
bjos-8641642	28	15	patients	patient	NOUN
bjos-8641642	28	16	with	with	ADP
bjos-8641642	28	17	oral	oral	ADJ
bjos-8641642	28	18	vp	vp	NOUN
bjos-8641642	28	19	.	.	PUNCT
bjos-8641642	29	1	in	in	ADP
bjos-8641642	29	2	the	the	DET
bjos-8641642	29	3	present	present	ADJ
bjos-8641642	29	4	study	study	NOUN
bjos-8641642	29	5	,	,	PUNCT
bjos-8641642	29	6	we	we	PRON
bjos-8641642	29	7	measured	measure	VERB
bjos-8641642	29	8	the	the	DET
bjos-8641642	29	9	serum	serum	NOUN
bjos-8641642	29	10	levels	level	NOUN
bjos-8641642	29	11	of	of	ADP
bjos-8641642	29	12	some	some	DET
bjos-8641642	29	13	proinflammatory	proinflammatory	ADJ
bjos-8641642	29	14	cytokines	cytokine	NOUN
bjos-8641642	29	15	(	(	PUNCT
bjos-8641642	29	16	il-2	il-2	NUM
bjos-8641642	29	17	,	,	PUNCT
bjos-8641642	29	18	il-6	il-6	NUM
bjos-8641642	29	19	,	,	PUNCT
bjos-8641642	29	20	tnf	tnf	PROPN
bjos-8641642	29	21	-	-	PUNCT
bjos-8641642	29	22	α	α	NOUN
bjos-8641642	29	23	)	)	PUNCT
bjos-8641642	29	24	and	and	CCONJ
bjos-8641642	29	25	the	the	DET
bjos-8641642	29	26	antiinflammatory	antiinflammatory	NOUN
bjos-8641642	29	27	cytokine	cytokine	NOUN
bjos-8641642	29	28	il-4	il-4	X
bjos-8641642	29	29	in	in	ADP
bjos-8641642	29	30	egyptian	egyptian	ADJ
bjos-8641642	29	31	patients	patient	NOUN
bjos-8641642	29	32	with	with	ADP
bjos-8641642	29	33	oral	oral	ADJ
bjos-8641642	29	34	pv	pv	NOUN
bjos-8641642	29	35	,	,	PUNCT
bjos-8641642	29	36	in	in	ADP
bjos-8641642	29	37	comparison	comparison	NOUN
bjos-8641642	29	38	to	to	ADP
bjos-8641642	29	39	healthy	healthy	ADJ
bjos-8641642	29	40	controls	control	NOUN
bjos-8641642	29	41	.	.	PUNCT
bjos-8641642	30	1	material	material	NOUN
bjos-8641642	30	2	and	and	CCONJ
bjos-8641642	30	3	methods	method	NOUN
bjos-8641642	30	4	all	all	DET
bjos-8641642	30	5	participants	participant	NOUN
bjos-8641642	30	6	were	be	AUX
bjos-8641642	30	7	recruited	recruit	VERB
bjos-8641642	30	8	from	from	ADP
bjos-8641642	30	9	the	the	DET
bjos-8641642	30	10	outpatient	outpatient	NOUN
bjos-8641642	30	11	clinics	clinic	NOUN
bjos-8641642	30	12	of	of	ADP
bjos-8641642	30	13	the	the	DET
bjos-8641642	30	14	department	department	NOUN
bjos-8641642	30	15	of	of	ADP
bjos-8641642	30	16	skin	skin	NOUN
bjos-8641642	30	17	and	and	CCONJ
bjos-8641642	30	18	venereal	venereal	ADJ
bjos-8641642	30	19	diseases	disease	NOUN
bjos-8641642	30	20	,	,	PUNCT
bjos-8641642	30	21	faculty	faculty	NOUN
bjos-8641642	30	22	of	of	ADP
bjos-8641642	30	23	medicine	medicine	NOUN
bjos-8641642	30	24	,	,	PUNCT
bjos-8641642	30	25	and	and	CCONJ
bjos-8641642	30	26	the	the	DET
bjos-8641642	30	27	department	department	NOUN
bjos-8641642	30	28	of	of	ADP
bjos-8641642	30	29	oral	oral	ADJ
bjos-8641642	30	30	medicine	medicine	NOUN
bjos-8641642	30	31	,	,	PUNCT
bjos-8641642	30	32	oral	oral	ADJ
bjos-8641642	30	33	diagnosis	diagnosis	NOUN
bjos-8641642	30	34	,	,	PUNCT
bjos-8641642	30	35	and	and	CCONJ
bjos-8641642	30	36	periodontology	periodontology	NOUN
bjos-8641642	30	37	,	,	PUNCT
bjos-8641642	30	38	faculty	faculty	NOUN
bjos-8641642	30	39	of	of	ADP
bjos-8641642	30	40	dentistry	dentistry	NOUN
bjos-8641642	30	41	,	,	PUNCT
bjos-8641642	30	42	suez	suez	PROPN
bjos-8641642	30	43	canal	canal	PROPN
bjos-8641642	30	44	university	university	PROPN
bjos-8641642	30	45	,	,	PUNCT
bjos-8641642	30	46	egypt	egypt	PROPN
bjos-8641642	30	47	.	.	PUNCT
bjos-8641642	31	1	ten	ten	NUM
bjos-8641642	31	2	patients	patient	NOUN
bjos-8641642	31	3	with	with	ADP
bjos-8641642	31	4	oral	oral	ADJ
bjos-8641642	31	5	pv	pv	NOUN
bjos-8641642	31	6	and	and	CCONJ
bjos-8641642	31	7	10	10	NUM
bjos-8641642	31	8	healthy	healthy	ADJ
bjos-8641642	31	9	controls	control	NOUN
bjos-8641642	31	10	were	be	AUX
bjos-8641642	31	11	enrolled	enrol	VERB
bjos-8641642	31	12	in	in	ADP
bjos-8641642	31	13	the	the	DET
bjos-8641642	31	14	study	study	NOUN
bjos-8641642	31	15	after	after	ADP
bjos-8641642	31	16	ethical	ethical	ADJ
bjos-8641642	31	17	approval	approval	NOUN
bjos-8641642	31	18	by	by	ADP
bjos-8641642	31	19	the	the	DET
bjos-8641642	31	20	suez	suez	PROPN
bjos-8641642	31	21	canal	canal	PROPN
bjos-8641642	31	22	university	university	PROPN
bjos-8641642	31	23	.	.	PUNCT
bjos-8641642	32	1	a	a	DET
bjos-8641642	32	2	written	write	VERB
bjos-8641642	32	3	informed	inform	VERB
bjos-8641642	32	4	consent	consent	NOUN
bjos-8641642	32	5	was	be	AUX
bjos-8641642	32	6	taken	take	VERB
bjos-8641642	32	7	from	from	ADP
bjos-8641642	32	8	all	all	DET
bjos-8641642	32	9	participants	participant	NOUN
bjos-8641642	32	10	prior	prior	ADV
bjos-8641642	32	11	to	to	ADP
bjos-8641642	32	12	enrollment	enrollment	NOUN
bjos-8641642	32	13	.	.	PUNCT
bjos-8641642	33	1	the	the	DET
bjos-8641642	33	2	group	group	NOUN
bjos-8641642	33	3	of	of	ADP
bjos-8641642	33	4	patients	patient	NOUN
bjos-8641642	33	5	with	with	ADP
bjos-8641642	33	6	oral	oral	ADJ
bjos-8641642	33	7	pv	pv	NOUN
bjos-8641642	33	8	consisted	consist	VERB
bjos-8641642	33	9	of	of	ADP
bjos-8641642	33	10	6	6	NUM
bjos-8641642	33	11	males	male	NOUN
bjos-8641642	33	12	and	and	CCONJ
bjos-8641642	33	13	4	4	NUM
bjos-8641642	33	14	females	female	NOUN
bjos-8641642	33	15	with	with	ADP
bjos-8641642	33	16	mean	mean	ADJ
bjos-8641642	33	17	age	age	NOUN
bjos-8641642	33	18	of	of	ADP
bjos-8641642	33	19	50.6	50.6	NUM
bjos-8641642	33	20	years	year	NOUN
bjos-8641642	33	21	(	(	PUNCT
bjos-8641642	33	22	range	range	NOUN
bjos-8641642	33	23	:	:	PUNCT
bjos-8641642	33	24	45	45	NUM
bjos-8641642	33	25	-	-	SYM
bjos-8641642	33	26	60	60	NUM
bjos-8641642	33	27	years	year	NOUN
bjos-8641642	33	28	)	)	PUNCT
bjos-8641642	33	29	.	.	PUNCT
bjos-8641642	34	1	the	the	DET
bjos-8641642	34	2	selection	selection	NOUN
bjos-8641642	34	3	and	and	CCONJ
bjos-8641642	34	4	diagnosis	diagnosis	NOUN
bjos-8641642	34	5	of	of	ADP
bjos-8641642	34	6	patients	patient	NOUN
bjos-8641642	34	7	was	be	AUX
bjos-8641642	34	8	based	base	VERB
bjos-8641642	34	9	on	on	ADP
bjos-8641642	34	10	the	the	DET
bjos-8641642	34	11	history	history	NOUN
bjos-8641642	34	12	,	,	PUNCT
bjos-8641642	34	13	clinical	clinical	ADJ
bjos-8641642	34	14	characteristics	characteristic	NOUN
bjos-8641642	34	15	of	of	ADP
bjos-8641642	34	16	oral	oral	ADJ
bjos-8641642	34	17	pv	pv	NOUN
bjos-8641642	34	18	lesions	lesion	NOUN
bjos-8641642	34	19	,	,	PUNCT
bjos-8641642	34	20	the	the	DET
bjos-8641642	34	21	histopathological	histopathological	ADJ
bjos-8641642	34	22	specimens	specimen	NOUN
bjos-8641642	34	23	and	and	CCONJ
bjos-8641642	34	24	the	the	DET
bjos-8641642	34	25	indirect	indirect	ADJ
bjos-8641642	34	26	immunofluorescence	immunofluorescence	NOUN
bjos-8641642	34	27	testing6	testing6	NOUN
bjos-8641642	34	28	of	of	ADP
bjos-8641642	34	29	pv	pv	INTJ
bjos-8641642	34	30	.	.	PUNCT
bjos-8641642	35	1	the	the	DET
bjos-8641642	35	2	duration	duration	NOUN
bjos-8641642	35	3	of	of	ADP
bjos-8641642	35	4	oral	oral	ADJ
bjos-8641642	35	5	pv	pv	NOUN
bjos-8641642	35	6	lesions	lesion	NOUN
bjos-8641642	35	7	ranged	range	VERB
bjos-8641642	35	8	from	from	ADP
bjos-8641642	35	9	1	1	NUM
bjos-8641642	35	10	-	-	SYM
bjos-8641642	35	11	3	3	NUM
bjos-8641642	35	12	years	year	NOUN
bjos-8641642	35	13	.	.	PUNCT
bjos-8641642	36	1	none	none	NOUN
bjos-8641642	36	2	of	of	ADP
bjos-8641642	36	3	the	the	DET
bjos-8641642	36	4	patients	patient	NOUN
bjos-8641642	36	5	had	have	AUX
bjos-8641642	36	6	received	receive	VERB
bjos-8641642	36	7	any	any	DET
bjos-8641642	36	8	topical	topical	ADJ
bjos-8641642	36	9	and/or	and/or	CCONJ
bjos-8641642	36	10	systemic	systemic	ADJ
bjos-8641642	36	11	treatment	treatment	NOUN
bjos-8641642	36	12	for	for	ADP
bjos-8641642	36	13	the	the	DET
bjos-8641642	36	14	present	present	ADJ
bjos-8641642	36	15	illness	illness	NOUN
bjos-8641642	36	16	at	at	ADV
bjos-8641642	36	17	least	least	ADV
bjos-8641642	36	18	1	1	NUM
bjos-8641642	36	19	month	month	NOUN
bjos-8641642	36	20	prior	prior	ADV
bjos-8641642	36	21	to	to	AUX
bjos-8641642	36	22	study	study	VERB
bjos-8641642	36	23	.	.	PUNCT
bjos-8641642	37	1	the	the	DET
bjos-8641642	37	2	control	control	PROPN
bjos-8641642	37	3	group	group	NOUN
bjos-8641642	37	4	consisted	consist	VERB
bjos-8641642	37	5	of	of	ADP
bjos-8641642	37	6	6	6	NUM
bjos-8641642	37	7	males	male	NOUN
bjos-8641642	37	8	and	and	CCONJ
bjos-8641642	37	9	4	4	NUM
bjos-8641642	37	10	females	female	NOUN
bjos-8641642	37	11	with	with	ADP
bjos-8641642	37	12	mean	mean	ADJ
bjos-8641642	37	13	age	age	NOUN
bjos-8641642	37	14	of	of	ADP
bjos-8641642	37	15	48.4	48.4	NUM
bjos-8641642	37	16	years	year	NOUN
bjos-8641642	37	17	(	(	PUNCT
bjos-8641642	37	18	range	range	NOUN
bjos-8641642	37	19	:	:	PUNCT
bjos-8641642	37	20	40	40	NUM
bjos-8641642	37	21	-	-	SYM
bjos-8641642	37	22	53	53	NUM
bjos-8641642	37	23	years	year	NOUN
bjos-8641642	37	24	)	)	PUNCT
bjos-8641642	37	25	.	.	PUNCT
bjos-8641642	38	1	they	they	PRON
bjos-8641642	38	2	were	be	AUX
bjos-8641642	38	3	healthy	healthy	ADJ
bjos-8641642	38	4	volunteers	volunteer	NOUN
bjos-8641642	38	5	completely	completely	ADV
bjos-8641642	38	6	free	free	ADJ
bjos-8641642	38	7	from	from	ADP
bjos-8641642	38	8	any	any	DET
bjos-8641642	38	9	local	local	ADJ
bjos-8641642	38	10	or	or	CCONJ
bjos-8641642	38	11	systemic	systemic	ADJ
bjos-8641642	38	12	diseases	disease	NOUN
bjos-8641642	38	13	who	who	PRON
bjos-8641642	38	14	were	be	AUX
bjos-8641642	38	15	not	not	PART
bjos-8641642	38	16	taking	take	VERB
bjos-8641642	38	17	any	any	DET
bjos-8641642	38	18	medication	medication	NOUN
bjos-8641642	38	19	or	or	CCONJ
bjos-8641642	38	20	contraceptives	contraceptive	NOUN
bjos-8641642	38	21	(	(	PUNCT
bjos-8641642	38	22	in	in	ADP
bjos-8641642	38	23	females	female	NOUN
bjos-8641642	38	24	)	)	PUNCT
bjos-8641642	38	25	.	.	PUNCT
bjos-8641642	39	1	serum	serum	NOUN
bjos-8641642	39	2	samples	sample	NOUN
bjos-8641642	39	3	were	be	AUX
bjos-8641642	39	4	collected	collect	VERB
bjos-8641642	39	5	from	from	ADP
bjos-8641642	39	6	the	the	DET
bjos-8641642	39	7	individuals	individual	NOUN
bjos-8641642	39	8	of	of	ADP
bjos-8641642	39	9	the	the	DET
bjos-8641642	39	10	two	two	NUM
bjos-8641642	39	11	groups	group	NOUN
bjos-8641642	39	12	and	and	CCONJ
bjos-8641642	39	13	used	use	VERB
bjos-8641642	39	14	to	to	PART
bjos-8641642	39	15	measure	measure	VERB
bjos-8641642	39	16	the	the	DET
bjos-8641642	39	17	levels	level	NOUN
bjos-8641642	39	18	of	of	ADP
bjos-8641642	39	19	the	the	DET
bjos-8641642	39	20	cytokines	cytokine	NOUN
bjos-8641642	39	21	tnf	tnf	PROPN
bjos-8641642	39	22	-	-	PUNCT
bjos-8641642	39	23	α	α	PROPN
bjos-8641642	39	24	,	,	PUNCT
bjos-8641642	39	25	il-2	il-2	NUM
bjos-8641642	39	26	,	,	PUNCT
bjos-8641642	39	27	il-4	il-4	NOUN
bjos-8641642	39	28	and	and	CCONJ
bjos-8641642	39	29	il-6	il-6	NOUN
bjos-8641642	39	30	using	use	VERB
bjos-8641642	39	31	commercially	commercially	ADV
bjos-8641642	39	32	available	available	ADJ
bjos-8641642	39	33	elisa	elisa	PROPN
bjos-8641642	39	34	kits	kit	NOUN
bjos-8641642	39	35	(	(	PUNCT
bjos-8641642	39	36	quantikine	quantikine	NOUN
bjos-8641642	39	37	,	,	PUNCT
bjos-8641642	39	38	r	r	NOUN
bjos-8641642	39	39	&	&	CCONJ
bjos-8641642	39	40	d	d	PROPN
bjos-8641642	39	41	,	,	PUNCT
bjos-8641642	39	42	minneapolis	minneapolis	PROPN
bjos-8641642	39	43	,	,	PUNCT
bjos-8641642	39	44	mn	mn	PROPN
bjos-8641642	39	45	,	,	PUNCT
bjos-8641642	39	46	usa	usa	PROPN
bjos-8641642	39	47	)	)	PUNCT
bjos-8641642	39	48	,	,	PUNCT
bjos-8641642	39	49	according	accord	VERB
bjos-8641642	39	50	to	to	ADP
bjos-8641642	39	51	manufacturer	manufacturer	NOUN
bjos-8641642	39	52	’s	’s	PART
bjos-8641642	39	53	procedure	procedure	NOUN
bjos-8641642	39	54	.	.	PUNCT
bjos-8641642	40	1	all	all	DET
bjos-8641642	40	2	results	result	NOUN
bjos-8641642	40	3	were	be	AUX
bjos-8641642	40	4	expressed	express	VERB
bjos-8641642	40	5	as	as	ADP
bjos-8641642	40	6	mean	mean	NOUN
bjos-8641642	40	7	±	±	NUM
bjos-8641642	40	8	sd	sd	NOUN
bjos-8641642	40	9	.	.	PUNCT
bjos-8641642	41	1	differences	difference	NOUN
bjos-8641642	41	2	between	between	ADP
bjos-8641642	41	3	two	two	NUM
bjos-8641642	41	4	means	mean	NOUN
bjos-8641642	41	5	were	be	AUX
bjos-8641642	41	6	analyzed	analyze	VERB
bjos-8641642	41	7	by	by	ADP
bjos-8641642	41	8	student	student	NOUN
bjos-8641642	41	9	’s	’s	PART
bjos-8641642	41	10	t	t	PROPN
bjos-8641642	41	11	-	-	PUNCT
bjos-8641642	41	12	test	test	NOUN
bjos-8641642	41	13	.	.	PUNCT
bjos-8641642	42	1	p	p	NOUN
bjos-8641642	42	2	values	value	NOUN
bjos-8641642	42	3	equal	equal	ADJ
bjos-8641642	42	4	or	or	CCONJ
bjos-8641642	42	5	less	less	ADJ
bjos-8641642	42	6	than	than	ADP
bjos-8641642	42	7	0.05	0.05	NUM
bjos-8641642	42	8	were	be	AUX
bjos-8641642	42	9	considered	consider	VERB
bjos-8641642	42	10	as	as	ADP
bjos-8641642	42	11	significant	significant	ADJ
bjos-8641642	42	12	.	.	PUNCT
bjos-8641642	43	1	results	result	VERB
bjos-8641642	43	2	the	the	DET
bjos-8641642	43	3	most	most	ADV
bjos-8641642	43	4	common	common	ADJ
bjos-8641642	43	5	sites	site	NOUN
bjos-8641642	43	6	of	of	ADP
bjos-8641642	43	7	oral	oral	ADJ
bjos-8641642	43	8	pv	pv	NOUN
bjos-8641642	43	9	lesions	lesion	NOUN
bjos-8641642	43	10	found	find	VERB
bjos-8641642	43	11	in	in	ADP
bjos-8641642	43	12	the	the	DET
bjos-8641642	43	13	present	present	ADJ
bjos-8641642	43	14	study	study	NOUN
bjos-8641642	43	15	were	be	AUX
bjos-8641642	43	16	the	the	DET
bjos-8641642	43	17	lip	lip	NOUN
bjos-8641642	43	18	,	,	PUNCT
bjos-8641642	43	19	buccal	buccal	ADJ
bjos-8641642	43	20	mucosa	mucosa	NOUN
bjos-8641642	43	21	,	,	PUNCT
bjos-8641642	43	22	palatal	palatal	ADJ
bjos-8641642	43	23	,	,	PUNCT
bjos-8641642	43	24	ventral	ventral	ADJ
bjos-8641642	43	25	surface	surface	NOUN
bjos-8641642	43	26	of	of	ADP
bjos-8641642	43	27	tongue	tongue	NOUN
bjos-8641642	43	28	,	,	PUNCT
bjos-8641642	43	29	and	and	CCONJ
bjos-8641642	43	30	gingival	gingival	NOUN
bjos-8641642	43	31	.	.	PUNCT
bjos-8641642	44	1	examples	example	NOUN
bjos-8641642	44	2	of	of	ADP
bjos-8641642	44	3	palatal	palatal	ADJ
bjos-8641642	44	4	mucosa	mucosa	NOUN
bjos-8641642	44	5	and	and	CCONJ
bjos-8641642	44	6	buccal	buccal	ADJ
bjos-8641642	44	7	mucosa	mucosa	NOUN
bjos-8641642	44	8	with	with	ADP
bjos-8641642	44	9	oral	oral	ADJ
bjos-8641642	44	10	lesions	lesion	NOUN
bjos-8641642	44	11	in	in	ADP
bjos-8641642	44	12	patients	patient	NOUN
bjos-8641642	44	13	with	with	ADP
bjos-8641642	44	14	pv	pv	PROPN
bjos-8641642	44	15	are	be	AUX
bjos-8641642	44	16	shown	show	VERB
bjos-8641642	44	17	in	in	ADP
bjos-8641642	44	18	figures	figure	NOUN
bjos-8641642	44	19	1	1	NUM
bjos-8641642	44	20	and	and	CCONJ
bjos-8641642	44	21	2	2	NUM
bjos-8641642	44	22	,	,	PUNCT
bjos-8641642	44	23	respectively	respectively	ADV
bjos-8641642	44	24	.	.	PUNCT
bjos-8641642	45	1	direct	direct	ADJ
bjos-8641642	45	2	immunofluorescence	immunofluorescence	NOUN
bjos-8641642	45	3	testing	testing	NOUN
bjos-8641642	45	4	revealed	reveal	VERB
bjos-8641642	45	5	circulating	circulate	VERB
bjos-8641642	45	6	pemphigus	pemphigus	NOUN
bjos-8641642	45	7	antibodies	antibody	NOUN
bjos-8641642	45	8	in	in	ADP
bjos-8641642	45	9	all	all	DET
bjos-8641642	45	10	patients	patient	NOUN
bjos-8641642	45	11	with	with	ADP
bjos-8641642	45	12	oral	oral	ADJ
bjos-8641642	45	13	pv	pv	NOUN
bjos-8641642	45	14	.	.	PUNCT
bjos-8641642	46	1	figure	figure	NOUN
bjos-8641642	46	2	3	3	NUM
bjos-8641642	46	3	shows	show	VERB
bjos-8641642	46	4	an	an	DET
bjos-8641642	46	5	example	example	NOUN
bjos-8641642	46	6	of	of	ADP
bjos-8641642	46	7	pv	pv	NOUN
bjos-8641642	46	8	with	with	ADP
bjos-8641642	46	9	intercellular	intercellular	ADJ
bjos-8641642	46	10	deposition	deposition	NOUN
bjos-8641642	46	11	of	of	ADP
bjos-8641642	46	12	antibodies	antibody	NOUN
bjos-8641642	46	13	in	in	ADP
bjos-8641642	46	14	stratum	stratum	NOUN
bjos-8641642	46	15	spinosum	spinosum	VERB
bjos-8641642	46	16	.	.	PUNCT
bjos-8641642	47	1	there	there	PRON
bjos-8641642	47	2	was	be	VERB
bjos-8641642	47	3	no	no	DET
bjos-8641642	47	4	statistically	statistically	ADV
bjos-8641642	47	5	significant	significant	ADJ
bjos-8641642	47	6	difference	difference	NOUN
bjos-8641642	47	7	(	(	PUNCT
bjos-8641642	47	8	p>0.05	p>0.05	NOUN
bjos-8641642	47	9	)	)	PUNCT
bjos-8641642	47	10	between	between	ADP
bjos-8641642	47	11	patients	patient	NOUN
bjos-8641642	47	12	with	with	ADP
bjos-8641642	47	13	oral	oral	ADJ
bjos-8641642	47	14	pv	pv	NOUN
bjos-8641642	47	15	and	and	CCONJ
bjos-8641642	47	16	controls	control	VERB
bjos-8641642	47	17	with	with	ADP
bjos-8641642	47	18	respect	respect	NOUN
bjos-8641642	47	19	to	to	ADP
bjos-8641642	47	20	the	the	DET
bjos-8641642	47	21	mean	mean	ADJ
bjos-8641642	47	22	age	age	NOUN
bjos-8641642	47	23	.	.	PUNCT
bjos-8641642	48	1	table	table	NOUN
bjos-8641642	48	2	1	1	NUM
bjos-8641642	48	3	shows	show	VERB
bjos-8641642	48	4	serum	serum	PROPN
bjos-8641642	48	5	cytokines	cytokine	NOUN
bjos-8641642	48	6	levels	level	NOUN
bjos-8641642	48	7	(	(	PUNCT
bjos-8641642	48	8	pg	pg	NOUN
bjos-8641642	48	9	/	/	SYM
bjos-8641642	48	10	ml	ml	NOUN
bjos-8641642	48	11	)	)	PUNCT
bjos-8641642	48	12	of	of	ADP
bjos-8641642	48	13	tnfα	tnfα	NOUN
bjos-8641642	48	14	,	,	PUNCT
bjos-8641642	48	15	il-2	il-2	PROPN
bjos-8641642	48	16	,	,	PUNCT
bjos-8641642	48	17	il-4	il-4	PRON
bjos-8641642	48	18	,	,	PUNCT
bjos-8641642	48	19	and	and	CCONJ
bjos-8641642	48	20	il-6	il-6	NOUN
bjos-8641642	48	21	in	in	ADP
bjos-8641642	48	22	patients	patient	NOUN
bjos-8641642	48	23	with	with	ADP
bjos-8641642	48	24	oral	oral	ADJ
bjos-8641642	48	25	pv	pv	NOUN
bjos-8641642	48	26	and	and	CCONJ
bjos-8641642	48	27	controls	control	NOUN
bjos-8641642	48	28	.	.	PUNCT
bjos-8641642	49	1	in	in	ADP
bjos-8641642	49	2	comparison	comparison	NOUN
bjos-8641642	49	3	with	with	ADP
bjos-8641642	49	4	controls	control	NOUN
bjos-8641642	49	5	,	,	PUNCT
bjos-8641642	49	6	patients	patient	NOUN
bjos-8641642	49	7	with	with	ADP
bjos-8641642	49	8	oral	oral	ADJ
bjos-8641642	49	9	pv	pv	NOUN
bjos-8641642	49	10	had	have	VERB
bjos-8641642	49	11	640	640	NUM
bjos-8641642	49	12	%	%	NOUN
bjos-8641642	49	13	and	and	CCONJ
bjos-8641642	49	14	179	179	NUM
bjos-8641642	49	15	%	%	NOUN
bjos-8641642	49	16	higher	high	ADJ
bjos-8641642	49	17	mean	mean	PROPN
bjos-8641642	49	18	tnf	tnf	PROPN
bjos-8641642	49	19	-	-	PUNCT
bjos-8641642	49	20	α	α	PROPN
bjos-8641642	49	21	and	and	CCONJ
bjos-8641642	49	22	il-6	il-6	NOUN
bjos-8641642	49	23	levels	level	NOUN
bjos-8641642	49	24	(	(	PUNCT
bjos-8641642	49	25	p<0.001	p<0.001	X
bjos-8641642	49	26	and	and	CCONJ
bjos-8641642	49	27	p<0.001	p<0.001	PROPN
bjos-8641642	49	28	)	)	PUNCT
bjos-8641642	49	29	,	,	PUNCT
bjos-8641642	49	30	respectively	respectively	ADV
bjos-8641642	49	31	.	.	PUNCT
bjos-8641642	50	1	on	on	ADP
bjos-8641642	50	2	the	the	DET
bjos-8641642	50	3	other	other	ADJ
bjos-8641642	50	4	hand	hand	NOUN
bjos-8641642	50	5	,	,	PUNCT
bjos-8641642	50	6	there	there	PRON
bjos-8641642	50	7	were	be	VERB
bjos-8641642	50	8	no	no	DET
bjos-8641642	50	9	significant	significant	ADJ
bjos-8641642	50	10	differences	difference	NOUN
bjos-8641642	50	11	in	in	ADP
bjos-8641642	50	12	the	the	DET
bjos-8641642	50	13	levels	level	NOUN
bjos-8641642	50	14	of	of	ADP
bjos-8641642	50	15	il-2	il-2	NUM
bjos-8641642	50	16	and	and	CCONJ
bjos-8641642	50	17	il-4	il-4	NOUN
bjos-8641642	50	18	of	of	ADP
bjos-8641642	50	19	patients	patient	NOUN
bjos-8641642	50	20	with	with	ADP
bjos-8641642	50	21	oral	oral	ADJ
bjos-8641642	50	22	pv	pv	NOUN
bjos-8641642	50	23	compared	compare	VERB
bjos-8641642	50	24	with	with	ADP
bjos-8641642	50	25	controls	control	NOUN
bjos-8641642	50	26	(	(	PUNCT
bjos-8641642	50	27	p>0.05	p>0.05	NOUN
bjos-8641642	50	28	and	and	CCONJ
bjos-8641642	50	29	p>0.05	p>0.05	PROPN
bjos-8641642	50	30	)	)	PUNCT
bjos-8641642	50	31	,	,	PUNCT
bjos-8641642	50	32	showing	show	VERB
bjos-8641642	50	33	only	only	ADV
bjos-8641642	50	34	1	1	NUM
bjos-8641642	50	35	%	%	NOUN
bjos-8641642	50	36	and	and	CCONJ
bjos-8641642	50	37	4	4	NUM
bjos-8641642	50	38	%	%	NOUN
bjos-8641642	50	39	increase	increase	NOUN
bjos-8641642	50	40	,	,	PUNCT
bjos-8641642	50	41	respectively	respectively	ADV
bjos-8641642	50	42	.	.	PUNCT
bjos-8641642	51	1	fig	fig	NOUN
bjos-8641642	51	2	.	.	PUNCT
bjos-8641642	52	1	1	1	NUM
bjos-8641642	52	2	:	:	PUNCT
bjos-8641642	52	3	pemphigus	pemphigus	NOUN
bjos-8641642	52	4	vulgaris	vulgaris	NOUN
bjos-8641642	52	5	oral	oral	ADJ
bjos-8641642	52	6	lesion	lesion	NOUN
bjos-8641642	52	7	(	(	PUNCT
bjos-8641642	52	8	palatal	palatal	ADJ
bjos-8641642	52	9	mucosa	mucosa	NOUN
bjos-8641642	52	10	)	)	PUNCT
bjos-8641642	52	11	fig	fig	NOUN
bjos-8641642	52	12	.	.	PUNCT
bjos-8641642	53	1	2	2	NUM
bjos-8641642	53	2	:	:	PUNCT
bjos-8641642	53	3	pemphigus	pemphigus	NOUN
bjos-8641642	53	4	vulgaris	vulgaris	NOUN
bjos-8641642	53	5	oral	oral	ADJ
bjos-8641642	53	6	lesion	lesion	NOUN
bjos-8641642	53	7	(	(	PUNCT
bjos-8641642	53	8	buccal	buccal	ADJ
bjos-8641642	53	9	mucosa	mucosa	NOUN
bjos-8641642	53	10	)	)	PUNCT
bjos-8641642	53	11	cytokine	cytokine	ADJ
bjos-8641642	53	12	profiles	profile	NOUN
bjos-8641642	53	13	in	in	ADP
bjos-8641642	53	14	the	the	DET
bjos-8641642	53	15	sera	sera	NOUN
bjos-8641642	53	16	of	of	ADP
bjos-8641642	53	17	egyptian	egyptian	ADJ
bjos-8641642	53	18	patients	patient	NOUN
bjos-8641642	53	19	with	with	ADP
bjos-8641642	53	20	oral	oral	ADJ
bjos-8641642	53	21	pemphigus	pemphigus	ADJ
bjos-8641642	53	22	vulgaris	vulgaris	NOUN
bjos-8641642	53	23	cytokines	cytokine	VERB
bjos-8641642	53	24	group	group	NOUN
bjos-8641642	53	25	range	range	NOUN
bjos-8641642	53	26	(	(	PUNCT
bjos-8641642	53	27	pg	pg	NOUN
bjos-8641642	53	28	/	/	SYM
bjos-8641642	53	29	ml	ml	NOUN
bjos-8641642	53	30	)	)	PUNCT
bjos-8641642	53	31	mean	mean	PROPN
bjos-8641642	53	32	±	±	NUM
bjos-8641642	53	33	s.d	s.d	PROPN
bjos-8641642	53	34	.	.	PUNCT
bjos-8641642	54	1	(	(	PUNCT
bjos-8641642	54	2	pg	pg	NOUN
bjos-8641642	54	3	/	/	SYM
bjos-8641642	54	4	ml	ml	NOUN
bjos-8641642	54	5	)	)	PUNCT
bjos-8641642	54	6	student	student	NOUN
bjos-8641642	54	7	’s	’s	PART
bjos-8641642	54	8	t	t	PROPN
bjos-8641642	54	9	test	test	PROPN
bjos-8641642	54	10	tnf	tnf	PROPN
bjos-8641642	54	11	-	-	PUNCT
bjos-8641642	54	12	α	α	PROPN
bjos-8641642	54	13	control	control	NOUN
bjos-8641642	54	14	group	group	NOUN
bjos-8641642	54	15	2.86	2.86	NUM
bjos-8641642	54	16	-	-	SYM
bjos-8641642	54	17	5.33	5.33	NUM
bjos-8641642	54	18	3.83	3.83	NUM
bjos-8641642	54	19	±	±	NUM
bjos-8641642	54	20	0.81	0.81	NUM
bjos-8641642	54	21	*	*	PUNCT
bjos-8641642	54	22	p<0.001	p<0.001	ADJ
bjos-8641642	54	23	pv	pv	NOUN
bjos-8641642	54	24	group	group	NOUN
bjos-8641642	54	25	19.69	19.69	NUM
bjos-8641642	54	26	-	-	SYM
bjos-8641642	54	27	36.90	36.90	NUM
bjos-8641642	54	28	28.35	28.35	NUM
bjos-8641642	54	29	±	±	NUM
bjos-8641642	54	30	5.91	5.91	NUM
bjos-8641642	54	31	il-6	il-6	NOUN
bjos-8641642	54	32	control	control	NOUN
bjos-8641642	54	33	group	group	NOUN
bjos-8641642	54	34	12.70	12.70	NUM
bjos-8641642	54	35	-	-	SYM
bjos-8641642	54	36	21.11	21.11	NUM
bjos-8641642	54	37	17.52	17.52	NUM
bjos-8641642	54	38	±	±	NOUN
bjos-8641642	54	39	2.80	2.80	NUM
bjos-8641642	54	40	*	*	PUNCT
bjos-8641642	54	41	p<0.001	p<0.001	ADJ
bjos-8641642	54	42	pv	pv	PROPN
bjos-8641642	54	43	group	group	NOUN
bjos-8641642	54	44	37.90	37.90	NUM
bjos-8641642	54	45	-	-	SYM
bjos-8641642	54	46	63.74	63.74	NUM
bjos-8641642	54	47	48.91	48.91	NUM
bjos-8641642	54	48	±	±	NUM
bjos-8641642	54	49	8.35	8.35	NUM
bjos-8641642	54	50	il-2	il-2	PROPN
bjos-8641642	54	51	control	control	PROPN
bjos-8641642	54	52	group	group	NOUN
bjos-8641642	54	53	7.32	7.32	NUM
bjos-8641642	54	54	-	-	SYM
bjos-8641642	54	55	12.51	12.51	NUM
bjos-8641642	54	56	9.90	9.90	NUM
bjos-8641642	54	57	±	±	NUM
bjos-8641642	54	58	1.80	1.80	NUM
bjos-8641642	54	59	p>0.05	p>0.05	PROPN
bjos-8641642	54	60	pv	pv	PROPN
bjos-8641642	54	61	group	group	NOUN
bjos-8641642	54	62	7.56	7.56	NUM
bjos-8641642	54	63	-	-	SYM
bjos-8641642	54	64	12.66	12.66	NUM
bjos-8641642	54	65	10.0	10.0	NUM
bjos-8641642	54	66	±	±	NUM
bjos-8641642	54	67	1.83	1.83	NUM
bjos-8641642	54	68	il-4	il-4	NOUN
bjos-8641642	54	69	control	control	NOUN
bjos-8641642	54	70	group	group	PROPN
bjos-8641642	54	71	14.81	14.81	NUM
bjos-8641642	54	72	-	-	SYM
bjos-8641642	54	73	23.60	23.60	NUM
bjos-8641642	54	74	18.93	18.93	NUM
bjos-8641642	54	75	±	±	NUM
bjos-8641642	54	76	2.81	2.81	NUM
bjos-8641642	54	77	p>0.05	p>0.05	PROPN
bjos-8641642	54	78	pv	pv	PROPN
bjos-8641642	54	79	group	group	NOUN
bjos-8641642	54	80	15.20	15.20	NUM
bjos-8641642	54	81	-	-	SYM
bjos-8641642	54	82	23.70	23.70	NUM
bjos-8641642	54	83	19.66	19.66	NUM
bjos-8641642	54	84	±	±	NUM
bjos-8641642	54	85	2.86	2.86	NUM
bjos-8641642	54	86	table	table	NOUN
bjos-8641642	54	87	1	1	NUM
bjos-8641642	54	88	:	:	PUNCT
bjos-8641642	54	89	table	table	NOUN
bjos-8641642	54	90	1	1	NUM
bjos-8641642	54	91	:	:	PUNCT
bjos-8641642	54	92	table	table	NOUN
bjos-8641642	54	93	1	1	NUM
bjos-8641642	54	94	:	:	PUNCT
bjos-8641642	54	95	table	table	NOUN
bjos-8641642	54	96	1	1	NUM
bjos-8641642	54	97	:	:	PUNCT
bjos-8641642	54	98	table	table	NOUN
bjos-8641642	54	99	1	1	NUM
bjos-8641642	54	100	:	:	PUNCT
bjos-8641642	54	101	cytokines	cytokine	VERB
bjos-8641642	54	102	levels	level	NOUN
bjos-8641642	54	103	in	in	ADP
bjos-8641642	54	104	the	the	DET
bjos-8641642	54	105	sera	sera	NOUN
bjos-8641642	54	106	of	of	ADP
bjos-8641642	54	107	patients	patient	NOUN
bjos-8641642	54	108	with	with	ADP
bjos-8641642	54	109	pemphigus	pemphigus	ADJ
bjos-8641642	54	110	vulgaris	vulgaris	NOUN
bjos-8641642	54	111	(	(	PUNCT
bjos-8641642	54	112	pv	pv	NOUN
bjos-8641642	54	113	)	)	PUNCT
bjos-8641642	54	114	(	(	PUNCT
bjos-8641642	54	115	n=10	n=10	NOUN
bjos-8641642	54	116	)	)	PUNCT
bjos-8641642	54	117	and	and	CCONJ
bjos-8641642	54	118	healthy	healthy	ADJ
bjos-8641642	54	119	controls	control	NOUN
bjos-8641642	54	120	(	(	PUNCT
bjos-8641642	54	121	n=10	n=10	NOUN
bjos-8641642	54	122	)	)	PUNCT
bjos-8641642	54	123	.	.	PUNCT
bjos-8641642	55	1	*	*	PUNCT
bjos-8641642	55	2	statistically	statistically	ADV
bjos-8641642	55	3	significant	significant	ADJ
bjos-8641642	55	4	difference	difference	NOUN
bjos-8641642	55	5	between	between	ADP
bjos-8641642	55	6	patients	patient	NOUN
bjos-8641642	55	7	with	with	ADP
bjos-8641642	55	8	pv	pv	NOUN
bjos-8641642	55	9	and	and	CCONJ
bjos-8641642	55	10	healthy	healthy	ADJ
bjos-8641642	55	11	control	control	NOUN
bjos-8641642	55	12	.	.	PUNCT
bjos-8641642	56	1	fig	fig	NOUN
bjos-8641642	56	2	.	.	PUNCT
bjos-8641642	57	1	3	3	NUM
bjos-8641642	57	2	:	:	PUNCT
bjos-8641642	57	3	direct	direct	ADJ
bjos-8641642	57	4	immunofluorescence	immunofluorescence	NOUN
bjos-8641642	57	5	examination	examination	NOUN
bjos-8641642	57	6	of	of	ADP
bjos-8641642	57	7	pemphigus	pemphigus	NOUN
bjos-8641642	57	8	vulgaris	vulgaris	NOUN
bjos-8641642	57	9	showing	show	VERB
bjos-8641642	57	10	intercellular	intercellular	ADJ
bjos-8641642	57	11	deposition	deposition	NOUN
bjos-8641642	57	12	of	of	ADP
bjos-8641642	57	13	antibodies	antibody	NOUN
bjos-8641642	57	14	in	in	ADP
bjos-8641642	57	15	stratum	stratum	NOUN
bjos-8641642	57	16	spinosum	spinosum	VERB
bjos-8641642	57	17	.	.	PUNCT
bjos-8641642	58	1	discussion	discussion	NOUN
bjos-8641642	58	2	pv	pv	PROPN
bjos-8641642	58	3	is	be	AUX
bjos-8641642	58	4	a	a	DET
bjos-8641642	58	5	chronic	chronic	NOUN
bjos-8641642	58	6	,	,	PUNCT
bjos-8641642	58	7	antibody	antibody	NOUN
bjos-8641642	58	8	mediated	mediate	VERB
bjos-8641642	58	9	autoimmune	autoimmune	ADJ
bjos-8641642	58	10	disease	disease	NOUN
bjos-8641642	58	11	that	that	PRON
bjos-8641642	58	12	affects	affect	VERB
bjos-8641642	58	13	the	the	DET
bjos-8641642	58	14	skin	skin	NOUN
bjos-8641642	58	15	and	and	CCONJ
bjos-8641642	58	16	oral	oral	ADJ
bjos-8641642	58	17	mucous	mucous	ADJ
bjos-8641642	58	18	membrane	membrane	NOUN
bjos-8641642	58	19	with	with	ADP
bjos-8641642	58	20	distinct	distinct	ADJ
bjos-8641642	58	21	clinical	clinical	NOUN
bjos-8641642	58	22	,	,	PUNCT
bjos-8641642	58	23	histopathological	histopathological	ADJ
bjos-8641642	58	24	,	,	PUNCT
bjos-8641642	58	25	and	and	CCONJ
bjos-8641642	58	26	immunological	immunological	ADJ
bjos-8641642	58	27	features16	features16	NOUN
bjos-8641642	58	28	.	.	PUNCT
bjos-8641642	59	1	the	the	DET
bjos-8641642	59	2	exact	exact	ADJ
bjos-8641642	59	3	cause	cause	NOUN
bjos-8641642	59	4	of	of	ADP
bjos-8641642	59	5	oral	oral	ADJ
bjos-8641642	59	6	pv	pv	NOUN
bjos-8641642	59	7	is	be	AUX
bjos-8641642	59	8	unknown	unknown	ADJ
bjos-8641642	59	9	.	.	PUNCT
bjos-8641642	60	1	several	several	ADJ
bjos-8641642	60	2	studies	study	NOUN
bjos-8641642	60	3	support	support	VERB
bjos-8641642	60	4	the	the	DET
bjos-8641642	60	5	immunological	immunological	ADJ
bjos-8641642	60	6	basis	basis	NOUN
bjos-8641642	60	7	for	for	ADP
bjos-8641642	60	8	the	the	DET
bjos-8641642	60	9	disease	disease	NOUN
bjos-8641642	60	10	.	.	PUNCT
bjos-8641642	61	1	of	of	ADP
bjos-8641642	61	2	importance	importance	NOUN
bjos-8641642	61	3	to	to	PART
bjos-8641642	61	4	dentist	dentist	VERB
bjos-8641642	61	5	is	be	AUX
bjos-8641642	61	6	the	the	DET
bjos-8641642	61	7	frequency	frequency	NOUN
bjos-8641642	61	8	with	with	ADP
bjos-8641642	61	9	which	which	PRON
bjos-8641642	61	10	oral	oral	ADJ
bjos-8641642	61	11	lesions	lesion	NOUN
bjos-8641642	61	12	were	be	AUX
bjos-8641642	61	13	the	the	DET
bjos-8641642	61	14	initial	initial	ADJ
bjos-8641642	61	15	presenting	present	VERB
bjos-8641642	61	16	feature	feature	NOUN
bjos-8641642	61	17	of	of	ADP
bjos-8641642	61	18	oral	oral	ADJ
bjos-8641642	61	19	pv	pv	NOUN
bjos-8641642	61	20	as	as	SCONJ
bjos-8641642	61	21	they	they	PRON
bjos-8641642	61	22	often	often	ADV
bjos-8641642	61	23	precede	precede	VERB
bjos-8641642	61	24	the	the	DET
bjos-8641642	61	25	skin	skin	NOUN
bjos-8641642	61	26	lesions	lesion	NOUN
bjos-8641642	61	27	by	by	ADP
bjos-8641642	61	28	several	several	ADJ
bjos-8641642	61	29	months	month	NOUN
bjos-8641642	61	30	or	or	CCONJ
bjos-8641642	61	31	may	may	AUX
bjos-8641642	61	32	be	be	AUX
bjos-8641642	61	33	the	the	DET
bjos-8641642	61	34	major	major	ADJ
bjos-8641642	61	35	,	,	PUNCT
bjos-8641642	61	36	if	if	SCONJ
bjos-8641642	61	37	not	not	PART
bjos-8641642	61	38	the	the	DET
bjos-8641642	61	39	only	only	ADJ
bjos-8641642	61	40	,	,	PUNCT
bjos-8641642	61	41	manifestation	manifestation	NOUN
bjos-8641642	61	42	in	in	ADP
bjos-8641642	61	43	some	some	DET
bjos-8641642	61	44	patients8	patients8	NOUN
bjos-8641642	61	45	.	.	PUNCT
bjos-8641642	62	1	serum	serum	PROPN
bjos-8641642	62	2	cytokine	cytokine	PROPN
bjos-8641642	62	3	levels	level	NOUN
bjos-8641642	62	4	were	be	AUX
bjos-8641642	62	5	recently	recently	ADV
bjos-8641642	62	6	investigated	investigate	VERB
bjos-8641642	62	7	in	in	ADP
bjos-8641642	62	8	many	many	ADJ
bjos-8641642	62	9	autoimmune	autoimmune	ADJ
bjos-8641642	62	10	disorders	disorder	NOUN
bjos-8641642	62	11	such	such	ADJ
bjos-8641642	62	12	as	as	ADP
bjos-8641642	62	13	lichen	lichen	NOUN
bjos-8641642	62	14	planus	planus	NOUN
bjos-8641642	62	15	(	(	PUNCT
bjos-8641642	62	16	lp	lp	NOUN
bjos-8641642	62	17	)	)	PUNCT
bjos-8641642	62	18	and	and	CCONJ
bjos-8641642	62	19	rheumatoid	rheumatoid	NOUN
bjos-8641642	62	20	arthritis6	arthritis6	NOUN
bjos-8641642	62	21	,	,	PUNCT
bjos-8641642	62	22	and	and	CCONJ
bjos-8641642	62	23	a	a	DET
bjos-8641642	62	24	relationship	relationship	NOUN
bjos-8641642	62	25	between	between	ADP
bjos-8641642	62	26	serum	serum	NOUN
bjos-8641642	62	27	cytokine	cytokine	NOUN
bjos-8641642	62	28	levels	level	NOUN
bjos-8641642	62	29	and	and	CCONJ
bjos-8641642	62	30	the	the	DET
bjos-8641642	62	31	clinical	clinical	ADJ
bjos-8641642	62	32	appearance	appearance	NOUN
bjos-8641642	62	33	of	of	ADP
bjos-8641642	62	34	these	these	DET
bjos-8641642	62	35	diseases	disease	NOUN
bjos-8641642	62	36	has	have	AUX
bjos-8641642	62	37	been	be	AUX
bjos-8641642	62	38	reported	report	VERB
bjos-8641642	62	39	.	.	PUNCT
bjos-8641642	63	1	previous	previous	ADJ
bjos-8641642	63	2	studies6,17	studies6,17	NOUN
bjos-8641642	63	3	have	have	AUX
bjos-8641642	63	4	reported	report	VERB
bjos-8641642	63	5	that	that	SCONJ
bjos-8641642	63	6	,	,	PUNCT
bjos-8641642	63	7	the	the	DET
bjos-8641642	63	8	increase	increase	NOUN
bjos-8641642	63	9	of	of	ADP
bjos-8641642	63	10	some	some	DET
bjos-8641642	63	11	cytokines	cytokine	NOUN
bjos-8641642	63	12	levels	level	NOUN
bjos-8641642	63	13	,	,	PUNCT
bjos-8641642	63	14	such	such	ADJ
bjos-8641642	63	15	as	as	ADP
bjos-8641642	63	16	il-1	il-1	X
bjos-8641642	63	17	,	,	PUNCT
bjos-8641642	63	18	il-6	il-6	NUM
bjos-8641642	63	19	,	,	PUNCT
bjos-8641642	63	20	il8	il8	PROPN
bjos-8641642	63	21	and	and	CCONJ
bjos-8641642	63	22	tnf	tnf	PROPN
bjos-8641642	63	23	-	-	PUNCT
bjos-8641642	63	24	α	α	PROPN
bjos-8641642	63	25	in	in	ADP
bjos-8641642	63	26	the	the	DET
bjos-8641642	63	27	serum	serum	NOUN
bjos-8641642	63	28	of	of	ADP
bjos-8641642	63	29	patients	patient	NOUN
bjos-8641642	63	30	with	with	ADP
bjos-8641642	63	31	inflammatory	inflammatory	ADJ
bjos-8641642	63	32	and	and	CCONJ
bjos-8641642	63	33	autoimmune	autoimmune	ADJ
bjos-8641642	63	34	diseases	disease	NOUN
bjos-8641642	63	35	is	be	AUX
bjos-8641642	63	36	well	well	ADV
bjos-8641642	63	37	known	know	VERB
bjos-8641642	63	38	,	,	PUNCT
bjos-8641642	63	39	and	and	CCONJ
bjos-8641642	63	40	these	these	DET
bjos-8641642	63	41	elevated	elevated	ADJ
bjos-8641642	63	42	cytokine	cytokine	NOUN
bjos-8641642	63	43	levels	level	NOUN
bjos-8641642	63	44	seem	seem	VERB
bjos-8641642	63	45	to	to	PART
bjos-8641642	63	46	be	be	AUX
bjos-8641642	63	47	important	important	ADJ
bjos-8641642	63	48	mediators	mediator	NOUN
bjos-8641642	63	49	restricting	restrict	VERB
bjos-8641642	63	50	each	each	DET
bjos-8641642	63	51	disease6,17	disease6,17	NOUN
bjos-8641642	63	52	.	.	PUNCT
bjos-8641642	64	1	in	in	ADP
bjos-8641642	64	2	the	the	DET
bjos-8641642	64	3	present	present	ADJ
bjos-8641642	64	4	study	study	NOUN
bjos-8641642	64	5	,	,	PUNCT
bjos-8641642	64	6	the	the	DET
bjos-8641642	64	7	serum	serum	NOUN
bjos-8641642	64	8	levels	level	NOUN
bjos-8641642	64	9	of	of	ADP
bjos-8641642	64	10	some	some	DET
bjos-8641642	64	11	proinflammatory	proinflammatory	ADJ
bjos-8641642	64	12	cytokines	cytokine	NOUN
bjos-8641642	64	13	(	(	PUNCT
bjos-8641642	64	14	il-2	il-2	NUM
bjos-8641642	64	15	,	,	PUNCT
bjos-8641642	64	16	il-6	il-6	NUM
bjos-8641642	64	17	,	,	PUNCT
bjos-8641642	64	18	tnf	tnf	PROPN
bjos-8641642	64	19	-	-	PUNCT
bjos-8641642	64	20	α	α	NOUN
bjos-8641642	64	21	)	)	PUNCT
bjos-8641642	64	22	and	and	CCONJ
bjos-8641642	64	23	the	the	DET
bjos-8641642	64	24	antiinflammatory	antiinflammatory	NOUN
bjos-8641642	64	25	cytokine	cytokine	NOUN
bjos-8641642	64	26	il-4	il-4	X
bjos-8641642	64	27	were	be	AUX
bjos-8641642	64	28	measured	measure	VERB
bjos-8641642	64	29	in	in	ADP
bjos-8641642	64	30	egyptian	egyptian	ADJ
bjos-8641642	64	31	patients	patient	NOUN
bjos-8641642	64	32	with	with	ADP
bjos-8641642	64	33	oral	oral	ADJ
bjos-8641642	64	34	pv	pv	NOUN
bjos-8641642	64	35	and	and	CCONJ
bjos-8641642	64	36	compared	compare	VERB
bjos-8641642	64	37	with	with	ADP
bjos-8641642	64	38	healthy	healthy	ADJ
bjos-8641642	64	39	controls	control	NOUN
bjos-8641642	64	40	.	.	PUNCT
bjos-8641642	65	1	cytokine	cytokine	ADJ
bjos-8641642	65	2	generation	generation	NOUN
bjos-8641642	65	3	is	be	AUX
bjos-8641642	65	4	regulated	regulate	VERB
bjos-8641642	65	5	by	by	ADP
bjos-8641642	65	6	other	other	ADJ
bjos-8641642	65	7	cytokines	cytokine	NOUN
bjos-8641642	65	8	and	and	CCONJ
bjos-8641642	65	9	also	also	ADV
bjos-8641642	65	10	by	by	ADP
bjos-8641642	65	11	itself6	itself6	PROPN
bjos-8641642	65	12	.	.	PUNCT
bjos-8641642	66	1	in	in	ADP
bjos-8641642	66	2	cytokine	cytokine	ADJ
bjos-8641642	66	3	network	network	NOUN
bjos-8641642	66	4	with	with	ADP
bjos-8641642	66	5	autocrine	autocrine	NOUN
bjos-8641642	66	6	and	and	CCONJ
bjos-8641642	66	7	paracrine	paracrine	NOUN
bjos-8641642	66	8	control	control	NOUN
bjos-8641642	66	9	,	,	PUNCT
bjos-8641642	66	10	cytokine	cytokine	ADJ
bjos-8641642	66	11	actions	action	NOUN
bjos-8641642	66	12	are	be	AUX
bjos-8641642	66	13	usually	usually	ADV
bjos-8641642	66	14	balanced	balanced	ADJ
bjos-8641642	66	15	;	;	PUNCT
bjos-8641642	66	16	however	however	ADV
bjos-8641642	66	17	,	,	PUNCT
bjos-8641642	66	18	cytokine	cytokine	ADJ
bjos-8641642	66	19	imbalance	imbalance	NOUN
bjos-8641642	66	20	occurs	occur	VERB
bjos-8641642	66	21	under	under	ADP
bjos-8641642	66	22	pathological	pathological	ADJ
bjos-8641642	66	23	conditions	condition	NOUN
bjos-8641642	66	24	and	and	CCONJ
bjos-8641642	66	25	large	large	ADJ
bjos-8641642	66	26	amounts	amount	NOUN
bjos-8641642	66	27	of	of	ADP
bjos-8641642	66	28	cytokines	cytokine	NOUN
bjos-8641642	66	29	are	be	AUX
bjos-8641642	66	30	generated	generate	VERB
bjos-8641642	66	31	,	,	PUNCT
bjos-8641642	66	32	which	which	PRON
bjos-8641642	66	33	may	may	AUX
bjos-8641642	66	34	be	be	AUX
bjos-8641642	66	35	beneficial	beneficial	ADJ
bjos-8641642	66	36	or	or	CCONJ
bjos-8641642	66	37	harmful	harmful	ADJ
bjos-8641642	66	38	to	to	ADP
bjos-8641642	66	39	the	the	DET
bjos-8641642	66	40	body17	body17	NOUN
bjos-8641642	66	41	.	.	PUNCT
bjos-8641642	67	1	unbalanced	unbalanced	ADJ
bjos-8641642	67	2	cytokine	cytokine	ADJ
bjos-8641642	67	3	actions	action	NOUN
bjos-8641642	67	4	are	be	AUX
bjos-8641642	67	5	considered	consider	VERB
bjos-8641642	67	6	to	to	PART
bjos-8641642	67	7	be	be	AUX
bjos-8641642	67	8	one	one	NUM
bjos-8641642	67	9	of	of	ADP
bjos-8641642	67	10	the	the	DET
bjos-8641642	67	11	immunopathogenesis	immunopathogenesis	NOUN
bjos-8641642	67	12	mechanisms	mechanism	NOUN
bjos-8641642	67	13	of	of	ADP
bjos-8641642	67	14	autoimmune	autoimmune	ADJ
bjos-8641642	67	15	disorders6	disorders6	PROPN
bjos-8641642	67	16	.	.	PUNCT
bjos-8641642	68	1	elevation	elevation	NOUN
bjos-8641642	68	2	of	of	ADP
bjos-8641642	68	3	cytokine	cytokine	ADJ
bjos-8641642	68	4	activities	activity	NOUN
bjos-8641642	68	5	and	and	CCONJ
bjos-8641642	68	6	unbalanced	unbalanced	ADJ
bjos-8641642	68	7	cytokine	cytokine	NOUN
bjos-8641642	68	8	network	network	NOUN
bjos-8641642	68	9	may	may	AUX
bjos-8641642	68	10	induce	induce	VERB
bjos-8641642	68	11	oral	oral	ADJ
bjos-8641642	68	12	mucosal	mucosal	NOUN
bjos-8641642	68	13	lesions6	lesions6	NOUN
bjos-8641642	68	14	.	.	PUNCT
bjos-8641642	69	1	the	the	DET
bjos-8641642	69	2	identification	identification	NOUN
bjos-8641642	69	3	of	of	ADP
bjos-8641642	69	4	cytokine	cytokine	ADJ
bjos-8641642	69	5	activities	activity	NOUN
bjos-8641642	69	6	in	in	ADP
bjos-8641642	69	7	patient	patient	NOUN
bjos-8641642	69	8	’s	’s	PART
bjos-8641642	69	9	tissues	tissue	NOUN
bjos-8641642	69	10	and	and	CCONJ
bjos-8641642	69	11	sera	sera	NOUN
bjos-8641642	69	12	seems	seem	VERB
bjos-8641642	69	13	to	to	PART
bjos-8641642	69	14	be	be	AUX
bjos-8641642	69	15	advantageous	advantageous	ADJ
bjos-8641642	69	16	for	for	ADP
bjos-8641642	69	17	pathological	pathological	ADJ
bjos-8641642	69	18	analysis	analysis	NOUN
bjos-8641642	69	19	of	of	ADP
bjos-8641642	69	20	oral	oral	ADJ
bjos-8641642	69	21	diseases6	diseases6	PROPN
bjos-8641642	69	22	.	.	PUNCT
bjos-8641642	70	1	the	the	DET
bjos-8641642	70	2	present	present	ADJ
bjos-8641642	70	3	study	study	NOUN
bjos-8641642	70	4	revealed	reveal	VERB
bjos-8641642	70	5	a	a	DET
bjos-8641642	70	6	640	640	NUM
bjos-8641642	70	7	%	%	NOUN
bjos-8641642	70	8	increase	increase	NOUN
bjos-8641642	70	9	in	in	ADP
bjos-8641642	70	10	serum	serum	NOUN
bjos-8641642	70	11	levels	level	NOUN
bjos-8641642	70	12	tnf	tnf	PROPN
bjos-8641642	70	13	-	-	PUNCT
bjos-8641642	70	14	α	α	PROPN
bjos-8641642	70	15	of	of	ADP
bjos-8641642	70	16	patients	patient	NOUN
bjos-8641642	70	17	with	with	ADP
bjos-8641642	70	18	oral	oral	ADJ
bjos-8641642	70	19	pv	pv	NOUN
bjos-8641642	70	20	compared	compare	VERB
bjos-8641642	70	21	to	to	ADP
bjos-8641642	70	22	controls	control	NOUN
bjos-8641642	70	23	.	.	PUNCT
bjos-8641642	71	1	increased	increase	VERB
bjos-8641642	71	2	serum	serum	NOUN
bjos-8641642	71	3	levels	level	NOUN
bjos-8641642	71	4	of	of	ADP
bjos-8641642	71	5	tnf	tnf	PROPN
bjos-8641642	71	6	-	-	PUNCT
bjos-8641642	71	7	α	α	PROPN
bjos-8641642	71	8	were	be	AUX
bjos-8641642	71	9	reported	report	VERB
bjos-8641642	71	10	by	by	ADP
bjos-8641642	71	11	many	many	ADJ
bjos-8641642	71	12	authors	author	NOUN
bjos-8641642	71	13	.	.	PUNCT
bjos-8641642	72	1	thus	thus	ADV
bjos-8641642	72	2	,	,	PUNCT
bjos-8641642	72	3	alecu	alecu	PROPN
bjos-8641642	72	4	et	et	PROPN
bjos-8641642	72	5	al.18	al.18	PROPN
bjos-8641642	72	6	found	find	VERB
bjos-8641642	72	7	increased	increase	VERB
bjos-8641642	72	8	tnf	tnf	PROPN
bjos-8641642	72	9	-	-	PUNCT
bjos-8641642	72	10	α	α	PROPN
bjos-8641642	72	11	levels	level	NOUN
bjos-8641642	72	12	in	in	ADP
bjos-8641642	72	13	the	the	DET
bjos-8641642	72	14	sera	sera	NOUN
bjos-8641642	72	15	and	and	CCONJ
bjos-8641642	72	16	blister	blister	NOUN
bjos-8641642	72	17	fluid	fluid	NOUN
bjos-8641642	72	18	obtained	obtain	VERB
bjos-8641642	72	19	from	from	ADP
bjos-8641642	72	20	patients	patient	NOUN
bjos-8641642	72	21	with	with	ADP
bjos-8641642	72	22	pv	pv	NOUN
bjos-8641642	72	23	.	.	PUNCT
bjos-8641642	73	1	similar	similar	ADJ
bjos-8641642	73	2	results	result	NOUN
bjos-8641642	73	3	were	be	AUX
bjos-8641642	73	4	obtained	obtain	VERB
bjos-8641642	73	5	by	by	ADP
bjos-8641642	73	6	d’auria	d’auria	PROPN
bjos-8641642	73	7	et	et	NOUN
bjos-8641642	73	8	al.1,13	al.1,13	PRON
bjos-8641642	73	9	who	who	PRON
bjos-8641642	73	10	showed	show	VERB
bjos-8641642	73	11	increased	increase	VERB
bjos-8641642	73	12	levels	level	NOUN
bjos-8641642	73	13	and	and	CCONJ
bjos-8641642	73	14	in	in	ADP
bjos-8641642	73	15	situ	situ	ADJ
bjos-8641642	73	16	expression	expression	NOUN
bjos-8641642	73	17	of	of	ADP
bjos-8641642	73	18	tnf	tnf	PROPN
bjos-8641642	73	19	-	-	PUNCT
bjos-8641642	73	20	α	α	PROPN
bjos-8641642	73	21	.	.	PUNCT
bjos-8641642	74	1	also	also	ADV
bjos-8641642	74	2	,	,	PUNCT
bjos-8641642	74	3	narbutt	narbutt	PROPN
bjos-8641642	74	4	et	et	NOUN
bjos-8641642	74	5	al.2	al.2	PROPN
bjos-8641642	74	6	showed	show	VERB
bjos-8641642	74	7	72	72	NUM
bjos-8641642	74	8	%	%	NOUN
bjos-8641642	74	9	increase	increase	NOUN
bjos-8641642	74	10	in	in	ADP
bjos-8641642	74	11	tnf	tnf	PROPN
bjos-8641642	74	12	-	-	PUNCT
bjos-8641642	74	13	α	α	PROPN
bjos-8641642	74	14	levels	level	NOUN
bjos-8641642	74	15	in	in	ADP
bjos-8641642	74	16	the	the	DET
bjos-8641642	74	17	sera	sera	NOUN
bjos-8641642	74	18	of	of	ADP
bjos-8641642	74	19	patients	patient	NOUN
bjos-8641642	74	20	with	with	ADP
bjos-8641642	74	21	pv	pv	INTJ
bjos-8641642	74	22	compared	compare	VERB
bjos-8641642	74	23	to	to	ADP
bjos-8641642	74	24	control	control	VERB
bjos-8641642	74	25	.	.	PUNCT
bjos-8641642	75	1	this	this	PRON
bjos-8641642	75	2	indicates	indicate	VERB
bjos-8641642	75	3	that	that	SCONJ
bjos-8641642	75	4	,	,	PUNCT
bjos-8641642	75	5	tnf	tnf	PROPN
bjos-8641642	75	6	-	-	PUNCT
bjos-8641642	75	7	α	α	PROPN
bjos-8641642	75	8	may	may	AUX
bjos-8641642	75	9	play	play	VERB
bjos-8641642	75	10	a	a	DET
bjos-8641642	75	11	role	role	NOUN
bjos-8641642	75	12	in	in	ADP
bjos-8641642	75	13	the	the	DET
bjos-8641642	75	14	disease	disease	NOUN
bjos-8641642	75	15	process	process	NOUN
bjos-8641642	75	16	of	of	ADP
bjos-8641642	75	17	pv	pv	INTJ
bjos-8641642	75	18	.	.	PUNCT
bjos-8641642	76	1	like	like	ADP
bjos-8641642	76	2	il-1	il-1	NUM
bjos-8641642	76	3	,	,	PUNCT
bjos-8641642	76	4	tnf	tnf	PROPN
bjos-8641642	76	5	-	-	PUNCT
bjos-8641642	76	6	α	α	PROPN
bjos-8641642	76	7	is	be	AUX
bjos-8641642	76	8	also	also	ADV
bjos-8641642	76	9	a	a	DET
bjos-8641642	76	10	key	key	ADJ
bjos-8641642	76	11	stone	stone	NOUN
bjos-8641642	76	12	in	in	ADP
bjos-8641642	76	13	the	the	DET
bjos-8641642	76	14	cytokine	cytokine	NOUN
bjos-8641642	76	15	network	network	NOUN
bjos-8641642	76	16	.	.	PUNCT
bjos-8641642	77	1	tnf	tnf	PROPN
bjos-8641642	77	2	-	-	PUNCT
bjos-8641642	77	3	α	α	PROPN
bjos-8641642	77	4	is	be	AUX
bjos-8641642	77	5	a	a	DET
bjos-8641642	77	6	cytokine	cytokine	NOUN
bjos-8641642	77	7	involved	involve	VERB
bjos-8641642	77	8	in	in	ADP
bjos-8641642	77	9	the	the	DET
bjos-8641642	77	10	majority	majority	NOUN
bjos-8641642	77	11	of	of	ADP
bjos-8641642	77	12	inflammatory	inflammatory	ADJ
bjos-8641642	77	13	processes	process	NOUN
bjos-8641642	77	14	,	,	PUNCT
bjos-8641642	77	15	and	and	CCONJ
bjos-8641642	77	16	its	its	PRON
bjos-8641642	77	17	increased	increase	VERB
bjos-8641642	77	18	activity	activity	NOUN
bjos-8641642	77	19	is	be	AUX
bjos-8641642	77	20	found	find	VERB
bjos-8641642	77	21	in	in	ADP
bjos-8641642	77	22	many	many	ADJ
bjos-8641642	77	23	skin	skin	NOUN
bjos-8641642	77	24	diseases	disease	NOUN
bjos-8641642	77	25	including	include	VERB
bjos-8641642	77	26	psoriasis	psoriasis	NOUN
bjos-8641642	77	27	,	,	PUNCT
bjos-8641642	77	28	sle	sle	PROPN
bjos-8641642	77	29	,	,	PUNCT
bjos-8641642	77	30	or	or	CCONJ
bjos-8641642	77	31	systemic	systemic	ADJ
bjos-8641642	77	32	sclerosis19	sclerosis19	NOUN
bjos-8641642	77	33	-	-	PUNCT
bjos-8641642	77	34	20	20	NUM
bjos-8641642	77	35	.	.	PUNCT
bjos-8641642	78	1	tnf	tnf	PROPN
bjos-8641642	78	2	-	-	PUNCT
bjos-8641642	78	3	α	α	PROPN
bjos-8641642	78	4	is	be	AUX
bjos-8641642	78	5	released	release	VERB
bjos-8641642	78	6	by	by	ADP
bjos-8641642	78	7	cells	cell	NOUN
bjos-8641642	78	8	under	under	ADP
bjos-8641642	78	9	various	various	ADJ
bjos-8641642	78	10	stimuli	stimulus	NOUN
bjos-8641642	78	11	including	include	VERB
bjos-8641642	78	12	bacterial	bacterial	ADJ
bjos-8641642	78	13	infections	infection	NOUN
bjos-8641642	78	14	or	or	CCONJ
bjos-8641642	78	15	ultraviolet	ultraviolet	ADJ
bjos-8641642	78	16	radiation	radiation	NOUN
bjos-8641642	78	17	.	.	PUNCT
bjos-8641642	79	1	it	it	PRON
bjos-8641642	79	2	plays	play	VERB
bjos-8641642	79	3	a	a	DET
bjos-8641642	79	4	role	role	NOUN
bjos-8641642	79	5	in	in	ADP
bjos-8641642	79	6	many	many	ADJ
bjos-8641642	79	7	biological	biological	ADJ
bjos-8641642	79	8	processes	process	NOUN
bjos-8641642	79	9	,	,	PUNCT
bjos-8641642	79	10	enhances	enhance	VERB
bjos-8641642	79	11	phagocytosis	phagocytosis	NOUN
bjos-8641642	79	12	,	,	PUNCT
bjos-8641642	79	13	cytotoxicity	cytotoxicity	NOUN
bjos-8641642	79	14	,	,	PUNCT
bjos-8641642	79	15	and	and	CCONJ
bjos-8641642	79	16	modulates	modulate	NOUN
bjos-8641642	79	17	activity	activity	NOUN
bjos-8641642	79	18	of	of	ADP
bjos-8641642	79	19	other	other	ADJ
bjos-8641642	79	20	cytokines	cytokine	NOUN
bjos-8641642	79	21	such	such	ADJ
bjos-8641642	79	22	as	as	ADP
bjos-8641642	79	23	il-1	il-1	NUM
bjos-8641642	79	24	and	and	CCONJ
bjos-8641642	79	25	il-421	il-421	PROPN
bjos-8641642	79	26	.	.	PUNCT
bjos-8641642	80	1	tnf	tnf	PROPN
bjos-8641642	80	2	-	-	PUNCT
bjos-8641642	80	3	α	α	PROPN
bjos-8641642	80	4	is	be	AUX
bjos-8641642	80	5	generated	generate	VERB
bjos-8641642	80	6	from	from	ADP
bjos-8641642	80	7	macrophages	macrophage	NOUN
bjos-8641642	80	8	,	,	PUNCT
bjos-8641642	80	9	t	t	PROPN
bjos-8641642	80	10	and	and	CCONJ
bjos-8641642	80	11	b	b	PROPN
bjos-8641642	80	12	cells	cell	NOUN
bjos-8641642	80	13	and	and	CCONJ
bjos-8641642	80	14	endothelial	endothelial	ADJ
bjos-8641642	80	15	cells17	cells17	NOUN
bjos-8641642	80	16	.	.	PUNCT
bjos-8641642	81	1	the	the	DET
bjos-8641642	81	2	important	important	ADJ
bjos-8641642	81	3	inducers	inducer	NOUN
bjos-8641642	81	4	of	of	ADP
bjos-8641642	81	5	tnf	tnf	PROPN
bjos-8641642	81	6	-	-	PUNCT
bjos-8641642	81	7	α	α	PROPN
bjos-8641642	81	8	production	production	NOUN
bjos-8641642	81	9	include	include	VERB
bjos-8641642	81	10	viruses	virus	NOUN
bjos-8641642	81	11	,	,	PUNCT
bjos-8641642	81	12	il-1	il-1	NUM
bjos-8641642	81	13	,	,	PUNCT
bjos-8641642	81	14	immune	immune	ADJ
bjos-8641642	81	15	complex	complex	NOUN
bjos-8641642	81	16	,	,	PUNCT
bjos-8641642	81	17	endotoxin	endotoxin	NOUN
bjos-8641642	81	18	and	and	CCONJ
bjos-8641642	81	19	tnf	tnf	PROPN
bjos-8641642	81	20	-	-	PUNCT
bjos-8641642	81	21	α	α	PROPN
bjos-8641642	81	22	itself6	itself6	NOUN
bjos-8641642	81	23	.	.	PUNCT
bjos-8641642	82	1	the	the	DET
bjos-8641642	82	2	tnf	tnf	PROPN
bjos-8641642	82	3	-	-	PUNCT
bjos-8641642	82	4	α	α	PROPN
bjos-8641642	82	5	plays	play	VERB
bjos-8641642	82	6	a	a	DET
bjos-8641642	82	7	major	major	ADJ
bjos-8641642	82	8	role	role	NOUN
bjos-8641642	82	9	in	in	ADP
bjos-8641642	82	10	cell	cell	NOUN
bjos-8641642	82	11	mediated	mediate	VERB
bjos-8641642	82	12	cytotoxicity	cytotoxicity	NOUN
bjos-8641642	82	13	being	be	AUX
bjos-8641642	82	14	able	able	ADJ
bjos-8641642	82	15	to	to	PART
bjos-8641642	82	16	induce	induce	VERB
bjos-8641642	82	17	cytotoxic	cytotoxic	ADJ
bjos-8641642	82	18	t	t	NOUN
bjos-8641642	82	19	-	-	PUNCT
bjos-8641642	82	20	cell	cell	NOUN
bjos-8641642	82	21	differentiation	differentiation	NOUN
bjos-8641642	82	22	,	,	PUNCT
bjos-8641642	82	23	enhances	enhance	VERB
bjos-8641642	82	24	monocyte	monocyte	ADJ
bjos-8641642	82	25	cytotoxicity	cytotoxicity	NOUN
bjos-8641642	82	26	,	,	PUNCT
bjos-8641642	82	27	and	and	CCONJ
bjos-8641642	82	28	stimulates	stimulate	NOUN
bjos-8641642	82	29	lymphokine	lymphokine	VERB
bjos-8641642	82	30	activated	activated	ADJ
bjos-8641642	82	31	natural	natural	ADJ
bjos-8641642	82	32	killer	killer	NOUN
bjos-8641642	82	33	cells22	cells22	NOUN
bjos-8641642	82	34	.	.	PUNCT
bjos-8641642	83	1	tnf	tnf	PROPN
bjos-8641642	83	2	-	-	PUNCT
bjos-8641642	83	3	α	α	PROPN
bjos-8641642	83	4	has	have	AUX
bjos-8641642	83	5	marked	mark	VERB
bjos-8641642	83	6	effects	effect	NOUN
bjos-8641642	83	7	on	on	ADP
bjos-8641642	83	8	epithelial	epithelial	ADJ
bjos-8641642	83	9	cells	cell	NOUN
bjos-8641642	83	10	.	.	PUNCT
bjos-8641642	84	1	it	it	PRON
bjos-8641642	84	2	is	be	AUX
bjos-8641642	84	3	cytotoxic	cytotoxic	ADJ
bjos-8641642	84	4	at	at	ADP
bjos-8641642	84	5	high	high	ADJ
bjos-8641642	84	6	concentration	concentration	NOUN
bjos-8641642	84	7	and	and	CCONJ
bjos-8641642	84	8	anti	anti	ADJ
bjos-8641642	84	9	-	-	ADJ
bjos-8641642	84	10	proliferative	proliferative	ADJ
bjos-8641642	84	11	at	at	ADP
bjos-8641642	84	12	lower	low	ADJ
bjos-8641642	84	13	concentration22	concentration22	NOUN
bjos-8641642	84	14	.	.	PUNCT
bjos-8641642	85	1	prolonged	prolong	VERB
bjos-8641642	85	2	release	release	NOUN
bjos-8641642	85	3	of	of	ADP
bjos-8641642	85	4	tnf	tnf	PROPN
bjos-8641642	85	5	-	-	PUNCT
bjos-8641642	85	6	α	α	PROPN
bjos-8641642	85	7	has	have	AUX
bjos-8641642	85	8	been	be	AUX
bjos-8641642	85	9	implicated	implicate	VERB
bjos-8641642	85	10	in	in	ADP
bjos-8641642	85	11	epithelial	epithelial	ADJ
bjos-8641642	85	12	cell	cell	NOUN
bjos-8641642	85	13	damage	damage	NOUN
bjos-8641642	85	14	.	.	PUNCT
bjos-8641642	86	1	so	so	ADV
bjos-8641642	86	2	in	in	ADP
bjos-8641642	86	3	the	the	DET
bjos-8641642	86	4	view	view	NOUN
bjos-8641642	86	5	of	of	ADP
bjos-8641642	86	6	the	the	DET
bjos-8641642	86	7	enhanced	enhance	VERB
bjos-8641642	86	8	cytotoxicity	cytotoxicity	NOUN
bjos-8641642	86	9	85	85	NUM
bjos-8641642	86	10	braz	braz	PROPN
bjos-8641642	86	11	j	j	PROPN
bjos-8641642	86	12	oral	oral	PROPN
bjos-8641642	86	13	sci	sci	PROPN
bjos-8641642	86	14	.	.	PUNCT
bjos-8641642	87	1	10(2):83	10(2):83	NUM
bjos-8641642	87	2	-	-	SYM
bjos-8641642	87	3	87	87	NUM
bjos-8641642	87	4	cytokine	cytokine	ADJ
bjos-8641642	87	5	profiles	profile	NOUN
bjos-8641642	87	6	in	in	ADP
bjos-8641642	87	7	the	the	DET
bjos-8641642	87	8	sera	sera	NOUN
bjos-8641642	87	9	of	of	ADP
bjos-8641642	87	10	egyptian	egyptian	ADJ
bjos-8641642	87	11	patients	patient	NOUN
bjos-8641642	87	12	with	with	ADP
bjos-8641642	87	13	oral	oral	ADJ
bjos-8641642	87	14	pemphigus	pemphigus	ADJ
bjos-8641642	87	15	vulgaris	vulgaris	NOUN
bjos-8641642	87	16	86	86	NUM
bjos-8641642	87	17	and	and	CCONJ
bjos-8641642	87	18	epithelial	epithelial	ADJ
bjos-8641642	87	19	cell	cell	NOUN
bjos-8641642	87	20	lysis	lysis	NOUN
bjos-8641642	87	21	reported	report	VERB
bjos-8641642	87	22	in	in	ADP
bjos-8641642	87	23	pv	pv	PROPN
bjos-8641642	87	24	,	,	PUNCT
bjos-8641642	87	25	tnf	tnf	PROPN
bjos-8641642	87	26	-	-	PUNCT
bjos-8641642	87	27	α	α	PROPN
bjos-8641642	87	28	seems	seem	VERB
bjos-8641642	87	29	to	to	PART
bjos-8641642	87	30	be	be	AUX
bjos-8641642	87	31	implicated	implicate	VERB
bjos-8641642	87	32	in	in	ADP
bjos-8641642	87	33	the	the	DET
bjos-8641642	87	34	pathologic	pathologic	ADJ
bjos-8641642	87	35	process	process	NOUN
bjos-8641642	87	36	of	of	ADP
bjos-8641642	87	37	pv	pv	NOUN
bjos-8641642	87	38	.	.	PUNCT
bjos-8641642	88	1	the	the	DET
bjos-8641642	88	2	increased	increase	VERB
bjos-8641642	88	3	serum	serum	NOUN
bjos-8641642	88	4	levels	level	NOUN
bjos-8641642	88	5	of	of	ADP
bjos-8641642	88	6	tnf	tnf	PROPN
bjos-8641642	88	7	-	-	PUNCT
bjos-8641642	88	8	α	α	PROPN
bjos-8641642	88	9	may	may	AUX
bjos-8641642	88	10	be	be	AUX
bjos-8641642	88	11	attributed	attribute	VERB
bjos-8641642	88	12	to	to	ADP
bjos-8641642	88	13	the	the	DET
bjos-8641642	88	14	activation	activation	NOUN
bjos-8641642	88	15	of	of	ADP
bjos-8641642	88	16	macrophages	macrophage	NOUN
bjos-8641642	88	17	during	during	ADP
bjos-8641642	88	18	recognizing	recognize	VERB
bjos-8641642	88	19	the	the	DET
bjos-8641642	88	20	antigenic	antigenic	ADJ
bjos-8641642	88	21	epitopes	epitope	NOUN
bjos-8641642	88	22	and	and	CCONJ
bjos-8641642	88	23	presenting	present	VERB
bjos-8641642	88	24	them	they	PRON
bjos-8641642	88	25	to	to	ADP
bjos-8641642	88	26	t	t	NOUN
bjos-8641642	88	27	-	-	PUNCT
bjos-8641642	88	28	lymphocytes	lymphocyte	NOUN
bjos-8641642	88	29	.	.	PUNCT
bjos-8641642	89	1	moreover	moreover	ADV
bjos-8641642	89	2	,	,	PUNCT
bjos-8641642	89	3	mononuclear	mononuclear	ADJ
bjos-8641642	89	4	leukocytes	leukocyte	NOUN
bjos-8641642	89	5	might	might	AUX
bjos-8641642	89	6	be	be	AUX
bjos-8641642	89	7	stimulated	stimulate	VERB
bjos-8641642	89	8	to	to	PART
bjos-8641642	89	9	migrate	migrate	VERB
bjos-8641642	89	10	into	into	ADP
bjos-8641642	89	11	the	the	DET
bjos-8641642	89	12	submucosal	submucosal	NOUN
bjos-8641642	89	13	area	area	NOUN
bjos-8641642	89	14	to	to	PART
bjos-8641642	89	15	produce	produce	VERB
bjos-8641642	89	16	cytokines	cytokine	NOUN
bjos-8641642	89	17	including	include	VERB
bjos-8641642	89	18	tnf	tnf	PROPN
bjos-8641642	89	19	-	-	PUNCT
bjos-8641642	89	20	α23	α23	NOUN
bjos-8641642	89	21	.	.	PUNCT
bjos-8641642	90	1	alternatively	alternatively	ADV
bjos-8641642	90	2	,	,	PUNCT
bjos-8641642	90	3	the	the	DET
bjos-8641642	90	4	predominant	predominant	ADJ
bjos-8641642	90	5	cellular	cellular	ADJ
bjos-8641642	90	6	sources	source	NOUN
bjos-8641642	90	7	of	of	ADP
bjos-8641642	90	8	tnf	tnf	PROPN
bjos-8641642	90	9	-	-	PUNCT
bjos-8641642	90	10	α	α	PROPN
bjos-8641642	90	11	are	be	AUX
bjos-8641642	90	12	the	the	DET
bjos-8641642	90	13	mast	mast	NOUN
bjos-8641642	90	14	cells	cell	NOUN
bjos-8641642	90	15	,	,	PUNCT
bjos-8641642	90	16	macrophages	macrophage	NOUN
bjos-8641642	90	17	,	,	PUNCT
bjos-8641642	90	18	monocytes	monocyte	NOUN
bjos-8641642	90	19	and	and	CCONJ
bjos-8641642	90	20	endothelial	endothelial	ADJ
bjos-8641642	90	21	cells	cell	NOUN
bjos-8641642	90	22	.	.	PUNCT
bjos-8641642	91	1	these	these	DET
bjos-8641642	91	2	cells	cell	NOUN
bjos-8641642	91	3	can	can	AUX
bjos-8641642	91	4	secrete	secrete	VERB
bjos-8641642	91	5	tnf	tnf	PROPN
bjos-8641642	91	6	-	-	PUNCT
bjos-8641642	91	7	α	α	NOUN
bjos-8641642	91	8	into	into	ADP
bjos-8641642	91	9	the	the	DET
bjos-8641642	91	10	circulation	circulation	NOUN
bjos-8641642	91	11	,	,	PUNCT
bjos-8641642	91	12	thus	thus	ADV
bjos-8641642	91	13	the	the	DET
bjos-8641642	91	14	tnf	tnf	PROPN
bjos-8641642	91	15	-	-	PUNCT
bjos-8641642	91	16	α	α	PROPN
bjos-8641642	91	17	serum	serum	NOUN
bjos-8641642	91	18	levels	level	NOUN
bjos-8641642	91	19	reach	reach	VERB
bjos-8641642	91	20	an	an	DET
bjos-8641642	91	21	appreciable	appreciable	ADJ
bjos-8641642	91	22	amount	amount	NOUN
bjos-8641642	91	23	that	that	PRON
bjos-8641642	91	24	could	could	AUX
bjos-8641642	91	25	play	play	VERB
bjos-8641642	91	26	a	a	DET
bjos-8641642	91	27	significant	significant	ADJ
bjos-8641642	91	28	role	role	NOUN
bjos-8641642	91	29	in	in	ADP
bjos-8641642	91	30	the	the	DET
bjos-8641642	91	31	immunopathogenesis	immunopathogenesis	NOUN
bjos-8641642	91	32	of	of	ADP
bjos-8641642	91	33	pv	pv	NOUN
bjos-8641642	91	34	,	,	PUNCT
bjos-8641642	91	35	and	and	CCONJ
bjos-8641642	91	36	in	in	ADP
bjos-8641642	91	37	the	the	DET
bjos-8641642	91	38	same	same	ADJ
bjos-8641642	91	39	time	time	NOUN
bjos-8641642	91	40	gets	get	AUX
bjos-8641642	91	41	reflected	reflect	VERB
bjos-8641642	91	42	in	in	ADP
bjos-8641642	91	43	the	the	DET
bjos-8641642	91	44	patient	patient	NOUN
bjos-8641642	91	45	’s	’s	PART
bjos-8641642	91	46	serum22	serum22	PROPN
bjos-8641642	91	47	.	.	PUNCT
bjos-8641642	92	1	consequently	consequently	ADV
bjos-8641642	92	2	,	,	PUNCT
bjos-8641642	92	3	it	it	PRON
bjos-8641642	92	4	seems	seem	VERB
bjos-8641642	92	5	that	that	SCONJ
bjos-8641642	92	6	,	,	PUNCT
bjos-8641642	92	7	in	in	ADP
bjos-8641642	92	8	pv	pv	INTJ
bjos-8641642	92	9	the	the	DET
bjos-8641642	92	10	antigen	antigen	NOUN
bjos-8641642	92	11	-	-	PUNCT
bjos-8641642	92	12	antibody	antibody	NOUN
bjos-8641642	92	13	complex	complex	ADJ
bjos-8641642	92	14	formation	formation	NOUN
bjos-8641642	92	15	within	within	ADP
bjos-8641642	92	16	the	the	DET
bjos-8641642	92	17	epithelial	epithelial	ADJ
bjos-8641642	92	18	layer	layer	NOUN
bjos-8641642	92	19	may	may	AUX
bjos-8641642	92	20	induce	induce	VERB
bjos-8641642	92	21	increased	increased	ADJ
bjos-8641642	92	22	cytokine	cytokine	NOUN
bjos-8641642	92	23	release	release	NOUN
bjos-8641642	92	24	including	include	VERB
bjos-8641642	92	25	tnf	tnf	PROPN
bjos-8641642	92	26	-	-	PUNCT
bjos-8641642	92	27	α	α	PROPN
bjos-8641642	92	28	,	,	PUNCT
bjos-8641642	92	29	which	which	PRON
bjos-8641642	92	30	enhances	enhance	VERB
bjos-8641642	92	31	the	the	DET
bjos-8641642	92	32	epithelial	epithelial	ADJ
bjos-8641642	92	33	cell	cell	NOUN
bjos-8641642	92	34	damage	damage	NOUN
bjos-8641642	92	35	.	.	PUNCT
bjos-8641642	93	1	the	the	DET
bjos-8641642	93	2	il-6	il-6	NOUN
bjos-8641642	93	3	is	be	AUX
bjos-8641642	93	4	a	a	DET
bjos-8641642	93	5	multifunctional	multifunctional	ADJ
bjos-8641642	93	6	cytokine	cytokine	NOUN
bjos-8641642	93	7	which	which	PRON
bjos-8641642	93	8	is	be	AUX
bjos-8641642	93	9	an	an	DET
bjos-8641642	93	10	important	important	ADJ
bjos-8641642	93	11	mediator	mediator	NOUN
bjos-8641642	93	12	in	in	ADP
bjos-8641642	93	13	host	host	NOUN
bjos-8641642	93	14	response	response	NOUN
bjos-8641642	93	15	to	to	ADP
bjos-8641642	93	16	injury	injury	NOUN
bjos-8641642	93	17	and	and	CCONJ
bjos-8641642	93	18	infection	infection	NOUN
bjos-8641642	93	19	.	.	PUNCT
bjos-8641642	94	1	it	it	PRON
bjos-8641642	94	2	stimulates	stimulate	VERB
bjos-8641642	94	3	the	the	DET
bjos-8641642	94	4	production	production	NOUN
bjos-8641642	94	5	of	of	ADP
bjos-8641642	94	6	acute	acute	ADJ
bjos-8641642	94	7	phase	phase	NOUN
bjos-8641642	94	8	protein	protein	NOUN
bjos-8641642	94	9	by	by	ADP
bjos-8641642	94	10	liver	liver	NOUN
bjos-8641642	94	11	cells24	cells24	NOUN
bjos-8641642	94	12	.	.	PUNCT
bjos-8641642	95	1	previous	previous	ADJ
bjos-8641642	95	2	studies24	studies24	NOUN
bjos-8641642	95	3	-	-	PUNCT
bjos-8641642	95	4	25	25	NUM
bjos-8641642	95	5	,	,	PUNCT
bjos-8641642	95	6	reported	report	VERB
bjos-8641642	95	7	that	that	SCONJ
bjos-8641642	95	8	,	,	PUNCT
bjos-8641642	95	9	the	the	DET
bjos-8641642	95	10	production	production	NOUN
bjos-8641642	95	11	of	of	ADP
bjos-8641642	95	12	il-6	il-6	NOUN
bjos-8641642	95	13	may	may	AUX
bjos-8641642	95	14	be	be	AUX
bjos-8641642	95	15	a	a	DET
bjos-8641642	95	16	response	response	NOUN
bjos-8641642	95	17	to	to	ADP
bjos-8641642	95	18	many	many	ADJ
bjos-8641642	95	19	inducers	inducer	NOUN
bjos-8641642	95	20	such	such	ADJ
bjos-8641642	95	21	as	as	ADP
bjos-8641642	95	22	tnf	tnf	PROPN
bjos-8641642	95	23	-	-	PUNCT
bjos-8641642	95	24	α	α	PROPN
bjos-8641642	95	25	,	,	PUNCT
bjos-8641642	95	26	il4	il4	ADJ
bjos-8641642	95	27	,	,	PUNCT
bjos-8641642	95	28	il-3	il-3	X
bjos-8641642	95	29	,	,	PUNCT
bjos-8641642	95	30	and	and	CCONJ
bjos-8641642	95	31	some	some	DET
bjos-8641642	95	32	viruses	virus	NOUN
bjos-8641642	95	33	.	.	PUNCT
bjos-8641642	96	1	moreover	moreover	ADV
bjos-8641642	96	2	,	,	PUNCT
bjos-8641642	96	3	the	the	DET
bjos-8641642	96	4	production	production	NOUN
bjos-8641642	96	5	of	of	ADP
bjos-8641642	96	6	il-6	il-6	NUM
bjos-8641642	96	7	by	by	ADP
bjos-8641642	96	8	epithelial	epithelial	ADJ
bjos-8641642	96	9	cells	cell	NOUN
bjos-8641642	96	10	is	be	AUX
bjos-8641642	96	11	increased	increase	VERB
bjos-8641642	96	12	in	in	ADP
bjos-8641642	96	13	many	many	ADJ
bjos-8641642	96	14	inflammatory	inflammatory	ADJ
bjos-8641642	96	15	autoimmune	autoimmune	ADJ
bjos-8641642	96	16	diseases	disease	NOUN
bjos-8641642	96	17	such	such	ADJ
bjos-8641642	96	18	as	as	ADP
bjos-8641642	96	19	lichen	lichen	NOUN
bjos-8641642	96	20	planus	planus	NOUN
bjos-8641642	96	21	and	and	CCONJ
bjos-8641642	96	22	psoriasis19,26	psoriasis19,26	NOUN
bjos-8641642	96	23	.	.	PUNCT
bjos-8641642	97	1	it	it	PRON
bjos-8641642	97	2	seems	seem	VERB
bjos-8641642	97	3	likely	likely	ADV
bjos-8641642	97	4	therefore	therefore	ADV
bjos-8641642	97	5	that	that	SCONJ
bjos-8641642	97	6	,	,	PUNCT
bjos-8641642	97	7	il-6	il-6	PRON
bjos-8641642	97	8	plays	play	VERB
bjos-8641642	97	9	an	an	DET
bjos-8641642	97	10	important	important	ADJ
bjos-8641642	97	11	role	role	NOUN
bjos-8641642	97	12	in	in	ADP
bjos-8641642	97	13	immunopathogenesis	immunopathogenesis	NOUN
bjos-8641642	97	14	of	of	ADP
bjos-8641642	97	15	a	a	DET
bjos-8641642	97	16	number	number	NOUN
bjos-8641642	97	17	of	of	ADP
bjos-8641642	97	18	immunoinflammatory	immunoinflammatory	ADJ
bjos-8641642	97	19	skin	skin	NOUN
bjos-8641642	97	20	diseases	disease	NOUN
bjos-8641642	97	21	,	,	PUNCT
bjos-8641642	97	22	and	and	CCONJ
bjos-8641642	97	23	since	since	SCONJ
bjos-8641642	97	24	several	several	ADJ
bjos-8641642	97	25	inflammatory	inflammatory	ADJ
bjos-8641642	97	26	skin	skin	NOUN
bjos-8641642	97	27	diseases	disease	NOUN
bjos-8641642	97	28	also	also	ADV
bjos-8641642	97	29	affect	affect	VERB
bjos-8641642	97	30	the	the	DET
bjos-8641642	97	31	oral	oral	ADJ
bjos-8641642	97	32	mucous	mucous	ADJ
bjos-8641642	97	33	membrane	membrane	NOUN
bjos-8641642	97	34	such	such	ADJ
bjos-8641642	97	35	as	as	ADP
bjos-8641642	97	36	lp	lp	NOUN
bjos-8641642	97	37	,	,	PUNCT
bjos-8641642	97	38	sle	sle	PROPN
bjos-8641642	97	39	,	,	PUNCT
bjos-8641642	97	40	and	and	CCONJ
bjos-8641642	97	41	pv	pv	INTJ
bjos-8641642	97	42	,	,	PUNCT
bjos-8641642	97	43	it	it	PRON
bjos-8641642	97	44	is	be	AUX
bjos-8641642	97	45	reasonable	reasonable	ADJ
bjos-8641642	97	46	to	to	PART
bjos-8641642	97	47	detect	detect	VERB
bjos-8641642	97	48	high	high	ADJ
bjos-8641642	97	49	serum	serum	NOUN
bjos-8641642	97	50	level	level	NOUN
bjos-8641642	97	51	of	of	ADP
bjos-8641642	97	52	il-6	il-6	NOUN
bjos-8641642	97	53	in	in	ADP
bjos-8641642	97	54	patients	patient	NOUN
bjos-8641642	97	55	with	with	ADP
bjos-8641642	97	56	active	active	ADJ
bjos-8641642	97	57	pv	pv	ADJ
bjos-8641642	97	58	oral	oral	ADJ
bjos-8641642	97	59	lesions24	lesions24	NOUN
bjos-8641642	97	60	.	.	PUNCT
bjos-8641642	98	1	the	the	DET
bjos-8641642	98	2	results	result	NOUN
bjos-8641642	98	3	of	of	ADP
bjos-8641642	98	4	the	the	DET
bjos-8641642	98	5	present	present	ADJ
bjos-8641642	98	6	study	study	NOUN
bjos-8641642	98	7	revealed	reveal	VERB
bjos-8641642	98	8	a	a	DET
bjos-8641642	98	9	marked	mark	VERB
bjos-8641642	98	10	increase	increase	NOUN
bjos-8641642	98	11	of	of	ADP
bjos-8641642	98	12	il-6	il-6	NOUN
bjos-8641642	98	13	serum	serum	NOUN
bjos-8641642	98	14	levels	level	NOUN
bjos-8641642	98	15	(	(	PUNCT
bjos-8641642	98	16	179	179	NUM
bjos-8641642	98	17	%	%	NOUN
bjos-8641642	98	18	)	)	PUNCT
bjos-8641642	98	19	in	in	ADP
bjos-8641642	98	20	patients	patient	NOUN
bjos-8641642	98	21	with	with	ADP
bjos-8641642	98	22	oral	oral	ADJ
bjos-8641642	98	23	pv	pv	NOUN
bjos-8641642	98	24	compared	compare	VERB
bjos-8641642	98	25	with	with	ADP
bjos-8641642	98	26	those	those	PRON
bjos-8641642	98	27	of	of	ADP
bjos-8641642	98	28	the	the	DET
bjos-8641642	98	29	control	control	NOUN
bjos-8641642	98	30	group	group	NOUN
bjos-8641642	98	31	.	.	PUNCT
bjos-8641642	99	1	as	as	ADV
bjos-8641642	99	2	much	much	ADJ
bjos-8641642	99	3	as	as	ADP
bjos-8641642	99	4	72	72	NUM
bjos-8641642	99	5	%	%	NOUN
bjos-8641642	99	6	increase	increase	NOUN
bjos-8641642	99	7	in	in	ADP
bjos-8641642	99	8	serum	serum	NOUN
bjos-8641642	99	9	il-6	il-6	NOUN
bjos-8641642	99	10	levels	level	NOUN
bjos-8641642	99	11	was	be	AUX
bjos-8641642	99	12	reported	report	VERB
bjos-8641642	99	13	by	by	ADP
bjos-8641642	99	14	others	other	NOUN
bjos-8641642	99	15	in	in	ADP
bjos-8641642	99	16	active	active	ADJ
bjos-8641642	99	17	stage	stage	NOUN
bjos-8641642	99	18	of	of	ADP
bjos-8641642	99	19	pv2	pv2	NOUN
bjos-8641642	99	20	.	.	PUNCT
bjos-8641642	100	1	the	the	DET
bjos-8641642	100	2	elevated	elevated	ADJ
bjos-8641642	100	3	il-6	il-6	NOUN
bjos-8641642	100	4	serum	serum	NOUN
bjos-8641642	100	5	levels	level	NOUN
bjos-8641642	100	6	in	in	ADP
bjos-8641642	100	7	patients	patient	NOUN
bjos-8641642	100	8	with	with	ADP
bjos-8641642	100	9	active	active	ADJ
bjos-8641642	100	10	pv	pv	ADJ
bjos-8641642	100	11	oral	oral	ADJ
bjos-8641642	100	12	lesions	lesion	NOUN
bjos-8641642	100	13	seem	seem	VERB
bjos-8641642	100	14	to	to	PART
bjos-8641642	100	15	be	be	AUX
bjos-8641642	100	16	compatible	compatible	ADJ
bjos-8641642	100	17	with	with	ADP
bjos-8641642	100	18	the	the	DET
bjos-8641642	100	19	high	high	ADJ
bjos-8641642	100	20	levels	level	NOUN
bjos-8641642	100	21	of	of	ADP
bjos-8641642	100	22	il-6	il-6	NOUN
bjos-8641642	100	23	generated	generate	VERB
bjos-8641642	100	24	and	and	CCONJ
bjos-8641642	100	25	released	release	VERB
bjos-8641642	100	26	in	in	ADP
bjos-8641642	100	27	acute	acute	ADJ
bjos-8641642	100	28	inflammatory	inflammatory	ADJ
bjos-8641642	100	29	conditions	condition	NOUN
bjos-8641642	100	30	.	.	PUNCT
bjos-8641642	101	1	the	the	DET
bjos-8641642	101	2	high	high	ADJ
bjos-8641642	101	3	il-6	il-6	NOUN
bjos-8641642	101	4	serum	serum	NOUN
bjos-8641642	101	5	levels	level	NOUN
bjos-8641642	101	6	in	in	ADP
bjos-8641642	101	7	patients	patient	NOUN
bjos-8641642	101	8	with	with	ADP
bjos-8641642	101	9	pv	pv	NOUN
bjos-8641642	101	10	may	may	AUX
bjos-8641642	101	11	be	be	AUX
bjos-8641642	101	12	attributed	attribute	VERB
bjos-8641642	101	13	to	to	ADP
bjos-8641642	101	14	the	the	DET
bjos-8641642	101	15	elevated	elevated	ADJ
bjos-8641642	101	16	serum	serum	NOUN
bjos-8641642	101	17	levels	level	NOUN
bjos-8641642	101	18	of	of	ADP
bjos-8641642	101	19	tnf	tnf	PROPN
bjos-8641642	101	20	-	-	PUNCT
bjos-8641642	101	21	α	α	PROPN
bjos-8641642	101	22	which	which	PRON
bjos-8641642	101	23	is	be	AUX
bjos-8641642	101	24	one	one	NUM
bjos-8641642	101	25	of	of	ADP
bjos-8641642	101	26	the	the	DET
bjos-8641642	101	27	strong	strong	ADJ
bjos-8641642	101	28	inducers	inducer	NOUN
bjos-8641642	101	29	for	for	ADP
bjos-8641642	101	30	generation	generation	NOUN
bjos-8641642	101	31	and	and	CCONJ
bjos-8641642	101	32	release	release	NOUN
bjos-8641642	101	33	of	of	ADP
bjos-8641642	101	34	il-624	il-624	NOUN
bjos-8641642	101	35	.	.	PUNCT
bjos-8641642	102	1	there	there	PRON
bjos-8641642	102	2	are	be	VERB
bjos-8641642	102	3	wide	wide	ADJ
bjos-8641642	102	4	variety	variety	NOUN
bjos-8641642	102	5	of	of	ADP
bjos-8641642	102	6	cells	cell	NOUN
bjos-8641642	102	7	that	that	PRON
bjos-8641642	102	8	are	be	AUX
bjos-8641642	102	9	responsible	responsible	ADJ
bjos-8641642	102	10	for	for	ADP
bjos-8641642	102	11	generation	generation	NOUN
bjos-8641642	102	12	and	and	CCONJ
bjos-8641642	102	13	release	release	NOUN
bjos-8641642	102	14	of	of	ADP
bjos-8641642	102	15	il-6	il-6	NOUN
bjos-8641642	102	16	including	include	VERB
bjos-8641642	102	17	lymphocytes	lymphocyte	NOUN
bjos-8641642	102	18	,	,	PUNCT
bjos-8641642	102	19	endothelial	endothelial	ADJ
bjos-8641642	102	20	cells	cell	NOUN
bjos-8641642	102	21	and	and	CCONJ
bjos-8641642	102	22	epithelial	epithelial	ADJ
bjos-8641642	102	23	cells	cell	NOUN
bjos-8641642	102	24	.	.	PUNCT
bjos-8641642	103	1	therefore	therefore	ADV
bjos-8641642	103	2	,	,	PUNCT
bjos-8641642	103	3	il-6	il-6	PRON
bjos-8641642	103	4	seems	seem	VERB
bjos-8641642	103	5	to	to	PART
bjos-8641642	103	6	be	be	AUX
bjos-8641642	103	7	generated	generate	VERB
bjos-8641642	103	8	and	and	CCONJ
bjos-8641642	103	9	released	release	VERB
bjos-8641642	103	10	into	into	ADP
bjos-8641642	103	11	the	the	DET
bjos-8641642	103	12	circulation	circulation	NOUN
bjos-8641642	103	13	in	in	ADP
bjos-8641642	103	14	acute	acute	ADJ
bjos-8641642	103	15	and	and	CCONJ
bjos-8641642	103	16	chronic	chronic	ADJ
bjos-8641642	103	17	immunoinflammatory	immunoinflammatory	NOUN
bjos-8641642	103	18	as	as	ADV
bjos-8641642	103	19	well	well	ADV
bjos-8641642	103	20	as	as	ADP
bjos-8641642	103	21	autoimmune	autoimmune	ADJ
bjos-8641642	103	22	disorders17,24	disorders17,24	PROPN
bjos-8641642	103	23	.	.	PUNCT
bjos-8641642	104	1	since	since	SCONJ
bjos-8641642	104	2	pv	pv	PROPN
bjos-8641642	104	3	is	be	VERB
bjos-8641642	104	4	a	a	DET
bjos-8641642	104	5	chronic	chronic	ADJ
bjos-8641642	104	6	inflammatory	inflammatory	ADJ
bjos-8641642	104	7	mucocutaneous	mucocutaneous	ADJ
bjos-8641642	104	8	disease	disease	NOUN
bjos-8641642	104	9	,	,	PUNCT
bjos-8641642	104	10	the	the	DET
bjos-8641642	104	11	higher	high	ADJ
bjos-8641642	104	12	il-6	il-6	NOUN
bjos-8641642	104	13	serum	serum	NOUN
bjos-8641642	104	14	levels	level	NOUN
bjos-8641642	104	15	in	in	ADP
bjos-8641642	104	16	patients	patient	NOUN
bjos-8641642	104	17	with	with	ADP
bjos-8641642	104	18	oral	oral	ADJ
bjos-8641642	104	19	pv	pv	NOUN
bjos-8641642	104	20	seem	seem	VERB
bjos-8641642	104	21	to	to	PART
bjos-8641642	104	22	be	be	AUX
bjos-8641642	104	23	a	a	DET
bjos-8641642	104	24	reasonable	reasonable	ADJ
bjos-8641642	104	25	finding	finding	NOUN
bjos-8641642	104	26	.	.	PUNCT
bjos-8641642	105	1	the	the	DET
bjos-8641642	105	2	findings	finding	NOUN
bjos-8641642	105	3	of	of	ADP
bjos-8641642	105	4	the	the	DET
bjos-8641642	105	5	present	present	ADJ
bjos-8641642	105	6	study	study	NOUN
bjos-8641642	105	7	revealed	reveal	VERB
bjos-8641642	105	8	a	a	DET
bjos-8641642	105	9	slight	slight	ADJ
bjos-8641642	105	10	,	,	PUNCT
bjos-8641642	105	11	nonsignificant	nonsignificant	ADJ
bjos-8641642	105	12	elevation	elevation	NOUN
bjos-8641642	105	13	of	of	ADP
bjos-8641642	105	14	il-4	il-4	NOUN
bjos-8641642	105	15	serum	serum	NOUN
bjos-8641642	105	16	levels	level	NOUN
bjos-8641642	105	17	in	in	ADP
bjos-8641642	105	18	patients	patient	NOUN
bjos-8641642	105	19	with	with	ADP
bjos-8641642	105	20	oral	oral	ADJ
bjos-8641642	105	21	pv	pv	NOUN
bjos-8641642	105	22	compared	compare	VERB
bjos-8641642	105	23	with	with	ADP
bjos-8641642	105	24	those	those	PRON
bjos-8641642	105	25	of	of	ADP
bjos-8641642	105	26	control	control	NOUN
bjos-8641642	105	27	.	.	PUNCT
bjos-8641642	106	1	however	however	ADV
bjos-8641642	106	2	,	,	PUNCT
bjos-8641642	106	3	satyam	satyam	PROPN
bjos-8641642	106	4	et	et	PROPN
bjos-8641642	106	5	al.9	al.9	PROPN
bjos-8641642	106	6	reported	report	VERB
bjos-8641642	106	7	significantly	significantly	ADV
bjos-8641642	106	8	higher	high	ADJ
bjos-8641642	106	9	levels	level	NOUN
bjos-8641642	106	10	of	of	ADP
bjos-8641642	106	11	serum	serum	NOUN
bjos-8641642	106	12	il-4	il-4	X
bjos-8641642	106	13	in	in	ADP
bjos-8641642	106	14	patients	patient	NOUN
bjos-8641642	106	15	with	with	ADP
bjos-8641642	106	16	pv	pv	INTJ
bjos-8641642	106	17	compared	compare	VERB
bjos-8641642	106	18	to	to	ADP
bjos-8641642	106	19	healthy	healthy	ADJ
bjos-8641642	106	20	controls	control	NOUN
bjos-8641642	106	21	and	and	CCONJ
bjos-8641642	106	22	suggested	suggest	VERB
bjos-8641642	106	23	that	that	SCONJ
bjos-8641642	106	24	this	this	DET
bjos-8641642	106	25	increase	increase	NOUN
bjos-8641642	106	26	shows	show	VERB
bjos-8641642	106	27	the	the	DET
bjos-8641642	106	28	induction	induction	NOUN
bjos-8641642	106	29	of	of	ADP
bjos-8641642	106	30	t(h)2	t(h)2	PROPN
bjos-8641642	106	31	cells	cell	NOUN
bjos-8641642	106	32	in	in	ADP
bjos-8641642	106	33	the	the	DET
bjos-8641642	106	34	pathogenesis	pathogenesis	NOUN
bjos-8641642	106	35	of	of	ADP
bjos-8641642	106	36	pv	pv	INTJ
bjos-8641642	106	37	.	.	PUNCT
bjos-8641642	107	1	also	also	ADV
bjos-8641642	107	2	,	,	PUNCT
bjos-8641642	107	3	keskin	keskin	PROPN
bjos-8641642	107	4	et	et	PROPN
bjos-8641642	107	5	al.11	al.11	PROPN
bjos-8641642	107	6	reported	report	VERB
bjos-8641642	107	7	elevated	elevated	ADJ
bjos-8641642	107	8	levels	level	NOUN
bjos-8641642	107	9	of	of	ADP
bjos-8641642	107	10	il-4	il-4	NOUN
bjos-8641642	107	11	in	in	ADP
bjos-8641642	107	12	serum	serum	NOUN
bjos-8641642	107	13	of	of	ADP
bjos-8641642	107	14	patients	patient	NOUN
bjos-8641642	107	15	with	with	ADP
bjos-8641642	107	16	pv	pv	ADV
bjos-8641642	107	17	and	and	CCONJ
bjos-8641642	107	18	showed	show	VERB
bjos-8641642	107	19	reduced	reduced	ADJ
bjos-8641642	107	20	levels	level	NOUN
bjos-8641642	107	21	of	of	ADP
bjos-8641642	107	22	this	this	DET
bjos-8641642	107	23	cytokine	cytokine	NOUN
bjos-8641642	107	24	to	to	ADP
bjos-8641642	107	25	the	the	DET
bjos-8641642	107	26	control	control	NOUN
bjos-8641642	107	27	values	value	NOUN
bjos-8641642	107	28	following	follow	VERB
bjos-8641642	107	29	treatment	treatment	NOUN
bjos-8641642	107	30	with	with	ADP
bjos-8641642	107	31	high	high	ADJ
bjos-8641642	107	32	-	-	PUNCT
bjos-8641642	107	33	dose	dose	NOUN
bjos-8641642	107	34	,	,	PUNCT
bjos-8641642	107	35	long	long	ADJ
bjos-8641642	107	36	term	term	NOUN
bjos-8641642	107	37	systemic	systemic	ADJ
bjos-8641642	107	38	corticosteroids	corticosteroid	NOUN
bjos-8641642	107	39	with	with	ADP
bjos-8641642	107	40	or	or	CCONJ
bjos-8641642	107	41	without	without	ADP
bjos-8641642	107	42	immunoglobulins	immunoglobulin	NOUN
bjos-8641642	107	43	.	.	PUNCT
bjos-8641642	108	1	the	the	PRON
bjos-8641642	108	2	il-4	il-4	X
bjos-8641642	108	3	has	have	VERB
bjos-8641642	108	4	a	a	DET
bjos-8641642	108	5	wide	wide	ADJ
bjos-8641642	108	6	range	range	NOUN
bjos-8641642	108	7	of	of	ADP
bjos-8641642	108	8	biological	biological	ADJ
bjos-8641642	108	9	functions	function	NOUN
bjos-8641642	108	10	that	that	PRON
bjos-8641642	108	11	include	include	VERB
bjos-8641642	108	12	activation	activation	NOUN
bjos-8641642	108	13	of	of	ADP
bjos-8641642	108	14	immunoglobulin	immunoglobulin	NOUN
bjos-8641642	108	15	synthesis	synthesis	NOUN
bjos-8641642	108	16	,	,	PUNCT
bjos-8641642	108	17	t	t	NOUN
bjos-8641642	108	18	-	-	PUNCT
bjos-8641642	108	19	cell	cell	NOUN
bjos-8641642	108	20	proliferation	proliferation	NOUN
bjos-8641642	108	21	,	,	PUNCT
bjos-8641642	108	22	and	and	CCONJ
bjos-8641642	108	23	t	t	NOUN
bjos-8641642	108	24	-	-	PUNCT
bjos-8641642	108	25	cell	cell	NOUN
bjos-8641642	108	26	adhesion	adhesion	NOUN
bjos-8641642	108	27	to	to	ADP
bjos-8641642	108	28	endothelial	endothelial	ADJ
bjos-8641642	108	29	cells	cell	NOUN
bjos-8641642	108	30	.	.	PUNCT
bjos-8641642	109	1	generation	generation	NOUN
bjos-8641642	109	2	of	of	ADP
bjos-8641642	109	3	il-4	il-4	NOUN
bjos-8641642	109	4	in	in	ADP
bjos-8641642	109	5	some	some	DET
bjos-8641642	109	6	patients	patient	NOUN
bjos-8641642	109	7	with	with	ADP
bjos-8641642	109	8	autoimmune	autoimmune	ADJ
bjos-8641642	109	9	disorders	disorder	NOUN
bjos-8641642	109	10	seems	seem	VERB
bjos-8641642	109	11	to	to	PART
bjos-8641642	109	12	be	be	AUX
bjos-8641642	109	13	likely	likely	ADJ
bjos-8641642	109	14	in	in	ADP
bjos-8641642	109	15	these	these	DET
bjos-8641642	109	16	diseases	disease	NOUN
bjos-8641642	109	17	.	.	PUNCT
bjos-8641642	110	1	in	in	ADP
bjos-8641642	110	2	the	the	DET
bjos-8641642	110	3	present	present	ADJ
bjos-8641642	110	4	study	study	NOUN
bjos-8641642	110	5	,	,	PUNCT
bjos-8641642	110	6	it	it	PRON
bjos-8641642	110	7	could	could	AUX
bjos-8641642	110	8	not	not	PART
bjos-8641642	110	9	be	be	AUX
bjos-8641642	110	10	confirmed	confirm	VERB
bjos-8641642	110	11	any	any	DET
bjos-8641642	110	12	significant	significant	ADJ
bjos-8641642	110	13	changes	change	NOUN
bjos-8641642	110	14	in	in	ADP
bjos-8641642	110	15	il-2	il-2	NUM
bjos-8641642	110	16	serum	serum	NOUN
bjos-8641642	110	17	levels	level	NOUN
bjos-8641642	110	18	in	in	ADP
bjos-8641642	110	19	patients	patient	NOUN
bjos-8641642	110	20	with	with	ADP
bjos-8641642	110	21	oral	oral	ADJ
bjos-8641642	110	22	pv	pv	NOUN
bjos-8641642	110	23	when	when	SCONJ
bjos-8641642	110	24	compared	compare	VERB
bjos-8641642	110	25	to	to	ADP
bjos-8641642	110	26	the	the	DET
bjos-8641642	110	27	healthy	healthy	ADJ
bjos-8641642	110	28	controls	control	NOUN
bjos-8641642	110	29	.	.	PUNCT
bjos-8641642	111	1	however	however	ADV
bjos-8641642	111	2	,	,	PUNCT
bjos-8641642	111	3	satyam	satyam	PROPN
bjos-8641642	111	4	et	et	PROPN
bjos-8641642	111	5	al.9	al.9	PROPN
bjos-8641642	111	6	reported	report	VERB
bjos-8641642	111	7	decreased	decrease	VERB
bjos-8641642	111	8	levels	level	NOUN
bjos-8641642	111	9	of	of	ADP
bjos-8641642	111	10	il-2	il-2	NUM
bjos-8641642	111	11	in	in	ADP
bjos-8641642	111	12	the	the	DET
bjos-8641642	111	13	sera	sera	NOUN
bjos-8641642	111	14	of	of	ADP
bjos-8641642	111	15	patients	patient	NOUN
bjos-8641642	111	16	with	with	ADP
bjos-8641642	111	17	pv	pv	INTJ
bjos-8641642	111	18	.	.	PUNCT
bjos-8641642	112	1	in	in	ADP
bjos-8641642	112	2	conclusion	conclusion	NOUN
bjos-8641642	112	3	,	,	PUNCT
bjos-8641642	112	4	the	the	DET
bjos-8641642	112	5	present	present	ADJ
bjos-8641642	112	6	findings	finding	NOUN
bjos-8641642	112	7	showed	show	VERB
bjos-8641642	112	8	that	that	SCONJ
bjos-8641642	112	9	tnf	tnf	PROPN
bjos-8641642	112	10	-	-	PUNCT
bjos-8641642	112	11	α	α	PROPN
bjos-8641642	112	12	and	and	CCONJ
bjos-8641642	112	13	il-6	il-6	NOUN
bjos-8641642	112	14	levels	level	NOUN
bjos-8641642	112	15	were	be	AUX
bjos-8641642	112	16	significantly	significantly	ADV
bjos-8641642	112	17	increased	increase	VERB
bjos-8641642	112	18	in	in	ADP
bjos-8641642	112	19	the	the	DET
bjos-8641642	112	20	sera	sera	NOUN
bjos-8641642	112	21	of	of	ADP
bjos-8641642	112	22	egyptian	egyptian	ADJ
bjos-8641642	112	23	patients	patient	NOUN
bjos-8641642	112	24	with	with	ADP
bjos-8641642	112	25	oral	oral	ADJ
bjos-8641642	112	26	pv	pv	NOUN
bjos-8641642	112	27	,	,	PUNCT
bjos-8641642	112	28	probably	probably	ADV
bjos-8641642	112	29	suggesting	suggest	VERB
bjos-8641642	112	30	its	its	PRON
bjos-8641642	112	31	role	role	NOUN
bjos-8641642	112	32	in	in	ADP
bjos-8641642	112	33	the	the	DET
bjos-8641642	112	34	pathogenesis	pathogenesis	NOUN
bjos-8641642	112	35	of	of	ADP
bjos-8641642	112	36	this	this	DET
bjos-8641642	112	37	disease	disease	NOUN
bjos-8641642	112	38	.	.	PUNCT
bjos-8641642	113	1	acknowledgements	acknowledgement	NOUN
bjos-8641642	113	2	we	we	PRON
bjos-8641642	113	3	acknowledge	acknowledge	VERB
bjos-8641642	113	4	the	the	DET
bjos-8641642	113	5	help	help	NOUN
bjos-8641642	113	6	and	and	CCONJ
bjos-8641642	113	7	guidance	guidance	NOUN
bjos-8641642	113	8	of	of	ADP
bjos-8641642	113	9	prof	prof	NOUN
bjos-8641642	113	10	mohmoud	mohmoud	PROPN
bjos-8641642	113	11	kandeel	kandeel	NOUN
bjos-8641642	113	12	of	of	ADP
bjos-8641642	113	13	oral	oral	ADJ
bjos-8641642	113	14	diagnosis	diagnosis	NOUN
bjos-8641642	113	15	,	,	PUNCT
bjos-8641642	113	16	oral	oral	ADJ
bjos-8641642	113	17	medicine	medicine	NOUN
bjos-8641642	113	18	&	&	CCONJ
bjos-8641642	113	19	periodontology	periodontology	PROPN
bjos-8641642	113	20	department	department	PROPN
bjos-8641642	113	21	,	,	PUNCT
bjos-8641642	113	22	faculty	faculty	NOUN
bjos-8641642	113	23	of	of	ADP
bjos-8641642	113	24	oral	oral	ADJ
bjos-8641642	113	25	&	&	CCONJ
bjos-8641642	113	26	dental	dental	ADJ
bjos-8641642	113	27	medicine	medicine	NOUN
bjos-8641642	113	28	,	,	PUNCT
bjos-8641642	113	29	cairo	cairo	PROPN
bjos-8641642	113	30	university	university	PROPN
bjos-8641642	113	31	,	,	PUNCT
bjos-8641642	113	32	egypt	egypt	PROPN
bjos-8641642	113	33	.	.	PUNCT
bjos-8641642	114	1	references	reference	NOUN
bjos-8641642	114	2	1	1	NUM
bjos-8641642	114	3	.	.	PUNCT
bjos-8641642	115	1	d’auria	d’auria	PROPN
bjos-8641642	115	2	l	l	NOUN
bjos-8641642	115	3	,	,	PUNCT
bjos-8641642	115	4	bonifati	bonifati	VERB
bjos-8641642	115	5	a	a	PRON
bjos-8641642	115	6	,	,	PUNCT
bjos-8641642	115	7	mussi	mussi	PROPN
bjos-8641642	115	8	a	a	X
bjos-8641642	115	9	,	,	PUNCT
bjos-8641642	115	10	d’agosto	d’agosto	NOUN
bjos-8641642	115	11	g	g	NOUN
bjos-8641642	115	12	,	,	PUNCT
bjos-8641642	115	13	de	de	X
bjos-8641642	115	14	simone	simone	PROPN
bjos-8641642	115	15	c	c	AUX
bjos-8641642	115	16	,	,	PUNCT
bjos-8641642	115	17	giacalone	giacalone	NOUN
bjos-8641642	115	18	et	et	PROPN
bjos-8641642	115	19	al	al	PROPN
bjos-8641642	115	20	.	.	PUNCT
bjos-8641642	116	1	cytokines	cytokine	NOUN
bjos-8641642	116	2	in	in	ADP
bjos-8641642	116	3	the	the	DET
bjos-8641642	116	4	sera	sera	NOUN
bjos-8641642	116	5	of	of	ADP
bjos-8641642	116	6	patients	patient	NOUN
bjos-8641642	116	7	with	with	ADP
bjos-8641642	116	8	pemphigus	pemphigus	NOUN
bjos-8641642	116	9	vulgaris	vulgaris	NOUN
bjos-8641642	116	10	:	:	PUNCT
bjos-8641642	116	11	interleukin-6	interleukin-6	NUM
bjos-8641642	116	12	and	and	CCONJ
bjos-8641642	116	13	tumour	tumour	NOUN
bjos-8641642	116	14	necrosis	necrosis	NOUN
bjos-8641642	116	15	factor	factor	NOUN
bjos-8641642	116	16	-	-	PUNCT
bjos-8641642	116	17	alpha	alpha	NOUN
bjos-8641642	116	18	levels	level	NOUN
bjos-8641642	116	19	are	be	AUX
bjos-8641642	116	20	significantly	significantly	ADV
bjos-8641642	116	21	increased	increase	VERB
bjos-8641642	116	22	as	as	SCONJ
bjos-8641642	116	23	compared	compare	VERB
bjos-8641642	116	24	to	to	ADP
bjos-8641642	116	25	healthy	healthy	ADJ
bjos-8641642	116	26	subjects	subject	NOUN
bjos-8641642	116	27	and	and	CCONJ
bjos-8641642	116	28	correlate	correlate	VERB
bjos-8641642	116	29	with	with	ADP
bjos-8641642	116	30	disease	disease	NOUN
bjos-8641642	116	31	activity	activity	NOUN
bjos-8641642	116	32	.	.	PUNCT
bjos-8641642	117	1	eur	eur	PROPN
bjos-8641642	117	2	cytok	cytok	PROPN
bjos-8641642	117	3	netw	netw	NOUN
bjos-8641642	117	4	.	.	PUNCT
bjos-8641642	118	1	1997	1997	NUM
bjos-8641642	118	2	;	;	PUNCT
bjos-8641642	118	3	8	8	NUM
bjos-8641642	118	4	:	:	SYM
bjos-8641642	118	5	383	383	NUM
bjos-8641642	118	6	-	-	SYM
bjos-8641642	118	7	7	7	NUM
bjos-8641642	118	8	.	.	NOUN
bjos-8641642	118	9	2	2	NUM
bjos-8641642	118	10	.	.	X
bjos-8641642	118	11	narbutt	narbutt	PROPN
bjos-8641642	118	12	j	j	PROPN
bjos-8641642	118	13	,	,	PUNCT
bjos-8641642	118	14	lukamowicz	lukamowicz	PROPN
bjos-8641642	118	15	j	j	PROPN
bjos-8641642	118	16	,	,	PUNCT
bjos-8641642	118	17	bogaczewicz	bogaczewicz	PROPN
bjos-8641642	118	18	j	j	PROPN
bjos-8641642	118	19	,	,	PUNCT
bjos-8641642	118	20	sysa	sysa	NOUN
bjos-8641642	118	21	-	-	PUNCT
bjos-8641642	118	22	jedrzejowska	jedrzejowska	NOUN
bjos-8641642	118	23	a	a	PRON
bjos-8641642	118	24	,	,	PUNCT
bjos-8641642	118	25	torzecka	torzecka	NOUN
bjos-8641642	118	26	jd	jd	PROPN
bjos-8641642	118	27	,	,	PUNCT
bjos-8641642	118	28	leslak	leslak	PROPN
bjos-8641642	118	29	a.	a.	PROPN
bjos-8641642	118	30	serum	serum	PROPN
bjos-8641642	118	31	concentrations	concentration	NOUN
bjos-8641642	118	32	of	of	ADP
bjos-8641642	118	33	interleukin-6	interleukin-6	PROPN
bjos-8641642	118	34	is	be	AUX
bjos-8641642	118	35	increased	increase	VERB
bjos-8641642	118	36	both	both	CCONJ
bjos-8641642	118	37	in	in	ADP
bjos-8641642	118	38	active	active	ADJ
bjos-8641642	118	39	and	and	CCONJ
bjos-8641642	118	40	remission	remission	NOUN
bjos-8641642	118	41	stages	stage	NOUN
bjos-8641642	118	42	of	of	ADP
bjos-8641642	118	43	pemphigus	pemphigus	NOUN
bjos-8641642	118	44	vulgaris	vulgaris	NOUN
bjos-8641642	118	45	.	.	PUNCT
bjos-8641642	119	1	mediators	mediator	NOUN
bjos-8641642	119	2	inflamm	inflamm	PROPN
bjos-8641642	119	3	.	.	PUNCT
bjos-8641642	120	1	2008	2008	NUM
bjos-8641642	120	2	;	;	PUNCT
bjos-8641642	120	3	2008	2008	NUM
bjos-8641642	120	4	:	:	PUNCT
bjos-8641642	121	1	875	875	NUM
bjos-8641642	121	2	-	-	SYM
bjos-8641642	121	3	94	94	NUM
bjos-8641642	121	4	.	.	PUNCT
bjos-8641642	122	1	3	3	X
bjos-8641642	122	2	.	.	PUNCT
bjos-8641642	122	3	stern	stern	ADJ
bjos-8641642	122	4	jnh	jnh	PROPN
bjos-8641642	122	5	,	,	PUNCT
bjos-8641642	122	6	keski	keski	PROPN
bjos-8641642	122	7	n	n	PRON
bjos-8641642	122	8	db	db	PROPN
bjos-8641642	122	9	,	,	PUNCT
bjos-8641642	122	10	barteneva	barteneva	PROPN
bjos-8641642	122	11	n	n	CCONJ
bjos-8641642	122	12	,	,	PUNCT
bjos-8641642	122	13	zuniga	zuniga	PROPN
bjos-8641642	122	14	j	j	PROPN
bjos-8641642	122	15	,	,	PUNCT
bjos-8641642	122	16	yunis	yunis	PROPN
bjos-8641642	122	17	ej	ej	PROPN
bjos-8641642	122	18	,	,	PUNCT
bjos-8641642	122	19	ahmed	ahmed	PROPN
bjos-8641642	122	20	ar	ar	PROPN
bjos-8641642	122	21	.	.	PROPN
bjos-8641642	122	22	possible	possible	ADJ
bjos-8641642	122	23	role	role	NOUN
bjos-8641642	122	24	of	of	ADP
bjos-8641642	122	25	natural	natural	ADJ
bjos-8641642	122	26	killer	killer	NOUN
bjos-8641642	122	27	cells	cell	NOUN
bjos-8641642	122	28	in	in	ADP
bjos-8641642	122	29	pemphigus	pemphigus	PROPN
bjos-8641642	122	30	vulgaris	vulgaris	NOUN
bjos-8641642	122	31	preliminary	preliminary	ADJ
bjos-8641642	122	32	observations	observation	NOUN
bjos-8641642	122	33	.	.	PUNCT
bjos-8641642	123	1	clin	clin	PROPN
bjos-8641642	123	2	exp	exp	NOUN
bjos-8641642	123	3	immunol	immunol	NOUN
bjos-8641642	123	4	.	.	PUNCT
bjos-8641642	123	5	2008	2008	NUM
bjos-8641642	123	6	;	;	PUNCT
bjos-8641642	123	7	15	15	NUM
bjos-8641642	123	8	:	:	PUNCT
bjos-8641642	123	9	472	472	NUM
bjos-8641642	123	10	-	-	SYM
bjos-8641642	123	11	81	81	NUM
bjos-8641642	123	12	.	.	PUNCT
bjos-8641642	124	1	4	4	X
bjos-8641642	124	2	.	.	X
bjos-8641642	124	3	raychaudhuri	raychaudhuri	PROPN
bjos-8641642	124	4	sp	sp	PROPN
bjos-8641642	124	5	,	,	PUNCT
bjos-8641642	124	6	smriti	smriti	PROPN
bjos-8641642	124	7	k.	k.	PROPN
bjos-8641642	124	8	biologics	biologics	PROPN
bjos-8641642	124	9	:	:	PUNCT
bjos-8641642	124	10	target	target	NOUN
bjos-8641642	124	11	-	-	PUNCT
bjos-8641642	124	12	specific	specific	ADJ
bjos-8641642	124	13	treatment	treatment	NOUN
bjos-8641642	124	14	of	of	ADP
bjos-8641642	124	15	systemic	systemic	ADJ
bjos-8641642	124	16	and	and	CCONJ
bjos-8641642	124	17	cutaneous	cutaneous	ADJ
bjos-8641642	124	18	autoimmune	autoimmune	ADJ
bjos-8641642	124	19	diseases	disease	NOUN
bjos-8641642	124	20	.	.	PUNCT
bjos-8641642	125	1	ind	ind	NOUN
bjos-8641642	125	2	j	j	PROPN
bjos-8641642	125	3	dermatol	dermatol	NOUN
bjos-8641642	125	4	.	.	PUNCT
bjos-8641642	126	1	2009	2009	NUM
bjos-8641642	126	2	;	;	PUNCT
bjos-8641642	126	3	54	54	NUM
bjos-8641642	126	4	:	:	SYM
bjos-8641642	126	5	100	100	NUM
bjos-8641642	126	6	-	-	SYM
bjos-8641642	126	7	9	9	NUM
bjos-8641642	126	8	.	.	NOUN
bjos-8641642	126	9	5	5	NUM
bjos-8641642	126	10	.	.	X
bjos-8641642	126	11	femiano	femiano	PROPN
bjos-8641642	126	12	f.	f.	PROPN
bjos-8641642	126	13	pemphigus	pemphigus	PROPN
bjos-8641642	126	14	vulgaris	vulgaris	PROPN
bjos-8641642	126	15	:	:	PUNCT
bjos-8641642	126	16	recent	recent	ADJ
bjos-8641642	126	17	advances	advance	NOUN
bjos-8641642	126	18	in	in	ADP
bjos-8641642	126	19	our	our	PRON
bjos-8641642	126	20	understanding	understanding	NOUN
bjos-8641642	126	21	of	of	ADP
bjos-8641642	126	22	its	its	PRON
bjos-8641642	126	23	pathogenesis	pathogenesis	NOUN
bjos-8641642	126	24	.	.	PUNCT
bjos-8641642	127	1	minerva	minerva	PROPN
bjos-8641642	127	2	stomatol	stomatol	PROPN
bjos-8641642	127	3	.	.	PUNCT
bjos-8641642	128	1	2007	2007	NUM
bjos-8641642	128	2	;	;	PUNCT
bjos-8641642	128	3	56	56	NUM
bjos-8641642	128	4	:	:	SYM
bjos-8641642	128	5	215	215	NUM
bjos-8641642	128	6	-	-	SYM
bjos-8641642	128	7	23	23	NUM
bjos-8641642	128	8	.	.	PUNCT
bjos-8641642	129	1	6	6	NUM
bjos-8641642	129	2	.	.	X
bjos-8641642	129	3	yamamoto	yamamoto	PROPN
bjos-8641642	129	4	t	t	PROPN
bjos-8641642	129	5	,	,	PUNCT
bjos-8641642	129	6	yoneda	yoneda	PROPN
bjos-8641642	129	7	k	k	PROPN
bjos-8641642	129	8	,	,	PUNCT
bjos-8641642	129	9	ueta	ueta	PROPN
bjos-8641642	129	10	e.	e.	PROPN
bjos-8641642	129	11	serum	serum	PROPN
bjos-8641642	129	12	cytokine	cytokine	PROPN
bjos-8641642	129	13	levels	level	NOUN
bjos-8641642	129	14	in	in	ADP
bjos-8641642	129	15	patients	patient	NOUN
bjos-8641642	129	16	with	with	ADP
bjos-8641642	129	17	oral	oral	ADJ
bjos-8641642	129	18	mucous	mucous	ADJ
bjos-8641642	129	19	membrane	membrane	NOUN
bjos-8641642	129	20	disorders	disorder	NOUN
bjos-8641642	129	21	.	.	PUNCT
bjos-8641642	130	1	j	j	PROPN
bjos-8641642	130	2	oral	oral	ADJ
bjos-8641642	130	3	pathol	pathol	NOUN
bjos-8641642	130	4	med	me	VERB
bjos-8641642	130	5	.	.	PUNCT
bjos-8641642	130	6	1991	1991	NUM
bjos-8641642	130	7	;	;	PUNCT
bjos-8641642	130	8	20	20	NUM
bjos-8641642	130	9	:	:	SYM
bjos-8641642	130	10	275	275	NUM
bjos-8641642	130	11	-	-	SYM
bjos-8641642	130	12	9	9	NUM
bjos-8641642	130	13	.	.	NOUN
bjos-8641642	130	14	7	7	X
bjos-8641642	130	15	.	.	X
bjos-8641642	131	1	shanmugasekar	shanmugasekar	PROPN
bjos-8641642	131	2	c	c	NOUN
bjos-8641642	131	3	,	,	PUNCT
bjos-8641642	131	4	ram	ram	NOUN
bjos-8641642	131	5	gaesh	gaesh	NOUN
bjos-8641642	131	6	vr	vr	PROPN
bjos-8641642	131	7	,	,	PUNCT
bjos-8641642	131	8	jayaramun	jayaramun	PROPN
bjos-8641642	131	9	a	a	PRON
bjos-8641642	131	10	,	,	PUNCT
bjos-8641642	131	11	srinivas	srinivas	PROPN
bjos-8641642	131	12	cr	cr	PROPN
bjos-8641642	131	13	.	.	PROPN
bjos-8641642	131	14	blister	blister	NOUN
bjos-8641642	131	15	fluid	fluid	NOUN
bjos-8641642	131	16	immunofluorescence	immunofluorescence	NOUN
bjos-8641642	131	17	in	in	ADP
bjos-8641642	131	18	case	case	NOUN
bjos-8641642	131	19	of	of	ADP
bjos-8641642	131	20	pemphigus	pemphigus	NOUN
bjos-8641642	131	21	vulgaris	vulgaris	NOUN
bjos-8641642	131	22	.	.	PUNCT
bjos-8641642	132	1	ind	ind	PROPN
bjos-8641642	132	2	j	j	PROPN
bjos-8641642	132	3	dermatol	dermatol	NOUN
bjos-8641642	132	4	.	.	PUNCT
bjos-8641642	133	1	2010	2010	NUM
bjos-8641642	133	2	;	;	PUNCT
bjos-8641642	133	3	55	55	NUM
bjos-8641642	133	4	:	:	PUNCT
bjos-8641642	133	5	188	188	NUM
bjos-8641642	133	6	-	-	SYM
bjos-8641642	133	7	9	9	NUM
bjos-8641642	133	8	.	.	NOUN
bjos-8641642	133	9	8	8	NUM
bjos-8641642	133	10	.	.	PUNCT
bjos-8641642	134	1	mignogna	mignogna	PROPN
bjos-8641642	134	2	md	md	PROPN
bjos-8641642	134	3	,	,	PUNCT
bjos-8641642	134	4	lorenzolo	lorenzolo	PROPN
bjos-8641642	134	5	m	m	PROPN
bjos-8641642	134	6	,	,	PUNCT
bjos-8641642	134	7	robert	robert	PROPN
bjos-8641642	134	8	c.	c.	PROPN
bjos-8641642	134	9	oral	oral	PROPN
bjos-8641642	134	10	pemphigus	pemphigus	NOUN
bjos-8641642	134	11	:	:	PUNCT
bjos-8641642	134	12	long	long	ADJ
bjos-8641642	134	13	term	term	NOUN
bjos-8641642	134	14	behaviour	behaviour	NOUN
bjos-8641642	134	15	and	and	CCONJ
bjos-8641642	134	16	clinical	clinical	ADJ
bjos-8641642	134	17	response	response	NOUN
bjos-8641642	134	18	to	to	ADP
bjos-8641642	134	19	treatment	treatment	NOUN
bjos-8641642	134	20	with	with	ADP
bjos-8641642	134	21	deflazacort	deflazacort	NOUN
bjos-8641642	134	22	in	in	ADP
bjos-8641642	134	23	sixteen	sixteen	NUM
bjos-8641642	134	24	cases	case	NOUN
bjos-8641642	134	25	.	.	PUNCT
bjos-8641642	135	1	j	j	PROPN
bjos-8641642	135	2	oral	oral	ADJ
bjos-8641642	135	3	surg	surg	NOUN
bjos-8641642	135	4	pathol	pathol	NOUN
bjos-8641642	135	5	med	me	VERB
bjos-8641642	135	6	.	.	PUNCT
bjos-8641642	135	7	2000	2000	NUM
bjos-8641642	135	8	;	;	PUNCT
bjos-8641642	135	9	29	29	NUM
bjos-8641642	135	10	:	:	SYM
bjos-8641642	135	11	145	145	NUM
bjos-8641642	135	12	-	-	SYM
bjos-8641642	135	13	52	52	NUM
bjos-8641642	135	14	.	.	NOUN
bjos-8641642	136	1	9	9	NUM
bjos-8641642	136	2	.	.	X
bjos-8641642	136	3	satyam	satyam	PROPN
bjos-8641642	136	4	a	a	DET
bjos-8641642	136	5	,	,	PUNCT
bjos-8641642	136	6	khandpur	khandpur	NOUN
bjos-8641642	136	7	s	s	X
bjos-8641642	136	8	,	,	PUNCT
bjos-8641642	136	9	sharma	sharma	PROPN
bjos-8641642	136	10	vk	vk	PROPN
bjos-8641642	136	11	,	,	PUNCT
bjos-8641642	136	12	sharma	sharma	PROPN
bjos-8641642	136	13	a.	a.	NOUN
bjos-8641642	136	14	involvement	involvement	NOUN
bjos-8641642	136	15	of	of	ADP
bjos-8641642	136	16	t(h)1/	t(h)1/	NOUN
bjos-8641642	137	1	t(h)2	t(h)2	NOUN
bjos-8641642	137	2	cytokines	cytokine	VERB
bjos-8641642	137	3	in	in	ADP
bjos-8641642	137	4	the	the	DET
bjos-8641642	137	5	pathogenesis	pathogenesis	NOUN
bjos-8641642	137	6	of	of	ADP
bjos-8641642	137	7	autoimmune	autoimmune	ADJ
bjos-8641642	137	8	skin	skin	NOUN
bjos-8641642	137	9	diseasepemphigus	diseasepemphigus	PROPN
bjos-8641642	137	10	vulgaris	vulgaris	PROPN
bjos-8641642	137	11	.	.	PUNCT
bjos-8641642	138	1	immunol	immunol	NOUN
bjos-8641642	138	2	invest	invest	PROPN
bjos-8641642	138	3	.	.	PUNCT
bjos-8641642	139	1	2009	2009	NUM
bjos-8641642	139	2	;	;	PUNCT
bjos-8641642	139	3	38	38	NUM
bjos-8641642	139	4	:	:	PUNCT
bjos-8641642	139	5	498	498	NUM
bjos-8641642	139	6	-	-	SYM
bjos-8641642	139	7	509	509	NUM
bjos-8641642	139	8	.	.	PUNCT
bjos-8641642	140	1	10	10	NUM
bjos-8641642	140	2	.	.	PUNCT
bjos-8641642	141	1	baroni	baroni	PROPN
bjos-8641642	141	2	a	a	PROPN
bjos-8641642	141	3	,	,	PUNCT
bjos-8641642	141	4	perfetto	perfetto	PROPN
bjos-8641642	141	5	b	b	PROPN
bjos-8641642	141	6	,	,	PUNCT
bjos-8641642	141	7	ruocco	ruocco	PROPN
bjos-8641642	141	8	e	e	NOUN
bjos-8641642	141	9	,	,	PUNCT
bjos-8641642	141	10	greco	greco	PROPN
bjos-8641642	141	11	r	r	PROPN
bjos-8641642	141	12	,	,	PUNCT
bjos-8641642	141	13	criscuolo	criscuolo	NOUN
bjos-8641642	141	14	d	d	NOUN
bjos-8641642	141	15	,	,	PUNCT
bjos-8641642	141	16	ruocco	ruocco	PROPN
bjos-8641642	141	17	v.	v.	ADP
bjos-8641642	141	18	cytokine	cytokine	ADJ
bjos-8641642	141	19	pattern	pattern	NOUN
bjos-8641642	141	20	in	in	ADP
bjos-8641642	141	21	blister	blister	NOUN
bjos-8641642	141	22	fluid	fluid	NOUN
bjos-8641642	141	23	and	and	CCONJ
bjos-8641642	141	24	sera	sera	NOUN
bjos-8641642	141	25	of	of	ADP
bjos-8641642	141	26	patients	patient	NOUN
bjos-8641642	141	27	with	with	ADP
bjos-8641642	141	28	pemphigus	pemphigus	PROPN
bjos-8641642	141	29	.	.	PUNCT
bjos-8641642	142	1	dermatology	dermatology	NOUN
bjos-8641642	142	2	.	.	PUNCT
bjos-8641642	143	1	2002	2002	NUM
bjos-8641642	143	2	;	;	PUNCT
bjos-8641642	143	3	205	205	NUM
bjos-8641642	143	4	:	:	SYM
bjos-8641642	143	5	116	116	NUM
bjos-8641642	143	6	-	-	SYM
bjos-8641642	143	7	21	21	NUM
bjos-8641642	143	8	.	.	PUNCT
bjos-8641642	144	1	11	11	NUM
bjos-8641642	144	2	.	.	PUNCT
bjos-8641642	145	1	keskin	keskin	PROPN
bjos-8641642	145	2	db	db	PROPN
bjos-8641642	145	3	,	,	PUNCT
bjos-8641642	145	4	stern	stern	PROPN
bjos-8641642	145	5	jn	jn	PROPN
bjos-8641642	145	6	,	,	PUNCT
bjos-8641642	145	7	fridkis	fridkis	PROPN
bjos-8641642	145	8	-	-	PUNCT
bjos-8641642	145	9	hareli	hareli	VERB
bjos-8641642	145	10	m	m	NOUN
bjos-8641642	145	11	,	,	PUNCT
bjos-8641642	145	12	razzaque	razzaque	VERB
bjos-8641642	145	13	ahme	ahme	ADJ
bjos-8641642	145	14	a.	a.	NOUN
bjos-8641642	145	15	cytokine	cytokine	NOUN
bjos-8641642	145	16	profiles	profile	NOUN
bjos-8641642	145	17	in	in	ADP
bjos-8641642	145	18	pemphi	pemphi	ADJ
bjos-8641642	145	19	-	-	PUNCT
bjos-8641642	145	20	gus	gus	NOUN
bjos-8641642	145	21	vulgaris	vulgaris	NOUN
bjos-8641642	145	22	patients	patient	NOUN
bjos-8641642	145	23	treated	treat	VERB
bjos-8641642	145	24	with	with	ADP
bjos-8641642	145	25	intravenous	intravenous	ADJ
bjos-8641642	145	26	igs	ig	NOUN
bjos-8641642	145	27	as	as	SCONJ
bjos-8641642	145	28	compared	compare	VERB
bjos-8641642	145	29	to	to	ADP
bjos-8641642	145	30	controlled	control	VERB
bjos-8641642	145	31	immunosuppressive	immunosuppressive	ADJ
bjos-8641642	145	32	therapy	therapy	NOUN
bjos-8641642	145	33	.	.	PUNCT
bjos-8641642	146	1	cytokine	cytokine	NOUN
bjos-8641642	146	2	.	.	PUNCT
bjos-8641642	146	3	2008	2008	NUM
bjos-8641642	146	4	;	;	PUNCT
bjos-8641642	146	5	4	4	NUM
bjos-8641642	146	6	:	:	SYM
bjos-8641642	146	7	15	15	NUM
bjos-8641642	146	8	-	-	SYM
bjos-8641642	146	9	21	21	NUM
bjos-8641642	146	10	.	.	PUNCT
bjos-8641642	147	1	braz	braz	PROPN
bjos-8641642	147	2	j	j	PROPN
bjos-8641642	147	3	oral	oral	PROPN
bjos-8641642	147	4	sci	sci	PROPN
bjos-8641642	147	5	.	.	PUNCT
bjos-8641642	148	1	10(2):83	10(2):83	NUM
bjos-8641642	148	2	-	-	SYM
bjos-8641642	148	3	87	87	NUM
bjos-8641642	148	4	cytokine	cytokine	ADJ
bjos-8641642	148	5	profiles	profile	NOUN
bjos-8641642	148	6	in	in	ADP
bjos-8641642	148	7	the	the	DET
bjos-8641642	148	8	sera	sera	NOUN
bjos-8641642	148	9	of	of	ADP
bjos-8641642	148	10	egyptian	egyptian	ADJ
bjos-8641642	148	11	patients	patient	NOUN
bjos-8641642	148	12	with	with	ADP
bjos-8641642	148	13	oral	oral	ADJ
bjos-8641642	148	14	pemphigus	pemphigus	ADJ
bjos-8641642	148	15	vulgaris	vulgaris	NOUN
bjos-8641642	148	16	87	87	NUM
bjos-8641642	148	17	12	12	NUM
bjos-8641642	148	18	.	.	PUNCT
bjos-8641642	149	1	feliciani	feliciani	PROPN
bjos-8641642	149	2	c	c	X
bjos-8641642	149	3	,	,	PUNCT
bjos-8641642	149	4	toto	toto	NOUN
bjos-8641642	149	5	p	p	X
bjos-8641642	149	6	,	,	PUNCT
bjos-8641642	149	7	amerio	amerio	ADP
bjos-8641642	149	8	p	p	X
bjos-8641642	149	9	,	,	PUNCT
bjos-8641642	149	10	pour	pour	PROPN
bjos-8641642	149	11	sm	sm	PROPN
bjos-8641642	149	12	,	,	PUNCT
bjos-8641642	149	13	coscione	coscione	NOUN
bjos-8641642	149	14	g	g	PROPN
bjos-8641642	149	15	,	,	PUNCT
bjos-8641642	149	16	shivji	shivji	PROPN
bjos-8641642	149	17	g	g	PROPN
bjos-8641642	149	18	et	et	PROPN
bjos-8641642	149	19	al	al	PROPN
bjos-8641642	149	20	.	.	PROPN
bjos-8641642	150	1	in	in	ADP
bjos-8641642	150	2	vitro	vitro	X
bjos-8641642	150	3	and	and	CCONJ
bjos-8641642	150	4	in	in	ADP
bjos-8641642	150	5	vivo	vivo	ADJ
bjos-8641642	150	6	expression	expression	NOUN
bjos-8641642	150	7	of	of	ADP
bjos-8641642	150	8	interleukin-1	interleukin-1	NOUN
bjos-8641642	150	9	-	-	PUNCT
bjos-8641642	150	10	alpha	alpha	NOUN
bjos-8641642	150	11	and	and	CCONJ
bjos-8641642	150	12	tumor	tumor	NOUN
bjos-8641642	150	13	necrosis	necrosis	NOUN
bjos-8641642	150	14	factor	factor	NOUN
bjos-8641642	150	15	-	-	PUNCT
bjos-8641642	150	16	alpha	alpha	NOUN
bjos-8641642	150	17	mrna	mrna	NOUN
bjos-8641642	150	18	in	in	ADP
bjos-8641642	150	19	pemphigus	pemphigus	NOUN
bjos-8641642	150	20	vulgaris	vulgaris	NOUN
bjos-8641642	150	21	:	:	PUNCT
bjos-8641642	150	22	interleukin-1	interleukin-1	NOUN
bjos-8641642	150	23	-	-	PUNCT
bjos-8641642	150	24	alpha	alpha	NOUN
bjos-8641642	150	25	and	and	CCONJ
bjos-8641642	150	26	tumor	tumor	NOUN
bjos-8641642	150	27	necrosis	necrosis	NOUN
bjos-8641642	150	28	factor	factor	NOUN
bjos-8641642	150	29	-	-	PUNCT
bjos-8641642	150	30	alpha	alpha	NOUN
bjos-8641642	150	31	are	be	AUX
bjos-8641642	150	32	involved	involve	VERB
bjos-8641642	150	33	in	in	ADP
bjos-8641642	150	34	acantholysis	acantholysis	NOUN
bjos-8641642	150	35	.	.	PUNCT
bjos-8641642	151	1	j	j	PROPN
bjos-8641642	151	2	invest	invest	VERB
bjos-8641642	151	3	dermatol	dermatol	NOUN
bjos-8641642	151	4	.	.	PUNCT
bjos-8641642	152	1	2002	2002	NUM
bjos-8641642	152	2	;	;	PUNCT
bjos-8641642	152	3	114	114	NUM
bjos-8641642	152	4	:	:	PUNCT
bjos-8641642	152	5	71	71	NUM
bjos-8641642	152	6	-	-	SYM
bjos-8641642	152	7	7	7	NUM
bjos-8641642	152	8	.	.	NOUN
bjos-8641642	152	9	13	13	NUM
bjos-8641642	152	10	.	.	PUNCT
bjos-8641642	153	1	lopez	lopez	NOUN
bjos-8641642	153	2	-	-	PUNCT
bjos-8641642	153	3	robles	robles	PROPN
bjos-8641642	153	4	e	e	PROPN
bjos-8641642	153	5	,	,	PUNCT
bjos-8641642	153	6	avalos	avalos	PROPN
bjos-8641642	153	7	-	-	PUNCT
bjos-8641642	153	8	diaz	diaz	PROPN
bjos-8641642	153	9	e	e	PROPN
bjos-8641642	153	10	,	,	PUNCT
bjos-8641642	153	11	vega	vega	PROPN
bjos-8641642	153	12	-	-	PUNCT
bjos-8641642	153	13	memije	memije	PROPN
bjos-8641642	153	14	e	e	NOUN
bjos-8641642	153	15	,	,	PUNCT
bjos-8641642	153	16	et	et	PROPN
bjos-8641642	153	17	al	al	PROPN
bjos-8641642	153	18	.	.	PROPN
bjos-8641642	153	19	tnfá	tnfá	PROPN
bjos-8641642	153	20	and	and	CCONJ
bjos-8641642	153	21	il-6	il-6	NOUN
bjos-8641642	153	22	are	be	AUX
bjos-8641642	153	23	mediators	mediator	NOUN
bjos-8641642	153	24	in	in	ADP
bjos-8641642	153	25	the	the	DET
bjos-8641642	153	26	blistering	blister	VERB
bjos-8641642	153	27	process	process	NOUN
bjos-8641642	153	28	of	of	ADP
bjos-8641642	153	29	pemphigus	pemphigus	PROPN
bjos-8641642	153	30	.	.	PUNCT
bjos-8641642	154	1	int	int	PROPN
bjos-8641642	154	2	j	j	PROPN
bjos-8641642	154	3	dermatol	dermatol	NOUN
bjos-8641642	154	4	.	.	PUNCT
bjos-8641642	155	1	2001	2001	NUM
bjos-8641642	155	2	;	;	PUNCT
bjos-8641642	155	3	40	40	NUM
bjos-8641642	155	4	:	:	SYM
bjos-8641642	155	5	185	185	NUM
bjos-8641642	155	6	-	-	SYM
bjos-8641642	155	7	8	8	NUM
bjos-8641642	155	8	.	.	PUNCT
bjos-8641642	155	9	14	14	NUM
bjos-8641642	155	10	.	.	PUNCT
bjos-8641642	156	1	ahmed	ahmed	PROPN
bjos-8641642	156	2	ar	ar	PROPN
bjos-8641642	156	3	,	,	PUNCT
bjos-8641642	156	4	yunis	yunis	PROPN
bjos-8641642	156	5	ej	ej	PROPN
bjos-8641642	156	6	,	,	PUNCT
bjos-8641642	156	7	kharti	kharti	PROPN
bjos-8641642	156	8	k	k	PROPN
bjos-8641642	156	9	,	,	PUNCT
bjos-8641642	156	10	wagner	wagner	PROPN
bjos-8641642	156	11	r	r	PROPN
bjos-8641642	156	12	,	,	PUNCT
bjos-8641642	156	13	notani	notani	VERB
bjos-8641642	156	14	g	g	NOUN
bjos-8641642	156	15	,	,	PUNCT
bjos-8641642	156	16	awdeh	awdeh	PROPN
bjos-8641642	156	17	z	z	PROPN
bjos-8641642	156	18	et	et	PROPN
bjos-8641642	156	19	al	al	PROPN
bjos-8641642	156	20	.	.	PUNCT
bjos-8641642	157	1	major	major	ADJ
bjos-8641642	157	2	histocompatibility	histocompatibility	NOUN
bjos-8641642	157	3	complexhaplotype	complexhaplotype	NOUN
bjos-8641642	157	4	in	in	ADP
bjos-8641642	157	5	ashkenazi	ashkenazi	ADJ
bjos-8641642	157	6	jewish	jewish	ADJ
bjos-8641642	157	7	patients	patient	NOUN
bjos-8641642	157	8	with	with	ADP
bjos-8641642	157	9	pemphigus	pemphigus	NOUN
bjos-8641642	157	10	vulgaris	vulgaris	NOUN
bjos-8641642	157	11	.	.	PUNCT
bjos-8641642	158	1	proc	proc	PROPN
bjos-8641642	158	2	natl	natl	PROPN
bjos-8641642	158	3	acad	acad	PROPN
bjos-8641642	158	4	sci	sci	PROPN
bjos-8641642	158	5	.	.	PROPN
bjos-8641642	158	6	1990	1990	NUM
bjos-8641642	158	7	;	;	PUNCT
bjos-8641642	158	8	87	87	NUM
bjos-8641642	158	9	:	:	PUNCT
bjos-8641642	158	10	7658	7658	NUM
bjos-8641642	158	11	-	-	SYM
bjos-8641642	158	12	62	62	NUM
bjos-8641642	158	13	.	.	PUNCT
bjos-8641642	159	1	15	15	NUM
bjos-8641642	159	2	.	.	PUNCT
bjos-8641642	160	1	brenner	brenner	PROPN
bjos-8641642	160	2	s	s	PROPN
bjos-8641642	160	3	,	,	PUNCT
bjos-8641642	160	4	tur	tur	PROPN
bjos-8641642	160	5	e	e	NOUN
bjos-8641642	160	6	,	,	PUNCT
bjos-8641642	160	7	shapio	shapio	PROPN
bjos-8641642	160	8	j	j	PROPN
bjos-8641642	160	9	,	,	PUNCT
bjos-8641642	160	10	ruocco	ruocco	PROPN
bjos-8641642	160	11	v	v	NOUN
bjos-8641642	160	12	,	,	PUNCT
bjos-8641642	160	13	a’avino	a’avino	PROPN
bjos-8641642	160	14	m	m	PROPN
bjos-8641642	160	15	,	,	PUNCT
bjos-8641642	160	16	ruocco	ruocco	PROPN
bjos-8641642	160	17	e	e	PROPN
bjos-8641642	160	18	et	et	PROPN
bjos-8641642	160	19	al	al	PROPN
bjos-8641642	160	20	.	.	PROPN
bjos-8641642	161	1	pemphigus	pemphigus	PROPN
bjos-8641642	161	2	vulgaris	vulgaris	PROPN
bjos-8641642	161	3	:	:	PUNCT
bjos-8641642	161	4	environmental	environmental	ADJ
bjos-8641642	161	5	factors	factor	NOUN
bjos-8641642	161	6	,	,	PUNCT
bjos-8641642	161	7	occupational	occupational	ADJ
bjos-8641642	161	8	,	,	PUNCT
bjos-8641642	161	9	behavioral	behavioral	ADJ
bjos-8641642	161	10	,	,	PUNCT
bjos-8641642	161	11	medical	medical	ADJ
bjos-8641642	161	12	and	and	CCONJ
bjos-8641642	161	13	frequently	frequently	ADV
bjos-8641642	161	14	quetionnaire	quetionnaire	NOUN
bjos-8641642	161	15	.	.	PUNCT
bjos-8641642	162	1	int	int	NOUN
bjos-8641642	162	2	j	j	PROPN
bjos-8641642	162	3	dermatol	dermatol	NOUN
bjos-8641642	162	4	.	.	PUNCT
bjos-8641642	163	1	2001	2001	NUM
bjos-8641642	163	2	;	;	PUNCT
bjos-8641642	163	3	40	40	NUM
bjos-8641642	163	4	:	:	PUNCT
bjos-8641642	163	5	562	562	NUM
bjos-8641642	163	6	-	-	SYM
bjos-8641642	163	7	9	9	NUM
bjos-8641642	163	8	.	.	NOUN
bjos-8641642	163	9	16	16	NUM
bjos-8641642	163	10	.	.	PUNCT
bjos-8641642	164	1	john	john	PROPN
bjos-8641642	164	2	c	c	PROPN
bjos-8641642	164	3	,	,	PUNCT
bjos-8641642	164	4	robinson	robinson	PROPN
bjos-8641642	164	5	ma	ma	PROPN
bjos-8641642	164	6	,	,	PUNCT
bjos-8641642	164	7	lozada	lozada	PROPN
bjos-8641642	164	8	f.	f.	PROPN
bjos-8641642	164	9	oral	oral	PROPN
bjos-8641642	164	10	pemphigus	pemphigus	PROPN
bjos-8641642	164	11	vulgaris	vulgaris	NOUN
bjos-8641642	164	12	.	.	PUNCT
bjos-8641642	165	1	oral	oral	ADJ
bjos-8641642	165	2	surg	surg	NOUN
bjos-8641642	165	3	oral	oral	ADJ
bjos-8641642	165	4	med	med	ADJ
bjos-8641642	165	5	oral	oral	ADJ
bjos-8641642	165	6	pathol	pathol	NOUN
bjos-8641642	165	7	.	.	PUNCT
bjos-8641642	166	1	1997	1997	NUM
bjos-8641642	166	2	;	;	PUNCT
bjos-8641642	166	3	84	84	NUM
bjos-8641642	166	4	:	:	PUNCT
bjos-8641642	166	5	349	349	NUM
bjos-8641642	166	6	-	-	SYM
bjos-8641642	166	7	55	55	NUM
bjos-8641642	166	8	.	.	PUNCT
bjos-8641642	167	1	17	17	NUM
bjos-8641642	167	2	.	.	PUNCT
bjos-8641642	168	1	tetsuya	tetsuya	PROPN
bjos-8641642	168	2	y	y	PROPN
bjos-8641642	168	3	,	,	PUNCT
bjos-8641642	168	4	kazunori	kazunori	PROPN
bjos-8641642	168	5	y	y	PROPN
bjos-8641642	168	6	,	,	PUNCT
bjos-8641642	168	7	osaki	osaki	PROPN
bjos-8641642	168	8	t.	t.	PROPN
bjos-8641642	168	9	serum	serum	PROPN
bjos-8641642	168	10	cytokines	cytokine	NOUN
bjos-8641642	168	11	,	,	PUNCT
bjos-8641642	168	12	interleukin-2	interleukin-2	NOUN
bjos-8641642	168	13	receptor	receptor	NOUN
bjos-8641642	168	14	,	,	PUNCT
bjos-8641642	168	15	and	and	CCONJ
bjos-8641642	168	16	soluble	soluble	ADJ
bjos-8641642	168	17	intercellular	intercellular	ADJ
bjos-8641642	168	18	adhesion	adhesion	NOUN
bjos-8641642	168	19	molecule-1	molecule-1	PROPN
bjos-8641642	168	20	in	in	ADP
bjos-8641642	168	21	oral	oral	ADJ
bjos-8641642	168	22	disorders	disorder	NOUN
bjos-8641642	168	23	.	.	PUNCT
bjos-8641642	169	1	oral	oral	ADJ
bjos-8641642	169	2	surg	surg	NOUN
bjos-8641642	169	3	oral	oral	ADJ
bjos-8641642	169	4	med	med	ADJ
bjos-8641642	169	5	oral	oral	ADJ
bjos-8641642	169	6	pathol	pathol	NOUN
bjos-8641642	169	7	.	.	PUNCT
bjos-8641642	169	8	1994	1994	NUM
bjos-8641642	169	9	;	;	PUNCT
bjos-8641642	169	10	78	78	NUM
bjos-8641642	169	11	:	:	PUNCT
bjos-8641642	169	12	727	727	NUM
bjos-8641642	169	13	-	-	SYM
bjos-8641642	169	14	35	35	NUM
bjos-8641642	169	15	.	.	PUNCT
bjos-8641642	169	16	18	18	NUM
bjos-8641642	169	17	.	.	PUNCT
bjos-8641642	170	1	alecu	alecu	NUM
bjos-8641642	170	2	m	m	PROPN
bjos-8641642	170	3	,	,	PUNCT
bjos-8641642	170	4	alecu	alecu	PROPN
bjos-8641642	170	5	s	s	PROPN
bjos-8641642	170	6	,	,	PUNCT
bjos-8641642	170	7	coman	coman	PROPN
bjos-8641642	170	8	g	g	PROPN
bjos-8641642	170	9	,	,	PUNCT
bjos-8641642	170	10	galatescu	galatescu	NOUN
bjos-8641642	170	11	e	e	NOUN
bjos-8641642	170	12	,	,	PUNCT
bjos-8641642	170	13	ursaciuc	ursaciuc	PROPN
bjos-8641642	170	14	c.	c.	PROPN
bjos-8641642	170	15	tnf	tnf	PROPN
bjos-8641642	170	16	-	-	PUNCT
bjos-8641642	170	17	á	á	PROPN
bjos-8641642	170	18	and	and	CCONJ
bjos-8641642	170	19	il6	il6	NOUN
bjos-8641642	170	20	in	in	ADP
bjos-8641642	170	21	serum	serum	NOUN
bjos-8641642	170	22	and	and	CCONJ
bjos-8641642	170	23	blister	blister	NOUN
bjos-8641642	170	24	liquid	liquid	NOUN
bjos-8641642	170	25	of	of	ADP
bjos-8641642	170	26	pemphigus	pemphigus	ADJ
bjos-8641642	170	27	vulgaris	vulgaris	NOUN
bjos-8641642	170	28	patients	patient	NOUN
bjos-8641642	170	29	.	.	PUNCT
bjos-8641642	171	1	roumanian	roumanian	ADJ
bjos-8641642	171	2	.	.	PUNCT
bjos-8641642	172	1	arch	arch	PROPN
bjos-8641642	172	2	microbiol	microbiol	PROPN
bjos-8641642	172	3	immunol	immunol	NOUN
bjos-8641642	172	4	.	.	PUNCT
bjos-8641642	173	1	1999	1999	NUM
bjos-8641642	173	2	;	;	PUNCT
bjos-8641642	174	1	58	58	NUM
bjos-8641642	174	2	:	:	SYM
bjos-8641642	174	3	121	121	NUM
bjos-8641642	174	4	-	-	SYM
bjos-8641642	174	5	30	30	NUM
bjos-8641642	174	6	.	.	PUNCT
bjos-8641642	175	1	19	19	NUM
bjos-8641642	175	2	.	.	PUNCT
bjos-8641642	175	3	gomi	gomi	PROPN
bjos-8641642	175	4	t	t	PROPN
bjos-8641642	175	5	,	,	PUNCT
bjos-8641642	175	6	shiohara	shiohara	PROPN
bjos-8641642	175	7	t	t	PROPN
bjos-8641642	175	8	,	,	PUNCT
bjos-8641642	175	9	munakata	munakata	PROPN
bjos-8641642	175	10	t	t	PROPN
bjos-8641642	175	11	,	,	PUNCT
bjos-8641642	175	12	imanishi	imanishi	PROPN
bjos-8641642	175	13	k	k	PROPN
bjos-8641642	175	14	,	,	PUNCT
bjos-8641642	175	15	nagashima	nagashima	NOUN
bjos-8641642	175	16	m.	m.	NOUN
bjos-8641642	175	17	interleukin	interleukin	NOUN
bjos-8641642	175	18	1á	1á	ADV
bjos-8641642	175	19	,	,	PUNCT
bjos-8641642	175	20	tumor	tumor	NOUN
bjos-8641642	175	21	necrosis	necrosis	NOUN
bjos-8641642	175	22	factor	factor	NOUN
bjos-8641642	175	23	á	á	NOUN
bjos-8641642	175	24	,	,	PUNCT
bjos-8641642	175	25	and	and	CCONJ
bjos-8641642	175	26	interferon	interferon	ADJ
bjos-8641642	175	27	ã	ã	X
bjos-8641642	175	28	in	in	ADP
bjos-8641642	175	29	psoriasis	psoriasis	NOUN
bjos-8641642	175	30	.	.	PUNCT
bjos-8641642	176	1	arch	arch	ADJ
bjos-8641642	176	2	dermatol	dermatol	NOUN
bjos-8641642	176	3	.	.	PUNCT
bjos-8641642	177	1	1991	1991	NUM
bjos-8641642	177	2	;	;	PUNCT
bjos-8641642	177	3	127	127	NUM
bjos-8641642	177	4	:	:	PUNCT
bjos-8641642	177	5	827	827	NUM
bjos-8641642	177	6	-	-	SYM
bjos-8641642	177	7	30	30	NUM
bjos-8641642	177	8	.	.	PUNCT
bjos-8641642	178	1	20	20	NUM
bjos-8641642	178	2	.	.	PUNCT
bjos-8641642	179	1	kantor	kantor	PROPN
bjos-8641642	179	2	tv	tv	PROPN
bjos-8641642	179	3	,	,	PUNCT
bjos-8641642	179	4	friberg	friberg	PROPN
bjos-8641642	179	5	d	d	PROPN
bjos-8641642	179	6	,	,	PUNCT
bjos-8641642	179	7	medsger	medsger	NOUN
bjos-8641642	179	8	ta	ta	PROPN
bjos-8641642	179	9	jr	jr	PROPN
bjos-8641642	179	10	,	,	PUNCT
bjos-8641642	179	11	buckingham	buckingham	PROPN
bjos-8641642	179	12	rb	rb	PROPN
bjos-8641642	179	13	,	,	PUNCT
bjos-8641642	179	14	whiteside	whiteside	PROPN
bjos-8641642	179	15	tl	tl	PROPN
bjos-8641642	179	16	.	.	PROPN
bjos-8641642	179	17	cytokine	cytokine	PROPN
bjos-8641642	179	18	production	production	NOUN
bjos-8641642	179	19	and	and	CCONJ
bjos-8641642	179	20	serum	serum	NOUN
bjos-8641642	179	21	levels	level	NOUN
bjos-8641642	179	22	in	in	ADP
bjos-8641642	179	23	systemic	systemic	ADJ
bjos-8641642	179	24	sclerosis	sclerosis	NOUN
bjos-8641642	179	25	.	.	PUNCT
bjos-8641642	180	1	clin	clin	PROPN
bjos-8641642	180	2	immunol	immunol	PROPN
bjos-8641642	180	3	immunopathol	immunopathol	PROPN
bjos-8641642	180	4	.	.	PUNCT
bjos-8641642	181	1	1992	1992	NUM
bjos-8641642	181	2	;	;	PUNCT
bjos-8641642	181	3	65	65	NUM
bjos-8641642	181	4	:	:	SYM
bjos-8641642	181	5	278	278	NUM
bjos-8641642	181	6	-	-	SYM
bjos-8641642	181	7	85	85	NUM
bjos-8641642	181	8	.	.	NUM
bjos-8641642	182	1	21	21	NUM
bjos-8641642	182	2	.	.	PUNCT
bjos-8641642	183	1	kock	kock	PROPN
bjos-8641642	183	2	a	a	PROPN
bjos-8641642	183	3	,	,	PUNCT
bjos-8641642	183	4	schwarz	schwarz	PROPN
bjos-8641642	183	5	t	t	PROPN
bjos-8641642	183	6	,	,	PUNCT
bjos-8641642	183	7	kimbauer	kimbauer	PROPN
bjos-8641642	183	8	r	r	PROPN
bjos-8641642	183	9	,	,	PUNCT
bjos-8641642	183	10	urbanski	urbanski	NOUN
bjos-8641642	183	11	a	a	PRON
bjos-8641642	183	12	,	,	PUNCT
bjos-8641642	183	13	perry	perry	PROPN
bjos-8641642	183	14	p	p	PROPN
bjos-8641642	183	15	,	,	PUNCT
bjos-8641642	183	16	ansel	ansel	PROPN
bjos-8641642	183	17	jc	jc	PROPN
bjos-8641642	183	18	et	et	PROPN
bjos-8641642	183	19	al	al	PROPN
bjos-8641642	183	20	.	.	PUNCT
bjos-8641642	184	1	human	human	ADJ
bjos-8641642	184	2	keratinocytes	keratinocyte	NOUN
bjos-8641642	184	3	are	be	AUX
bjos-8641642	184	4	a	a	DET
bjos-8641642	184	5	source	source	NOUN
bjos-8641642	184	6	for	for	ADP
bjos-8641642	184	7	tumor	tumor	NOUN
bjos-8641642	184	8	necrosis	necrosis	NOUN
bjos-8641642	184	9	factor	factor	NOUN
bjos-8641642	184	10	á	á	NOUN
bjos-8641642	184	11	:	:	PUNCT
bjos-8641642	184	12	evidence	evidence	NOUN
bjos-8641642	184	13	for	for	ADP
bjos-8641642	184	14	synthesis	synthesis	NOUN
bjos-8641642	184	15	and	and	CCONJ
bjos-8641642	184	16	release	release	VERB
bjos-8641642	184	17	upon	upon	SCONJ
bjos-8641642	184	18	stimulation	stimulation	NOUN
bjos-8641642	184	19	with	with	ADP
bjos-8641642	184	20	endotoxin	endotoxin	NOUN
bjos-8641642	184	21	or	or	CCONJ
bjos-8641642	184	22	ultraviolet	ultraviolet	ADJ
bjos-8641642	184	23	light	light	NOUN
bjos-8641642	184	24	.	.	PUNCT
bjos-8641642	185	1	j	j	PROPN
bjos-8641642	185	2	exp	exp	NOUN
bjos-8641642	185	3	med	med	PROPN
bjos-8641642	185	4	.	.	PUNCT
bjos-8641642	185	5	1990	1990	NUM
bjos-8641642	185	6	;	;	PUNCT
bjos-8641642	185	7	172):1609	172):1609	NUM
bjos-8641642	185	8	-	-	SYM
bjos-8641642	185	9	14	14	NUM
bjos-8641642	185	10	.	.	PUNCT
bjos-8641642	186	1	22	22	NUM
bjos-8641642	186	2	.	.	PUNCT
bjos-8641642	186	3	sugermann	sugermann	PROPN
bjos-8641642	186	4	nw	nw	PROPN
bjos-8641642	186	5	,	,	PUNCT
bjos-8641642	186	6	savage	savage	NOUN
bjos-8641642	186	7	gj	gj	PROPN
bjos-8641642	186	8	,	,	PUNCT
bjos-8641642	186	9	seymour	seymour	PROPN
bjos-8641642	186	10	l.	l.	PROPN
bjos-8641642	186	11	is	be	AUX
bjos-8641642	186	12	there	there	PRON
bjos-8641642	186	13	a	a	DET
bjos-8641642	186	14	role	role	NOUN
bjos-8641642	186	15	for	for	ADP
bjos-8641642	186	16	tumor	tumor	NOUN
bjos-8641642	186	17	necrosis	necrosis	NOUN
bjos-8641642	186	18	factor	factor	NOUN
bjos-8641642	186	19	-	-	PUNCT
bjos-8641642	186	20	alpha	alpha	NOUN
bjos-8641642	186	21	(	(	PUNCT
bjos-8641642	186	22	tnf	tnf	PROPN
bjos-8641642	186	23	-	-	PUNCT
bjos-8641642	186	24	á	á	PROPN
bjos-8641642	186	25	)	)	PUNCT
bjos-8641642	186	26	in	in	ADP
bjos-8641642	186	27	oral	oral	ADJ
bjos-8641642	186	28	lichen	lichen	NOUN
bjos-8641642	186	29	planus	planus	NOUN
bjos-8641642	186	30	?	?	PUNCT
bjos-8641642	187	1	j	j	PROPN
bjos-8641642	187	2	oral	oral	ADJ
bjos-8641642	187	3	pathol	pathol	NOUN
bjos-8641642	187	4	med	me	VERB
bjos-8641642	187	5	.	.	PUNCT
bjos-8641642	187	6	1996	1996	NUM
bjos-8641642	187	7	;	;	PUNCT
bjos-8641642	188	1	25	25	NUM
bjos-8641642	188	2	:	:	SYM
bjos-8641642	188	3	219	219	NUM
bjos-8641642	188	4	-	-	SYM
bjos-8641642	188	5	24	24	NUM
bjos-8641642	188	6	.	.	PUNCT
bjos-8641642	188	7	23	23	NUM
bjos-8641642	188	8	.	.	PUNCT
bjos-8641642	189	1	takeuchi	takeuchi	PROPN
bjos-8641642	189	2	y	y	PROPN
bjos-8641642	189	3	,	,	PUNCT
bjos-8641642	189	4	tohani	tohani	PROPN
bjos-8641642	189	5	i	i	PROPN
bjos-8641642	189	6	,	,	PUNCT
bjos-8641642	189	7	kaneda	kaneda	PROPN
bjos-8641642	189	8	t.	t.	PROPN
bjos-8641642	189	9	immuno	immuno	PROPN
bjos-8641642	189	10	-	-	ADJ
bjos-8641642	189	11	histochemical	histochemical	ADJ
bjos-8641642	189	12	analysis	analysis	NOUN
bjos-8641642	189	13	of	of	ADP
bjos-8641642	189	14	cells	cell	NOUN
bjos-8641642	189	15	in	in	ADP
bjos-8641642	189	16	mucosal	mucosal	ADJ
bjos-8641642	189	17	lesions	lesion	NOUN
bjos-8641642	189	18	of	of	ADP
bjos-8641642	189	19	lichen	lichen	NOUN
bjos-8641642	189	20	planus	planus	NOUN
bjos-8641642	189	21	.	.	PUNCT
bjos-8641642	190	1	j	j	PROPN
bjos-8641642	190	2	oral	oral	ADJ
bjos-8641642	190	3	pathol	pathol	NOUN
bjos-8641642	190	4	med	me	VERB
bjos-8641642	190	5	.	.	PUNCT
bjos-8641642	190	6	1988	1988	NUM
bjos-8641642	190	7	;	;	PUNCT
bjos-8641642	190	8	17	17	NUM
bjos-8641642	190	9	:	:	SYM
bjos-8641642	190	10	367	367	NUM
bjos-8641642	190	11	-	-	SYM
bjos-8641642	190	12	71	71	NUM
bjos-8641642	190	13	.	.	PUNCT
bjos-8641642	190	14	24	24	NUM
bjos-8641642	190	15	.	.	X
bjos-8641642	191	1	farthing	farthe	VERB
bjos-8641642	191	2	pm	pm	PROPN
bjos-8641642	191	3	,	,	PUNCT
bjos-8641642	191	4	thornhill	thornhill	PROPN
bjos-8641642	191	5	mh	mh	PROPN
bjos-8641642	191	6	.	.	PUNCT
bjos-8641642	191	7	il-1	il-1	PART
bjos-8641642	192	1	á	á	PROPN
bjos-8641642	192	2	and	and	CCONJ
bjos-8641642	192	3	il-6	il-6	NOUN
bjos-8641642	192	4	production	production	NOUN
bjos-8641642	192	5	by	by	ADP
bjos-8641642	192	6	oral	oral	ADJ
bjos-8641642	192	7	and	and	CCONJ
bjos-8641642	192	8	skin	skin	NOUN
bjos-8641642	192	9	keratinocytes	keratinocyte	NOUN
bjos-8641642	192	10	:	:	PUNCT
bjos-8641642	192	11	similarities	similarity	NOUN
bjos-8641642	192	12	and	and	CCONJ
bjos-8641642	192	13	differences	difference	NOUN
bjos-8641642	192	14	in	in	ADP
bjos-8641642	192	15	response	response	NOUN
bjos-8641642	192	16	to	to	PART
bjos-8641642	192	17	cytokine	cytokine	VERB
bjos-8641642	192	18	treatment	treatment	NOUN
bjos-8641642	192	19	in	in	ADP
bjos-8641642	192	20	vitro	vitro	X
bjos-8641642	192	21	.	.	PUNCT
bjos-8641642	193	1	j	j	PROPN
bjos-8641642	193	2	oral	oral	ADJ
bjos-8641642	193	3	pathol	pathol	NOUN
bjos-8641642	193	4	med	me	VERB
bjos-8641642	193	5	.	.	PUNCT
bjos-8641642	193	6	1996	1996	NUM
bjos-8641642	193	7	;	;	PUNCT
bjos-8641642	193	8	25	25	NUM
bjos-8641642	193	9	:	:	SYM
bjos-8641642	193	10	157	157	NUM
bjos-8641642	193	11	-	-	SYM
bjos-8641642	193	12	62	62	NUM
bjos-8641642	193	13	.	.	PUNCT
bjos-8641642	194	1	25	25	NUM
bjos-8641642	194	2	.	.	PUNCT
bjos-8641642	194	3	wilson	wilson	PROPN
bjos-8641642	194	4	m	m	PROPN
bjos-8641642	194	5	,	,	PUNCT
bjos-8641642	194	6	reddi	reddi	PROPN
bjos-8641642	194	7	,	,	PUNCT
bjos-8641642	194	8	henderson	henderson	PROPN
bjos-8641642	194	9	b.	b.	PROPN
bjos-8641642	194	10	cytokine	cytokine	PROPN
bjos-8641642	194	11	-	-	PUNCT
bjos-8641642	194	12	inducing	induce	VERB
bjos-8641642	194	13	components	component	NOUN
bjos-8641642	194	14	of	of	ADP
bjos-8641642	194	15	periodonto	periodonto	NOUN
bjos-8641642	194	16	-	-	PUNCT
bjos-8641642	194	17	pathogenic	pathogenic	ADJ
bjos-8641642	194	18	bacteria	bacteria	NOUN
bjos-8641642	194	19	.	.	PUNCT
bjos-8641642	195	1	j	j	PROPN
bjos-8641642	195	2	priodont	priodont	PROPN
bjos-8641642	195	3	res	re	NOUN
bjos-8641642	195	4	.	.	PUNCT
bjos-8641642	195	5	1996	1996	NUM
bjos-8641642	195	6	;	;	PUNCT
bjos-8641642	195	7	31	31	NUM
bjos-8641642	195	8	:	:	SYM
bjos-8641642	195	9	393	393	NUM
bjos-8641642	195	10	-	-	SYM
bjos-8641642	195	11	407	407	NUM
bjos-8641642	195	12	.	.	PUNCT
bjos-8641642	196	1	26	26	NUM
bjos-8641642	196	2	.	.	PUNCT
bjos-8641642	197	1	yamamoto	yamamoto	PROPN
bjos-8641642	197	2	t	t	PROPN
bjos-8641642	197	3	,	,	PUNCT
bjos-8641642	197	4	osaki	osaki	PROPN
bjos-8641642	197	5	t	t	PROPN
bjos-8641642	197	6	,	,	PUNCT
bjos-8641642	197	7	ueta	ueta	PROPN
bjos-8641642	197	8	k.	k.	PROPN
bjos-8641642	197	9	cytokine	cytokine	PROPN
bjos-8641642	197	10	production	production	NOUN
bjos-8641642	197	11	by	by	ADP
bjos-8641642	197	12	keratinocytes	keratinocyte	NOUN
bjos-8641642	197	13	and	and	CCONJ
bjos-8641642	197	14	mononuclear	mononuclear	ADJ
bjos-8641642	197	15	infiltrates	infiltrate	NOUN
bjos-8641642	197	16	in	in	ADP
bjos-8641642	197	17	oral	oral	ADJ
bjos-8641642	197	18	lichen	lichen	NOUN
bjos-8641642	197	19	planus	planus	NOUN
bjos-8641642	197	20	.	.	PUNCT
bjos-8641642	198	1	j	j	PROPN
bjos-8641642	198	2	oral	oral	ADJ
bjos-8641642	198	3	pathol	pathol	NOUN
bjos-8641642	198	4	med	me	VERB
bjos-8641642	198	5	.	.	PUNCT
bjos-8641642	198	6	1994	1994	NUM
bjos-8641642	198	7	;	;	PUNCT
bjos-8641642	198	8	23	23	NUM
bjos-8641642	198	9	:	:	PUNCT
bjos-8641642	198	10	309	309	NUM
bjos-8641642	198	11	-	-	SYM
bjos-8641642	198	12	15	15	NUM
bjos-8641642	198	13	.	.	PUNCT
bjos-8641642	199	1	braz	braz	PROPN
bjos-8641642	199	2	j	j	PROPN
bjos-8641642	199	3	oral	oral	PROPN
bjos-8641642	199	4	sci	sci	PROPN
bjos-8641642	199	5	.	.	PUNCT
bjos-8641642	200	1	10(2):83	10(2):83	NUM
bjos-8641642	200	2	-	-	SYM
bjos-8641642	200	3	87	87	NUM
bjos-8641642	200	4	cytokine	cytokine	ADJ
bjos-8641642	200	5	profiles	profile	NOUN
bjos-8641642	200	6	in	in	ADP
bjos-8641642	200	7	the	the	DET
bjos-8641642	200	8	sera	sera	NOUN
bjos-8641642	200	9	of	of	ADP
bjos-8641642	200	10	egyptian	egyptian	ADJ
bjos-8641642	200	11	patients	patient	NOUN
bjos-8641642	200	12	with	with	ADP
bjos-8641642	200	13	oral	oral	ADJ
bjos-8641642	200	14	pemphigus	pemphigus	NOUN
bjos-8641642	200	15	vulgaris	vulgaris	NOUN